menu
    • menu
    [{"orgOrder":0,"company":"Rise Therapeutics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"R-2487","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Rise Therapeutics LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-2487","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Rise Therapeutics LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics LLC","sponsor":"Mayo Clinic | University of Colorado, Denver","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"R-3750","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Rise Therapeutics LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics LLC \/ Mayo Clinic | University of Colorado, Denver","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics LLC \/ Mayo Clinic | University of Colorado, Denver"},{"orgOrder":0,"company":"Shanghai Pharma Biotherapeutics USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SPH3127","moa":"Renin","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Pharma Biotherapeutics USA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharma Biotherapeutics USA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Pharma Biotherapeutics USA \/ Undisclosed"},{"orgOrder":0,"company":"Chelsea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CH-4051","moa":"\nDHFR","graph1":"Immunology","graph2":"Phase II","graph3":"Chelsea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chelsea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chelsea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"MT-2990","moa":"\nIL-33","graph1":"Immunology","graph2":"Phase I","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MTPS9579A","moa":"\nTryptase","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chinese SLE Treatment And Research Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chinese SLE Treatment And Research Group \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Immunology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Dana-Farber Cancer Institute | Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Dana-Farber Cancer Institute | Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Dana-Farber Cancer Institute | Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Molecular Research Center","sponsor":"Camargo Pharmaceutical | Clin Data Services | Harrison Clinical Research | BARC Global Central Laboratory | Bilcare Global Clinical Supplies","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"MRC375","moa":"30S subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Molecular Research Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Research Center \/ Camargo Pharmaceutical | Clin Data Services | Harrison Clinical Research | BARC Global Central Laboratory | Bilcare Global Clinical Supplies","highestDevelopmentStatusID":"8","companyTruncated":"Molecular Research Center \/ Camargo Pharmaceutical | Clin Data Services | Harrison Clinical Research | BARC Global Central Laboratory | Bilcare Global Clinical Supplies"},{"orgOrder":0,"company":"IMBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IMB-101","moa":"3-ketoacyl-CoA thiolase, mitochondrial (ACAA2)","graph1":"Immunology","graph2":"Phase I","graph3":"IMBiologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMBiologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMBiologics \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"IASO Bio","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"IASO Bio \/ Cabaletta Bio"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ TD Cowen","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ TD Cowen"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ TD Cowen","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ TD Cowen"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Advanced Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"WuXi Advanced Therapies \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Advanced Therapies \/ Cabaletta Bio"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"RHB-104","moa":"50S ribosomal subunit","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mescaline","moa":"5-HT 2A receptor (HTR2A)","graph1":"Immunology","graph2":"IND Enabling","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"PF-06444753","moa":"5-HT1A receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BGP-014","moa":"5-HT1A\/2A receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Korea University Anam Hospital","sponsor":"Hanlim Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bepotastine Salicylate","moa":"5-HT1A\/2A\/2B receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Korea University Anam Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea University Anam Hospital \/ Hanlim Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Korea University Anam Hospital \/ Hanlim Pharmaceutical"},{"orgOrder":0,"company":"AnaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AM1476","moa":"5-HT2B receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnaMar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ Undisclosed"},{"orgOrder":0,"company":"AnaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AM1476","moa":"5-HT2B receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnaMar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||70S ribosome","graph1":"Immunology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Palo Biofarma","sponsor":"Qualitecfarma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PBF-677","moa":"A2AR","graph1":"Immunology","graph2":"Phase II","graph3":"Palo Biofarma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palo Biofarma \/ Qualitecfarma","highestDevelopmentStatusID":"8","companyTruncated":"Palo Biofarma \/ Qualitecfarma"},{"orgOrder":0,"company":"Asia Cell Therapeutics","sponsor":"RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Asia Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asia Cell Therapeutics \/ RenJi Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Asia Cell Therapeutics \/ RenJi Hospital"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"NMD PHARMA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Immunology","graph2":"Phase III","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leiden University Medical Center \/ NMD PHARMA","highestDevelopmentStatusID":"10","companyTruncated":"Leiden University Medical Center \/ NMD PHARMA"},{"orgOrder":0,"company":"Acella Pharmaceuticals","sponsor":"Milla Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Acella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Acella Pharmaceuticals \/ Milla Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acella Pharmaceuticals \/ Milla Pharmaceuticals"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Milla Pharmaceuticals \/ Alter Pharma group","highestDevelopmentStatusID":"15","companyTruncated":"Milla Pharmaceuticals \/ Alter Pharma group"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Toronto \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"University of Toronto \/ Allergan"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Immunology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Immunology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Allergan","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Allergan"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Immunology","graph2":"Phase III","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University \/ Allergan","highestDevelopmentStatusID":"10","companyTruncated":"Johns Hopkins University \/ Allergan"},{"orgOrder":0,"company":"Singota Solutions","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Singota Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Singota Solutions \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Singota Solutions \/ Noveome Biotherapeutics"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Commonwealth Of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Commonwealth Of Pennsylvania","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Commonwealth Of Pennsylvania"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"BYM338","moa":"Activin receptor type-2B","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GB242","moa":"Adalimumab target","graph1":"Immunology","graph2":"Phase III","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PNV-6005","moa":"ADORA2A","graph1":"Immunology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dipivefrin","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Schreiner MediPharm","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Hormone","year":"2020","type":"Partnership","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Schreiner MediPharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Schreiner MediPharm \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Schreiner MediPharm \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Recordati","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ITALY","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recordati \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Hadassah Medical Organization | Medis | Pharma Medica Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nasus Pharma \/ Hadassah Medical Organization | Medis | Pharma Medica Research","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Hadassah Medical Organization | Medis | Pharma Medica Research"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Nasus Pharma \/ Laidlaw & Company","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Laidlaw & Company"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Lovelace Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Lovelace Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Lovelace Biomedical"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Termination","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adamis Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Adamis Pharmaceuticals \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ US WorldMeds"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"KALEO INC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Hormone","year":"2022","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ KALEO INC","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ KALEO INC"},{"orgOrder":0,"company":"KALEO INC","sponsor":"Pan Canadian Pharmaceutical Alliance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"KALEO INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"KALEO INC \/ Pan Canadian Pharmaceutical Alliance","highestDevelopmentStatusID":"15","companyTruncated":"KALEO INC \/ Pan Canadian Pharmaceutical Alliance"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"HLK Pharmacin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ HLK Pharmacin","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ HLK Pharmacin"},{"orgOrder":0,"company":"Windgap Medical","sponsor":"Taiwania Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Series B Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Windgap Medical","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Windgap Medical \/ Taiwania Capital","highestDevelopmentStatusID":"1","companyTruncated":"Windgap Medical \/ Taiwania Capital"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Merger","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Silverback Therapeutics \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Silverback Therapeutics \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"ALK-ABELLO INC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0.46999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.46999999999999997,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ ALK-ABELLO INC","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ ALK-ABELLO INC"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"ALK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ ALK","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ ALK"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurelis","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.20999999999999999,"dosageForm":"Spray","sponsorNew":"Neurelis \/ OrbiMed Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ OrbiMed Advisors"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Series D Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ RA Capital Management"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Merger","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Silverback Therapeutics \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Silverback Therapeutics \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"ALK-ABELLO INC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ ALK-ABELLO INC","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ ALK-ABELLO INC"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Seqirus","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharmaceuticals \/ Seqirus"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aptar Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptar Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aptar Pharma \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Series A Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"De Motu Cordis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"De Motu Cordis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"De Motu Cordis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"De Motu Cordis \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Grandpharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Epinephrine Bitartrate","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection, Pre-Filled","sponsorNew":"ALK \/ Grandpharma","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Grandpharma"},{"orgOrder":0,"company":"Association Asthma, Bulgaria","sponsor":"Nasaleze","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BULGARIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Association Asthma, Bulgaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Association Asthma, Bulgaria \/ Nasaleze","highestDevelopmentStatusID":"8","companyTruncated":"Association Asthma, Bulgaria \/ Nasaleze"},{"orgOrder":0,"company":"Association Asthma, Bulgaria","sponsor":"Nasaleze","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BULGARIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Xylometazoline","moa":"Adrenergic receptor alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Association Asthma, Bulgaria","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Association Asthma, Bulgaria \/ Nasaleze","highestDevelopmentStatusID":"11","companyTruncated":"Association Asthma, Bulgaria \/ Nasaleze"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Immunology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Ocugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Immunology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocugen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Undisclosed"},{"orgOrder":0,"company":"Ocugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Immunology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocugen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Immunology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seoul National University Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Khon Kaen University","sponsor":"Farmaline","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"THAILAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Immunology","graph2":"Phase III","graph3":"Khon Kaen University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Khon Kaen University \/ Farmaline","highestDevelopmentStatusID":"10","companyTruncated":"Khon Kaen University \/ Farmaline"},{"orgOrder":0,"company":"Mesoblast","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Immunology","graph2":"Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mesoblast \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"Mesoblast \/ PPD"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"AllianThera Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"YUQA-1007","moa":"AHR","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ AllianThera Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Falk Pharma \/ AllianThera Biopharma"},{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"3i Nature | Naturop\u00f4le Nutrition sant\u00e9","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Clermont-Ferrand \/ 3i Nature | Naturop\u00f4le Nutrition sant\u00e9","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Clermont-Ferrand \/ 3i Nature | Naturop\u00f4le Nutrition sant\u00e9"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Verdure Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Chicago \/ Verdure Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of Illinois, Chicago \/ Verdure Sciences"},{"orgOrder":0,"company":"Epiceutical Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Undisclosed","graph3":"Epiceutical Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epiceutical Labs \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Epiceutical Labs \/ Undisclosed"},{"orgOrder":0,"company":"Medinutra LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Undisclosed","graph3":"Medinutra LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medinutra LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Medinutra LLC \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ EQT Life Sciences"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Series D Financing","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Sanofi"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Pfizer Inc"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"Biomay","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BM32","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Biomay","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomay \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomay \/ Undisclosed"},{"orgOrder":0,"company":"Biomay","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"BM32","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Biomay","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomay \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomay \/ Undisclosed"},{"orgOrder":0,"company":"Biomay","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"BM32","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Biomay","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biomay \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomay \/ Undisclosed"},{"orgOrder":0,"company":"Biomay","sponsor":"Medical University of Vienna","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BM32","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Biomay","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biomay \/ Medical University of Vienna","highestDevelopmentStatusID":"8","companyTruncated":"Biomay \/ Medical University of Vienna"},{"orgOrder":0,"company":"Labo'Life","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"2LALERG","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase IV","graph3":"Labo'Life","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Labo'Life \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Labo'Life \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"5-grass Mix Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ALK \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Syneos Health"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Alktree Ait","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Alternaria Alternata Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tongren Hospital","sponsor":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Artemisia Annua Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Beijing Tongren Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Beijing Tongren Hospital \/ Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Tongren Hospital \/ Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Artemisia Vulgaris","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Avanz Mite","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Avanz Olea Europaea","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Avanz Phleum Pratense","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Avanz Salsola","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Betula Verrucosa Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Quintiles Inc | Evotec | Cenduit | PHT Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Birch Pollen Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stallergenes Greer \/ Quintiles Inc | Evotec | Cenduit | PHT Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Quintiles Inc | Evotec | Cenduit | PHT Corporation"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Blomia Tropicalis Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Chenopodium Album Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Dactylis Glomerata Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"LETI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Depigoid Birch","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"LETI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LETI Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LETI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Plaza del Hospital Civil","sponsor":"Laboratorios Leti","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Depigoid Phleum","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Plaza del Hospital Civil","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plaza del Hospital Civil \/ Laboratorios Leti","highestDevelopmentStatusID":"8","companyTruncated":"Plaza del Hospital Civil \/ Laboratorios Leti"},{"orgOrder":0,"company":"LETI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Depigoid Phleum","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"LETI Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LETI Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LETI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"BioClever 2005 | NTS Hub S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ BioClever 2005 | NTS Hub S.L.","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ BioClever 2005 | NTS Hub S.L."},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inimmune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Inimmune","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inimmune"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Circuit Clinical","sponsor":"Intrommune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"IND Enabling","graph3":"Circuit Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Circuit Clinical \/ Intrommune Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Circuit Clinical \/ Intrommune Therapeutics"},{"orgOrder":0,"company":"ALK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Peanut Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"ALK \/ Parexel"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Peanut Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Phleum Pratense Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Phleum Pratense Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Platanus Acerifolia Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Poa Pratensis Allergen Etract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Ergomed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Purethal Birch","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase IV","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Ergomed","highestDevelopmentStatusID":"11","companyTruncated":"HAL Allergy \/ Ergomed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Purethal Birch","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Purethal Birch","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase IV","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Purethal Grasses","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase IV","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Ergomed | ClinCompetence Cologne GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Purethal Mites","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HAL Allergy \/ Ergomed | ClinCompetence Cologne GmbH","highestDevelopmentStatusID":"10","companyTruncated":"HAL Allergy \/ Ergomed | ClinCompetence Cologne GmbH"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Purethal Mites","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Ragweed Pollen Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stallergenes Greer \/ Quintiles Inc","highestDevelopmentStatusID":"6","companyTruncated":"Stallergenes Greer \/ Quintiles Inc"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Ragweed-Spire","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Circassia \/ Adiga Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Adiga Life Sciences"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Ragweed-Spire","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Circassia \/ Adiga Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Adiga Life Sciences"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Secale Cereale Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Short Ragweed Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase IV","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Sublivac Fix Phleum Prat","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Sublivac Fix Phleum Prat","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"Imperial College London","sponsor":"King's College London | ALK | Wellcome Trust","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Timothy Grass Pollen Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imperial College London \/ King's College London | ALK | Wellcome Trust","highestDevelopmentStatusID":"8","companyTruncated":"Imperial College London \/ King's College London | ALK | Wellcome Trust"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Timothy Grass Pollen Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase IV","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Timothy Grass Pollen Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences | Pharm-Olam","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Toleromune Grass","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Circassia \/ Adiga Life Sciences | Pharm-Olam","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Adiga Life Sciences | Pharm-Olam"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Toleromune Grass","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circassia \/ Adiga Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Adiga Life Sciences"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences | Cetero Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Toleromune Ragweed","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Circassia \/ Adiga Life Sciences | Cetero Research","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Adiga Life Sciences | Cetero Research"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences | Cetero Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Toleromune Ragweed","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circassia \/ Adiga Life Sciences | Cetero Research","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Adiga Life Sciences | Cetero Research"},{"orgOrder":0,"company":"ALK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tree Slit","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Parexel"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Mesoblast","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Mesoblast","highestDevelopmentStatusID":"7","companyTruncated":"Cleveland Clinic \/ Mesoblast"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Mesoblast","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Mesoblast","highestDevelopmentStatusID":"7","companyTruncated":"Cleveland Clinic \/ Mesoblast"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Quintiles Inc","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Quintiles Inc"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Quintiles Inc","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Quintiles Inc"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"BMT CTN","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ BMT CTN","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ BMT CTN"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Private Placement","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Gregory George","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Gregory George","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Gregory George"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Cleveland Clinic"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SPY001","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spyre Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Earendil Labs","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"HXN-1002","moa":"Alpha-4-beta-7\/TL1A","graph1":"Immunology","graph2":"Preclinical","graph3":"Earendil Labs","amount2":1.8500000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.8500000000000001,"dosageForm":"Undisclosed","sponsorNew":"Earendil Labs \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Earendil Labs \/ Sanofi"},{"orgOrder":0,"company":"AbSci","sponsor":"Alpha Cancer Technologies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant Human Alpha-Fetoprotein","moa":"Alpha-fetoprotein receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbSci \/ Alpha Cancer Technologies","highestDevelopmentStatusID":"6","companyTruncated":"AbSci \/ Alpha Cancer Technologies"},{"orgOrder":0,"company":"Convalife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CVL237","moa":"Alpha-synuclein","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Convalife","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Convalife \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Convalife \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mercaptopurine","moa":"Amidophosphoribosyltransferase | DNA||Hypoxanthine-guanine phosphoribosyltransferase; Inosine-5'-monophosphate dehydrogenase 1; Amidophosphoribosyltransferase; Inosine-5'-monophosphate dehydrogenase","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mercaptopurine","moa":"Amidophosphoribosyltransferase | DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Propionylcarnitine","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Phase III","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadiant Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leadiant Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Propionylcarnitine","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Phase III","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadiant Biosciences \/ PRA Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Leadiant Biosciences \/ PRA Health Sciences"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Ginsenoside Compound K","moa":"AMPK","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HavaH Therapeutics","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Testosterone","moa":"||Androgen Receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"HavaH Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"HavaH Therapeutics \/ Clarus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"HavaH Therapeutics \/ Clarus Therapeutics"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen Receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Lupus Research Alliance","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Immunology","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Northwell Health \/ Lupus Research Alliance","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Lupus Research Alliance"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Immunology","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"||Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Medison Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Medison Pharma"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"||Antibodies","graph1":"Immunology","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Argenx","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Argenx"},{"orgOrder":0,"company":"BlackfinBio","sponsor":"Boston Children's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BFB-101","moa":"AP4B1","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"BlackfinBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"BlackfinBio \/ Boston Children's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"BlackfinBio \/ Boston Children's Hospital"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Radiolabeled Compound","year":"2014","type":"Inapplicable","leadProduct":"99m-Tc rhAnnexin V-128","moa":"Apoptosis","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Accelerator Applications \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Advanced Accelerator Applications \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Immunology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Immunology","graph2":"Phase II","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Veralox Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veralox Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Diosmin","moa":"Aryl hydrocarbon receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primus Pharmaceutical \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Primus Pharmaceutical \/ KGK Science"},{"orgOrder":0,"company":"Equillium","sponsor":"ADAR1 Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"EQ504","moa":"Aryl hydrocarbon receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Equillium","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Equillium \/ ADAR1 Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Equillium \/ ADAR1 Capital Management"},{"orgOrder":0,"company":"Lycera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LYC-30937","moa":"ATP phosphatase (ATPase)","graph1":"Immunology","graph2":"Phase II","graph3":"Lycera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lycera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lycera \/ Undisclosed"},{"orgOrder":0,"company":"Lycera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LYC-30937","moa":"ATP phosphatase (ATPase)","graph1":"Immunology","graph2":"Phase II","graph3":"Lycera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lycera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lycera \/ Undisclosed"},{"orgOrder":0,"company":"Lycera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LYC-30937","moa":"ATP phosphatase (ATPase)","graph1":"Immunology","graph2":"Phase II","graph3":"Lycera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lycera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lycera \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Edecesertib","moa":"ATR","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Edecesertib","moa":"ATR","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VIC-1911","moa":"||Aurora kinase A (AURKA)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VITRAC Therapeutics \/ University of Minnesota","highestDevelopmentStatusID":"7","companyTruncated":"VITRAC Therapeutics \/ University of Minnesota"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LY3361237","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"LY3361237","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prota Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prota Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Prota Therapeutics \/ SPRIM Global Investments","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Intralytix","sponsor":"Icahn School of Medicine at Mount Sinai | Johns Hopkins University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2019","type":"Inapplicable","leadProduct":"Bacteriophage","moa":"Bacteria","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Intralytix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intralytix \/ Icahn School of Medicine at Mount Sinai | Johns Hopkins University","highestDevelopmentStatusID":"7","companyTruncated":"Intralytix \/ Icahn School of Medicine at Mount Sinai | Johns Hopkins University"},{"orgOrder":0,"company":"Linkoeping University","sponsor":"BioGaia Pharma | The Ekhaga Foundation, Sweden | The Heart and Lung foundation, Sweden | The Research Council for the South-East Sweden | The Swedish Asthma and Allergy Association, Sweden | The Swedish Research Council | University Hospital, Linkoeping","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Immunology","graph2":"Phase II","graph3":"Linkoeping University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linkoeping University \/ BioGaia Pharma | The Ekhaga Foundation, Sweden | The Heart and Lung foundation, Sweden | The Research Council for the South-East Sweden | The Swedish Asthma and Allergy Association, Sweden | The Swedish Research Council | University Hospital, Linkoeping","highestDevelopmentStatusID":"8","companyTruncated":"Linkoeping University \/ BioGaia Pharma | The Ekhaga Foundation, Sweden | The Heart and Lung foundation, Sweden | The Research Council for the South-East Sweden | The Swedish Asthma and Allergy Association, Sweden | The Swedish Research Council | University Hospital, Linkoeping"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"Vaginal Microbiota","moa":"Bacteria microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase II","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Human Drug Research \/ Maruho","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Human Drug Research \/ Maruho"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laval University","sponsor":"Ministry of Agriculture, Fisheries and Food, Quebec | Ministry of economic development, innovation and export trade, Quebec | Diana Food, Symrise | Atrium Innovations | NutriAgaves, Mexico | Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Cranberry","moa":"Bacterial adhesion","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Ministry of Agriculture, Fisheries and Food, Quebec | Ministry of economic development, innovation and export trade, Quebec | Diana Food, Symrise | Atrium Innovations | NutriAgaves, Mexico | Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Laval University \/ Ministry of Agriculture, Fisheries and Food, Quebec | Ministry of economic development, innovation and export trade, Quebec | Diana Food, Symrise | Atrium Innovations | NutriAgaves, Mexico | Nestle Health Sciences SA"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Immunology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pulmatrix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibafloxacin","moa":"Bacterial DNA gyrase","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"OPS-2071","moa":"Bacterial DNA replication","graph1":"Immunology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ IQVIA"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Cromsource","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Immunology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Cromsource","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Cromsource"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Salix Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Salix Pharmaceuticals"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Salix Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Salix Pharmaceuticals"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Immunology","graph2":"Phase II","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Cedars-Sinai \/ Bausch Health"},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AstraGin","moa":"Bacterial gut","graph1":"Immunology","graph2":"Undisclosed","graph3":"NuLiv Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NuLiv Science \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NuLiv Science \/ Undisclosed"},{"orgOrder":0,"company":"Clalit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Clalit","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clalit \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Clalit \/ Undisclosed"},{"orgOrder":0,"company":"Saskatchewan Health Authority \u2013 Regina Area","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Saskatchewan Health Authority \u2013 Regina Area","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saskatchewan Health Authority \u2013 Regina Area \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Saskatchewan Health Authority \u2013 Regina Area \/ Undisclosed"},{"orgOrder":0,"company":"Duke University","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Aztreonam Lysine","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Phase IV","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Duke University \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Duke University \/ Gilead Sciences"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Clinartis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Phase I","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wockhardt \/ Clinartis","highestDevelopmentStatusID":"6","companyTruncated":"Wockhardt \/ Clinartis"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Catholic University of the Sacred Heart","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Ertapenem","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Phase IV","graph3":"Catholic University of the Sacred Heart","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catholic University of the Sacred Heart \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of the Sacred Heart \/ Merck & Co"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ALPN-30x","moa":"BAFF","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Thunderbolt","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"IND Enabling","graph3":"Thunderbolt","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Thunderbolt \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Thunderbolt \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"VT-109","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Undisclosed","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Vera Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Stanford University \/ Vera Therapeutics"},{"orgOrder":0,"company":"Aravax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PVX108","moa":"Basophil","graph1":"Immunology","graph2":"Phase I","graph3":"Aravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aravax \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aravax \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Immunology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Immunology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Immunology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"iCell Gene Therapeutics","sponsor":"iCAR Bio Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BCMA-CD19 cCAR-T Cell","moa":"B-cell maturation antigen\/CD19","graph1":"Immunology","graph2":"Phase I","graph3":"iCell Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iCell Gene Therapeutics \/ iCAR Bio Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"iCell Gene Therapeutics \/ iCAR Bio Therapeutics"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Cartesian Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Merger","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Cartesian Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Cartesian Therapeutics"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Private Placement","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase I","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tongji Hospital \/ IASO Bio","highestDevelopmentStatusID":"1","companyTruncated":"Tongji Hospital \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Gracell Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ RenJi Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ RenJi Hospital"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca | Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca | Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ AstraZeneca | Gracell Biotechnologies"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Daishi Tian","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GC012F","moa":"BCMA","graph1":"Immunology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Daishi Tian","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Daishi Tian"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Qiong Fu","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GC012F","moa":"BCMA","graph1":"Immunology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Qiong Fu","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Qiong Fu"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Neukio Biotherapeutics (Shanghai) Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"NEUK203-215","moa":"BCMA | CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Neukio Biotherapeutics (Shanghai) Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neukio Biotherapeutics (Shanghai) Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neukio Biotherapeutics (Shanghai) Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tongji Hospital \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"Tongji Hospital \/ IASO Bio"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cizutamig","moa":"BCMA\/CD3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Immunology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BCD-256","moa":"BDCA2","graph1":"Immunology","graph2":"Phase I","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Immunology","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Forest Laboratories | Lahey Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Forest Laboratories | Lahey Clinic","highestDevelopmentStatusID":"1","companyTruncated":"Brigham and Women's Hospital \/ Forest Laboratories | Lahey Clinic"},{"orgOrder":0,"company":"Prism Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"C-82","moa":"Beta-catenin","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Prism Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Prism Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prism Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"Beta-lactam antibiotics","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theriva Biologics \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"||Beta-lactam antibiotics","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"Beta-lactam antibiotics","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"||Beta-lactam antibiotics","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"||Beta-lactam antibiotics","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"Beta-lactam antibiotics","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"LITHUANIA","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northway Biotechpharma \/ Revolo Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Northway Biotechpharma \/ Revolo Biotherapeutics"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series B Financing","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Merck & Co","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"MK-8237","moa":"Birch pollen allergen","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ ALK","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ ALK"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Archigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"SAIT101","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Archigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Archigen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Archigen \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"BI695500","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"BI695500","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"CT-P10","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"GP2013","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"MK-8808","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Case Comprehensive Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Case Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Case Comprehensive Cancer Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Case Comprehensive Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"PF-05280586","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Tours \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Tours \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Tours \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Tours \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chinese SLE Treatment And Research Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ Undisclosed"},{"orgOrder":0,"company":"University of Tokyo","sponsor":"Japan Agency for Medical Research and Development | Zenyaku Kogyo","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"University of Tokyo","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Tokyo \/ Japan Agency for Medical Research and Development | Zenyaku Kogyo","highestDevelopmentStatusID":"9","companyTruncated":"University of Tokyo \/ Japan Agency for Medical Research and Development | Zenyaku Kogyo"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ PPD"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"ZENOAQ","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"ZENOAQ","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ZENOAQ \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"ZENOAQ \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"University of Giessen","sponsor":"Heidelberg University | German Cancer Research Center | Astellas Pharma | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"University of Giessen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Giessen \/ Heidelberg University | German Cancer Research Center | Astellas Pharma | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Giessen \/ Heidelberg University | German Cancer Research Center | Astellas Pharma | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Dutch Kidney Foundation | ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ Dutch Kidney Foundation | ZonMw","highestDevelopmentStatusID":"8","companyTruncated":"Leiden University Medical Center \/ Dutch Kidney Foundation | ZonMw"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Arthritis Research UK | F. Hoffmann-La Roche | Genentech | University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Arthritis Research UK | F. Hoffmann-La Roche | Genentech | University of Pennsylvania","highestDevelopmentStatusID":"10","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Arthritis Research UK | F. Hoffmann-La Roche | Genentech | University of Pennsylvania"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Mabion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabion SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Undisclosed"},{"orgOrder":0,"company":"Mabion SA","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabion SA \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Parexel"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Genentech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Genentech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Karolinska Institutet | Ohio State University | Dutch Working Party on Systemic Lupus Erythematosus | EULAR Lupus Nephritis Trial Network Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Karolinska Institutet | Ohio State University | Dutch Working Party on Systemic Lupus Erythematosus | EULAR Lupus Nephritis Trial Network Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Imperial College London \/ Karolinska Institutet | Ohio State University | Dutch Working Party on Systemic Lupus Erythematosus | EULAR Lupus Nephritis Trial Network Study Group"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Hexal AG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sandoz B2B \/ Hexal AG","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Hexal AG"},{"orgOrder":0,"company":"Mashhad University of Medical Sciences","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"Mashhad University of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mashhad University of Medical Sciences \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"11","companyTruncated":"Mashhad University of Medical Sciences \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Leumit Health Services","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Undisclosed","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabin Medical Center \/ Leumit Health Services","highestDevelopmentStatusID":"1","companyTruncated":"Rabin Medical Center \/ Leumit Health Services"},{"orgOrder":0,"company":"Northside Hospital","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Northside Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northside Hospital \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Northside Hospital \/ Pharmacyclics"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Celgene Corporation"},{"orgOrder":0,"company":"Diako","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Diako","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Diako \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Diako \/ Undisclosed"},{"orgOrder":0,"company":"Mabscale","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Mabscale","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabscale \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabscale \/ Undisclosed"},{"orgOrder":0,"company":"Biointegrator","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Biointegrator","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biointegrator \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biointegrator \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Autoimmunity Centers of Excellence | TG Therapeutics | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ublituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | TG Therapeutics | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | TG Therapeutics | Rho, Inc"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Veltuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ATA3219","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"KITE-363","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Miltenyi Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MB-CART19.1","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Miltenyi Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Miltenyi Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NKX019","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NKX019","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"YTB323","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"YTB323","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"RC18","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"RC18","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"RC18","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"RC18","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"RC18","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"RemeGen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ RemeGen","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ RemeGen"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS|APRIL","graph1":"Immunology","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chinese SLE Treatment And Research Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Approved FDF","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Approved FDF","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Approved FDF","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Approved FDF","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Telitacicept","moa":"||BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Approved FDF","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":4.1299999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":4.1299999999999999,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Vor Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Vor Biopharma"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Lilly Asia Ventures","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Private Placement","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"Vor Biopharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Vor Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Immunology","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Chengdu Yunke Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"99m-Tc Methylene Diphosphonate","moa":"Bone resorption","graph1":"Immunology","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Chengdu Yunke Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ Chengdu Yunke Pharmaceutical"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ PPD"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University Medical Center \/ SHIRE PLC","highestDevelopmentStatusID":"11","companyTruncated":"Vanderbilt University Medical Center \/ SHIRE PLC"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ZEN003365","moa":"BRM","graph1":"Immunology","graph2":"Phase I","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zenith Epigenetics \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BI705564","moa":"BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK||Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"SinoMab BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SN1011","moa":"BTK","graph1":"Immunology","graph2":"Phase I","graph3":"SinoMab BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SinoMab BioScience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SinoMab BioScience \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tolebrutininb","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ANB032","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"BIIB057","moa":"BTLA","graph1":"Immunology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"MiroBio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Gilead Sciences"},{"orgOrder":0,"company":"MiroBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Undisclosed"},{"orgOrder":0,"company":"MiroBio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Gilead Sciences"},{"orgOrder":0,"company":"MiroBio","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Series B Financing","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Medicxi","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Medicxi"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LT-02","moa":"Butyrate-producing bacteria","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LT-02","moa":"Butyrate-producing bacteria","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Nestle Health Sciences SA | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LT-02","moa":"Butyrate-producing bacteria","graph1":"Immunology","graph2":"Phase III","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROMETHEUS LABS \/ Nestle Health Sciences SA | Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"PROMETHEUS LABS \/ Nestle Health Sciences SA | Syneos Health"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Claseprubart","moa":"C1","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Claseprubart","moa":"C1","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"C1 Esterase Inhibitor, Human","moa":"C1 esterase","graph1":"Immunology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ CSL Behring","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ CSL Behring"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tanruprubart","moa":"C1q","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Celerion | Assign Data Management and Biostatistics | ABF Pharmaceutical Services | Quest Diagnostics-Nichols Insitute | Covance | PPD | Softworld","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"BIV009","moa":"C1S","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Celerion | Assign Data Management and Biostatistics | ABF Pharmaceutical Services | Quest Diagnostics-Nichols Insitute | Covance | PPD | Softworld","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Celerion | Assign Data Management and Biostatistics | ABF Pharmaceutical Services | Quest Diagnostics-Nichols Insitute | Covance | PPD | Softworld"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dianthus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Dianthus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Merger","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Magenta Therapeutics \/ Dianthus Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Dianthus Therapeutics"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase I","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dianthus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dianthus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Hesperos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dianthus Therapeutics \/ Hesperos","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Hesperos"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Empasiprubart","moa":"C2","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ASC930","moa":"C3 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"ASC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"SLN501","moa":"C3 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":2.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":2.02,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Gefurulimab","moa":"C5","graph1":"Immunology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ImmunAbs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IM-101","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"ImmunAbs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunAbs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmunAbs \/ Undisclosed"},{"orgOrder":0,"company":"ImmunAbs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IM-101","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"ImmunAbs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunAbs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmunAbs \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CANbridge Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"RLYB-116","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Chiba University","sponsor":"Kissei Pharmaceutical | International University of Health and Welfare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Chiba University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiba University \/ Kissei Pharmaceutical | International University of Health and Welfare","highestDevelopmentStatusID":"11","companyTruncated":"Chiba University \/ Kissei Pharmaceutical | International University of Health and Welfare"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":3.7000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":3.7000000000000002,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":3.7000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":3.7000000000000002,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"CSL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Undisclosed"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL \/ ChemoCentryx","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ ChemoCentryx"},{"orgOrder":0,"company":"CSL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Undisclosed"},{"orgOrder":0,"company":"Capella Bioscience","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CBS001","moa":"C5a receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Capella Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capella Bioscience \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Capella Bioscience \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"14-C CCX168","moa":"C5a1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"FK506E","moa":"Calcineurin","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HT-005 Z-PODS","moa":"Calcineurin","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HT-005 Z-PODS","moa":"Calcineurin","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LIFE-001","moa":"Calcineurin","graph1":"Immunology","graph2":"Phase I","graph3":"LifeMine Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LifeMine Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LifeMine Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus Extended Release","moa":"Calcineurin","graph1":"Immunology","graph2":"Phase I","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Yale University \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Yale University \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus Extended Release","moa":"Calcineurin","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"University of Illinois, Chicago \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Illinois, Chicago \/ Astellas Pharma"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ronacaleret","moa":"Calcium sensing receptor","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ronacaleret","moa":"Calcium sensing receptor","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Institute for Clinical and Experimental Medicine","sponsor":"Charite University, Berlin, Germany | Miltenyi Biomedicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CZECH REPUBLIC","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Immunology","graph2":"Undisclosed","graph3":"Institute for Clinical and Experimental Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute for Clinical and Experimental Medicine \/ Charite University, Berlin, Germany | Miltenyi Biomedicine","highestDevelopmentStatusID":"1","companyTruncated":"Institute for Clinical and Experimental Medicine \/ Charite University, Berlin, Germany | Miltenyi Biomedicine"},{"orgOrder":0,"company":"University of Oxford","sponsor":"National Health Service, UK | Pfizer Inc | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ National Health Service, UK | Pfizer Inc | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ National Health Service, UK | Pfizer Inc | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"GW Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"GW Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GW Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GW Research \/ Undisclosed"},{"orgOrder":0,"company":"Kalytera Therapeutics Israel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Kalytera Therapeutics Israel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalytera Therapeutics Israel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kalytera Therapeutics Israel \/ Undisclosed"},{"orgOrder":0,"company":"Stero Biotechs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Stero Biotechs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Stero Biotechs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stero Biotechs \/ Undisclosed"},{"orgOrder":0,"company":"Stero Biotechs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Stero Biotechs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stero Biotechs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stero Biotechs \/ Undisclosed"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"Stero Biotechs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Stero Biotechs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stero Biotechs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stero Biotechs \/ Undisclosed"},{"orgOrder":0,"company":"NextEvo Inc.","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"NextEvo Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextEvo Inc. \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"NextEvo Inc. \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"The Valens Company","sponsor":"PMI Mexico","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Valens Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"The Valens Company \/ PMI Mexico","highestDevelopmentStatusID":"1","companyTruncated":"The Valens Company \/ PMI Mexico"},{"orgOrder":0,"company":"Salzman Group","sponsor":"Kalytera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Salzman Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salzman Group \/ Kalytera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Salzman Group \/ Kalytera Therapeutics"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GenBio","sponsor":"Strainsforpains","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"GenBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenBio \/ Strainsforpains","highestDevelopmentStatusID":"5","companyTruncated":"GenBio \/ Strainsforpains"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"CannaMore Biotechs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"CannaMore Biotechs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"CannaMore Biotechs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CannaMore Biotechs \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Olorinab","moa":"Cannabinoid CB2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"AM-411","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Immunology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Anandamide","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Anandamide","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases | University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases | University of Pennsylvania","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases | University of Pennsylvania"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Corbus Pharmaceuticals | Autoimmunity Centers of Excellence | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Corbus Pharmaceuticals | Autoimmunity Centers of Excellence | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Corbus Pharmaceuticals | Autoimmunity Centers of Excellence | Rho, Inc"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Orion Corporation"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ TCGX"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Kreos Capital"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ TCGX"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"FT819","moa":"||CAR19 T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"FT819","moa":"CAR19 T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CAS 139481-59-7","moa":"CASP1\/IL-1-beta","graph1":"Immunology","graph2":"Phase II","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"TWi Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TWi Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"RO5459072","moa":"Cathepsin S","graph1":"Immunology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Raphael Pharma","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Raphael Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raphael Pharma \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Raphael Pharma \/ Citruslabs"},{"orgOrder":0,"company":"Vitality","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Cannabosides","moa":"CB1 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Vitality","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Vitality \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vitality \/ Undisclosed"},{"orgOrder":0,"company":"Innovo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"INV-101","moa":"CB1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Innovo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innovo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"INV-101","moa":"CB1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Innovo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"IHL-675A","moa":"CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"BMS-817399","moa":"C-C chemokine receptor type 1","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CCX354-C","moa":"C-C chemokine receptor type 1","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Immunology","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Amarex Clinical Research"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Immunology","graph2":"Phase I","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PF-07054894","moa":"C-C chemokine receptor type 6 (CCR6)","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CCL2||Stromal cell-derived factor 1 (CXCL12)","graph1":"Immunology","graph2":"Phase I","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CM-101","moa":"CCL24","graph1":"Immunology","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChemomAb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Undisclosed"},{"orgOrder":0,"company":"Leeds University","sponsor":"ChemomAb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Immunology","graph2":"Phase I","graph3":"Leeds University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leeds University \/ ChemomAb","highestDevelopmentStatusID":"6","companyTruncated":"Leeds University \/ ChemomAb"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Immunology","graph2":"Phase I","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ChemomAb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ChemomAb \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AZD7798","moa":"CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AZD7798","moa":"CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AZD7798","moa":"CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AZD7798","moa":"CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AZD7798","moa":"CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vercirnon","moa":"C-C chemokine receptor type 9||CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vercirnon","moa":"C-C chemokine receptor type 9||CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vercirnon","moa":"C-C chemokine receptor type 9||CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vercirnon","moa":"C-C chemokine receptor type 9||CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vercirnon","moa":"CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vercirnon","moa":"CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vercirnon","moa":"CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vercirnon","moa":"CCR9","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vercirnon","moa":"C-C chemokine receptor type 9||CCR9","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"MediBeacon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Relmapirazin","moa":"CD123","graph1":"Immunology","graph2":"Phase I","graph3":"MediBeacon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"MediBeacon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MediBeacon \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Makana Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"TNX-1500","moa":"||CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Makana Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Makana Therapeutics"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Boston Children's Hospital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Boston Children's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Boston Children's Hospital"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Maryland","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ University of Maryland"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TG Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MaxCyte","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MaxCyte \/ TG Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ TG Therapeutics"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.31,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.32000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ TG Therapeutics"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.32000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.32000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ TG Therapeutics"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BMS-986515","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CABA-201","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CABA-201","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CABA-201","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CB-010","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CC-97540","moa":"CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Juno Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CC-97540","moa":"CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RenJi Hospital","sponsor":"Ruishun Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19 CAR-DNT Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"RenJi Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RenJi Hospital \/ Ruishun Biotech","highestDevelopmentStatusID":"6","companyTruncated":"RenJi Hospital \/ Ruishun Biotech"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Guangzhou Bio-gene Technology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wuhan Union Hospital \/ Guangzhou Bio-gene Technology","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan Union Hospital \/ Guangzhou Bio-gene Technology"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Guangzhou Bio-gene Technology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wuhan Union Hospital \/ Guangzhou Bio-gene Technology","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan Union Hospital \/ Guangzhou Bio-gene Technology"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Undisclosed"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PersonGen BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PersonGen BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PersonGen BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PersonGen BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ruishun Biotech","sponsor":"RenJi Hospital | Peking University People's Hospital | Changhai Hospital | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19-CAR-DNT Cell","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Ruishun Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ruishun Biotech \/ RenJi Hospital | Peking University People's Hospital | Changhai Hospital | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"6","companyTruncated":"Ruishun Biotech \/ RenJi Hospital | Peking University People's Hospital | Changhai Hospital | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CNCT19","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Juventas Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Juventas Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juventas Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Century Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Century Therapeutics \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"CPTX2309","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Capstan Therapeutics","amount2":2.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":2.1000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Capstan Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Capstan Therapeutics \/ Abbvie Inc"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Series B Financing","leadProduct":"CPTX2309","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Capstan Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Capstan Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Capstan Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"CPTX2309","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Capstan Therapeutics","amount2":2.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":2.1000000000000001,"dosageForm":"Infusion","sponsorNew":"Capstan Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Capstan Therapeutics \/ Abbvie Inc"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"CUE-501","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0.35999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.35999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IASO-782","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IASO-782","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IASO-782","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Inaticabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Juventas Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juventas Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juventas Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Kyverna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Charite University, Berlin, Germany \/ Kyverna Therapeutics"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Licensing Agreement","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biomedica \/ Kyverna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biomedica \/ Kyverna Therapeutics"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kyverna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Series B Financing","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Series B Financing","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"Kyverna Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Northpond Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Kyverna Therapeutics \/ Northpond Ventures"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"KYV-201","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Kyverna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Kyverna Therapeutics"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Ming Ju Biotechnology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Shanghai Ming Ju Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Ming Ju Biotechnology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Ming Ju Biotechnology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Ming Ju Biotechnology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Shanghai Ming Ju Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Ming Ju Biotechnology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Ming Ju Biotechnology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"JW Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JW Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"VectorBuilder","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"UC101","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"Chengdu Yousino Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Yousino Biotechnology \/ VectorBuilder","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu Yousino Biotechnology \/ VectorBuilder"},{"orgOrder":0,"company":"Hinge Bio","sponsor":"Ridgeback Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series A Financing","leadProduct":"HB2198","moa":"CD19\/20","graph1":"Immunology","graph2":"Preclinical","graph3":"Hinge Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Hinge Bio \/ Ridgeback Capital","highestDevelopmentStatusID":"4","companyTruncated":"Hinge Bio \/ Ridgeback Capital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"KJ-C2219","moa":"CD19\/CD20","graph1":"Immunology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"QT-019B","moa":"CD19|BCMA","graph1":"Immunology","graph2":"IND Enabling","graph3":"Qihan Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qihan Biotech \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Qihan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ABP 798","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ACE1831","moa":"CD20","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ACE1831","moa":"CD20","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Acellbia","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BT595","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Biotest \/ Syneos Health"},{"orgOrder":0,"company":"RenJi Hospital","sponsor":"AbelZeta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD20 CAR-T Cell","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"RenJi Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RenJi Hospital \/ AbelZeta Pharma","highestDevelopmentStatusID":"6","companyTruncated":"RenJi Hospital \/ AbelZeta Pharma"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Divozilimab","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"DR-0201","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Dren Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dren Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dren Bio \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GR1501","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GR1501","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"HLX01","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"HLX01","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGM Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGM Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"JHL1101","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eden Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"KN019","moa":"CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jiangsu Alphamab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Immunology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MIL62","moa":"CD20","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Beijing Mabworks Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"SAR448501","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Dren Bio","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Injection","sponsorNew":"Dren Bio \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Dren Bio \/ Sanofi"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"SAR448501","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Dren Bio","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Injection","sponsorNew":"Dren Bio \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Dren Bio \/ Sanofi"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CND261","moa":"CD20 | CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Candid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneCare Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"IMC-002","moa":"CD20\/CD47","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"ImmuneCare Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneCare Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneCare Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase III","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase III","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase III","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase III","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"99m-Tc Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase III","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase I","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Tilmanocept","moa":"CD206","graph1":"Immunology","graph2":"Phase I","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Pharmaceutical Research Associates | Richmond Pharmacology | ACM Global Laboratories | Eurofins CDMO | The Doctors Laboratory Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Epratuzumab","moa":"CD22","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Pharmaceutical Research Associates | Richmond Pharmacology | ACM Global Laboratories | Eurofins CDMO | The Doctors Laboratory Ltd","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Pharmaceutical Research Associates | Richmond Pharmacology | ACM Global Laboratories | Eurofins CDMO | The Doctors Laboratory Ltd"},{"orgOrder":0,"company":"IASO Bio","sponsor":"The First Affiliated Hospital with Nanjing Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"UB-VV410","moa":"CD22","graph1":"Immunology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ The First Affiliated Hospital with Nanjing Medical University","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ The First Affiliated Hospital with Nanjing Medical University"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Access Biotechnology"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8500000000000001,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8500000000000001,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OSE Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OSE Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"OSE Immunotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Nantes University Hospital \/ OSE Immunotherapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.39000000000000001,"dosageForm":"Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Nantes University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Nantes University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"OSE Immunotherapeutics SA \/ Nantes University Hospital"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Bristol Myers Squibb | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lulizumab","moa":"CD28","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Bristol Myers Squibb | PPD","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Bristol Myers Squibb | PPD"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ALPN-101","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ALPN-101","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ViGenCell Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VM-001","moa":"CD3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"ViGenCell Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViGenCell Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ViGenCell Inc \/ Undisclosed"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xenikos B.V \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ Undisclosed"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dafsolimab Setaritox","moa":"CD3\/7||CD3\/CD7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xenikos B.V \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Xenikos B.V","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dafsolimab Setaritox","moa":"CD3\/7||CD3\/CD7","graph1":"Immunology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ Xenikos B.V","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Xenikos B.V"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA052","moa":"CD30","graph1":"Immunology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"PRV-3279","moa":"CD32B","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.28999999999999998,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Huadong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Huadong Pharmaceutical"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRV-3279","moa":"CD32B","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CID-103","moa":"CD-38","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CID-103","moa":"CD-38","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CID-103","moa":"CD-38","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Gebro Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CID-103","moa":"CD-38","graph1":"Immunology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"CASI Pharmaceuticals \/ Gebro Pharma","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharmaceuticals \/ Gebro Pharma"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CID-103","moa":"CD-38","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CM313","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CM313","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CM313","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Timberlyne Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"CM313","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Timberlyne Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Timberlyne Therapeutics"},{"orgOrder":0,"company":"Timberlyne Therapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series A Financing","leadProduct":"CM313","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"Timberlyne Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Timberlyne Therapeutics \/ Abingworth","highestDevelopmentStatusID":"8","companyTruncated":"Timberlyne Therapeutics \/ Abingworth"},{"orgOrder":0,"company":"Biotest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"BT061","moa":"CD4","graph1":"Immunology","graph2":"Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ASP5094","moa":"CD40","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ASP5094","moa":"CD40","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"BI655064","moa":"CD40","graph1":"Immunology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"BI655064","moa":"CD40","graph1":"Immunology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"BITT","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"BITT-101","moa":"CD40","graph1":"Immunology","graph2":"Preclinical","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"BITT \/ National Institutes of Health"},{"orgOrder":0,"company":"BITT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BITT-CD4D11","moa":"CD40","graph1":"Immunology","graph2":"Preclinical","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"BITT \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BMS-986325","moa":"CD40","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AT-1501","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AT-1501","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"CDP7657","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"CDP7657","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Biogen","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Biogen"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Biogen"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ravagalimab","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"CareDx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ CareDx","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ CareDx"},{"orgOrder":0,"company":"eGenesis","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Preclinical","graph3":"eGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"eGenesis \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"eGenesis \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ BVF Partners"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CareDx","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CareDx \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CareDx \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"VIB4920","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"VIB4920","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"VIB4920","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IBI355","moa":"CD40L","graph1":"Immunology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SAR441344","moa":"CD40L","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SAR441344","moa":"CD40L","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"KPL-404","moa":"CD40L receptor (CD40)","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aboleris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ABO21009","moa":"CD45RC","graph1":"Immunology","graph2":"Phase I","graph3":"Aboleris Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aboleris Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aboleris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneMed, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Burfiralimab","moa":"CD47","graph1":"Immunology","graph2":"Phase II","graph3":"ImmuneMed, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneMed, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmuneMed, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"RLYB-211","moa":"CD61","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"RLYB-211","moa":"CD61","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"RLYB-211","moa":"CD61","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"RLYB-211","moa":"CD61","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Pivotal Bioventure Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series B Financing","leadProduct":"RLYB-211","moa":"CD61","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Pivotal Bioventure Partners","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Pivotal Bioventure Partners"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Immunology","graph2":"Undisclosed","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PersonGen BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PersonGen BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"The Children's Hospital of Zhejiang University School of Medicine","sponsor":"Chongqing Precision Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD70 CAR-T Cell","moa":"CD70","graph1":"Immunology","graph2":"Phase I","graph3":"The Children's Hospital of Zhejiang University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Children's Hospital of Zhejiang University School of Medicine \/ Chongqing Precision Biotech","highestDevelopmentStatusID":"6","companyTruncated":"The Children's Hospital of Zhejiang University School of Medicine \/ Chongqing Precision Biotech"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Edinburgh \/ Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Edinburgh \/ Cyclacel Pharmaceuticals"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KPG-818","moa":"Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"KPG-818","moa":"Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KPG-818","moa":"Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KPG-818","moa":"Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KPG-818","moa":"Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KPG-818","moa":"Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"KPG-818","moa":"Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"NM8074","moa":"CFB","graph1":"Immunology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovelMed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"NM8074","moa":"CFB","graph1":"Immunology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovelMed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"CFB","graph1":"Immunology","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovelMed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"CFB","graph1":"Immunology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovelMed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VENT-03","moa":"cGAS","graph1":"Immunology","graph2":"Phase I","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ventus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VENT-03","moa":"cGAS","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Ventus Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VENT-03","moa":"cGAS","graph1":"Immunology","graph2":"Phase I","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ventus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Partnership","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0.70999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.70999999999999996,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ AbbVie Inc"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0.70999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.70999999999999996,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ AbbVie Inc"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Undisclosed"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"Rui Therapeutics | AlloRunning Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Allogeneic CAR-T Therapy","moa":"Chimeric antigen receptor","graph1":"Immunology","graph2":"Phase I","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ Rui Therapeutics | AlloRunning Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ Rui Therapeutics | AlloRunning Therapeutics"},{"orgOrder":0,"company":"EdiGene","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology | Changping Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Athena Car-T Cell","moa":"Chimeric antigen receptor","graph1":"Immunology","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EdiGene \/ The First Affiliated Hospital of Henan University of Science and Technology | Changping Laboratory","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ The First Affiliated Hospital of Henan University of Science and Technology | Changping Laboratory"},{"orgOrder":0,"company":"Beijing GoBroad Hospital","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Beijing GoBroad Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing GoBroad Hospital \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Beijing GoBroad Hospital \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAR-T Cell Therapy","moa":"Chimeric antigen receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAR-T Cell Therapy","moa":"Chimeric antigen receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Arthritis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Butyrate","moa":"Cholinesterase; Histone deacetylase 1; (S)-2-haloacid dehalogenase; 2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Arthritis Foundation","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Arthritis Foundation"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tanzisertib","moa":"c-Jun N-terminal kinase 2 | c-Jun N-terminal kinase 3 | c-Jun N-terminal kinase 1","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Xigen SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"XG-102","moa":"c-Jun N-terminal kinase 3","graph1":"Immunology","graph2":"Phase III","graph3":"Xigen SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xigen SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xigen SA \/ Undisclosed"},{"orgOrder":0,"company":"Xigen SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"XG-102","moa":"c-Jun N-terminal kinase 3","graph1":"Immunology","graph2":"Phase III","graph3":"Xigen SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xigen SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xigen SA \/ Undisclosed"},{"orgOrder":0,"company":"Xigen SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"XG-102","moa":"c-Jun N-terminal kinase 3","graph1":"Immunology","graph2":"Phase III","graph3":"Xigen SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xigen SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xigen SA \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CDX-0159","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"THB001","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0.16,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THB001","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Undisclosed"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"THB001","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.19,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Morgan Stanley"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"THB335","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Undisclosed"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"ValenzaBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"VB517","moa":"c-KIT receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novelty Nobility \/ ValenzaBio","highestDevelopmentStatusID":"5","companyTruncated":"Novelty Nobility \/ ValenzaBio"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NMD PHARMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Undisclosed"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NMD PHARMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Undisclosed"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NMD PHARMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Undisclosed"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NMD PHARMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Undisclosed"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NMD PHARMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Undisclosed"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"NMD PHARMA \/ Jeito Capital","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Jeito Capital"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NMD PHARMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Undisclosed"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Glucocorticoid","moa":"||CLDN1","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GlucoCorticoid","moa":"||CLDN1","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scott C. Woller, MD","sponsor":"Bristol Myers Squibb | University of Utah","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Immunology","graph2":"Phase IV","graph3":"Scott C. Woller, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scott C. Woller, MD \/ Bristol Myers Squibb | University of Utah","highestDevelopmentStatusID":"11","companyTruncated":"Scott C. Woller, MD \/ Bristol Myers Squibb | University of Utah"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Heart and Stroke Foundation | Bayer AG | Hamilton Health Sciences | Jewish General Hospital | University of Alberta | The Ottawa Hospital | Queen Elizabeth II Health Sciences Centre","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Immunology","graph2":"Phase IV","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Heart and Stroke Foundation | Bayer AG | Hamilton Health Sciences | Jewish General Hospital | University of Alberta | The Ottawa Hospital | Queen Elizabeth II Health Sciences Centre","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Heart and Stroke Foundation | Bayer AG | Hamilton Health Sciences | Jewish General Hospital | University of Alberta | The Ottawa Hospital | Queen Elizabeth II Health Sciences Centre"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Bayer AG"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Catridecacog","moa":"Coagulation factor XIII","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Hawthorne Effect Inc.","sponsor":"HLNatural, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hawthorne Effect Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hawthorne Effect Inc. \/ HLNatural, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Hawthorne Effect Inc. \/ HLNatural, Inc."},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"EN3835","moa":"Collagenase","graph1":"Immunology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"Complement C1s","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"ResearchPoint Global | International Centre for Diarrhoeal Disease Research, Bangladesh","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ ResearchPoint Global | International Centre for Diarrhoeal Disease Research, Bangladesh","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ ResearchPoint Global | International Centre for Diarrhoeal Disease Research, Bangladesh"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Redmile Group","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Redmile Group"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SAR445088","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SAR445088","moa":"Complement C1s component (C1S)","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Amyndas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"AMY-101","moa":"Complement C3","graph1":"Immunology","graph2":"Phase I","graph3":"Amyndas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amyndas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amyndas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Immunology","graph2":"Phase II","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Alexion Pharmaceuticals | National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of North Carolina \/ Alexion Pharmaceuticals | National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Alexion Pharmaceuticals | National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"ALXN1007","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"ALXN1007","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Crovalimab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"INSERM | Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Alexion Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Brigham and Women's Hospital \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cedars-Sinai \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Cedars-Sinai \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":39,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":39,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":39,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":39,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"Austin Neuromuscular Center","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pozelimab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase I","graph3":"Austin Neuromuscular Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Austin Neuromuscular Center \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Austin Neuromuscular Center \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pozelimab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Tesidolumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ra Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ra Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ra Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ra Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":2.2999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":2.2999999999999998,"dosageForm":"Injection","sponsorNew":"Ra Pharmaceuticals \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ra Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ALXN1720","moa":"Complement C5 (CO5)","graph1":"Immunology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MP-435","moa":"Complement C5 (CO5)","graph1":"Immunology","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ALXN2050","moa":"Complement factor B","graph1":"Immunology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Iptacopan Hydrochloride","moa":"Complement factor B","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iptacopan Hydrochloride","moa":"Complement factor B","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Iptacopan Hydrochloride","moa":"Complement factor B","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP144G","moa":"Complement factor B","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"KP104","moa":"Complement pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kira Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"KP104","moa":"Complement pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kira Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Immunology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Immunology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Immunology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"CTI Clinical Trial and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"RLS-0071","moa":"Complement pathway","graph1":"Immunology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReAlta Life Sciences \/ CTI Clinical Trial and Consulting","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ CTI Clinical Trial and Consulting"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Immunology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pelubiprofen","moa":"anti-inflammatory\/analgesic agents (ibuprofen type)","graph1":"Immunology","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Iberdomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Iberdomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Jiangxi Provincial People's Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Jiangxi Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangxi Provincial People's Hospital \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Jiangxi Provincial People's Hospital \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Thalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"ISIS CRP Rx","moa":"CRP","graph1":"Immunology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PRV-6527","moa":"CSF-1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Immunology","graph2":"Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"INCA034176","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"INCA034176","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"INCA034176","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"INCA034176","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Immunology","graph2":"Phase I","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Immunology","graph2":"Preclinical","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Immunology","graph2":"Phase I","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Immunology","graph2":"Phase I","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Feinstein Institutes","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Feinstein Institutes","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Feinstein Institutes"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Biogen \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Royalty Pharma"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PF-06835375","moa":"C-X-C chemokine receptor type 5 (CXCR5)","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PF-06835375","moa":"C-X-C chemokine receptor type 5 (CXCR5)","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SAR113244","moa":"C-X-C chemokine receptor type 5 (CXCR5)","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"SAR113244","moa":"C-X-C chemokine receptor type 5 (CXCR5)","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"BMS-936557","moa":"C-X-C motif chemokine 10","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Eltrekibart","moa":"CXCR1","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"CXCR-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"MEXICO","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bromfenac","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase I","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Sophia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Sophia \/ Undisclosed"},{"orgOrder":0,"company":"Toyos Clinic","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bromfenac","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase IV","graph3":"Toyos Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toyos Clinic \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"11","companyTruncated":"Toyos Clinic \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkem Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Endo International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"QATAR","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase I","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase IV","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Columbia University \/ Cumberland Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Columbia University \/ Cumberland Pharmaceuticals"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Pediatric Rheumatology Collaborative Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Pediatric Rheumatology Collaborative Study Group","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Pediatric Rheumatology Collaborative Study Group"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Mantecorp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase IV","graph3":"Mantecorp","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mantecorp \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mantecorp \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase I","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Assertio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Assertio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Naproxen","moa":"||Cyclooxygenase","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sen-Jam Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sen-Jam Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nanoform","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piroxicam","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanoform \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Undisclosed"},{"orgOrder":0,"company":"Nanoform","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Piroxicam","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanoform \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Undisclosed"},{"orgOrder":0,"company":"Nanoform","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piroxicam","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Preclinical","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanoform \/ Quotient Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Nanoform \/ Quotient Sciences"},{"orgOrder":0,"company":"Belgian Inflammatory Bowel Disease Research and Development","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase||Prostaglandin G\/H synthase 2; Prostaglandin G\/H synthase 1; Polyunsaturated fatty acid 5-lipoxygenase; Peroxisome proliferator-activated receptor gamma; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Inhibitor of nuclear factor kappa-B kinase subunit beta; Nitric oxide synthase, inducible","graph1":"Immunology","graph2":"Phase IV","graph3":"Belgian Inflammatory Bowel Disease Research and Development","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belgian Inflammatory Bowel Disease Research and Development \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Belgian Inflammatory Bowel Disease Research and Development \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Zeria Pharmaceutical \/ Kyowa Kirin"},{"orgOrder":0,"company":"Anbison","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Anbison","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anbison \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Anbison \/ Ethypharm"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faes Farma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Upsher-Smith Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Rising Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rising Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Rising Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rising Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Phase I","graph3":"Vanderbilt University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vanderbilt University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Vanderbilt University \/ Pfizer Inc"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Phase IV","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inova Health Care Services \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Inova Health Care Services \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Astellas Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"German Center for Diabetes Research","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Immunology","graph2":"Phase IV","graph3":"German Center for Diabetes Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"German Center for Diabetes Research \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"German Center for Diabetes Research \/ Allergan"},{"orgOrder":0,"company":"ExesaLibero Pharma","sponsor":"SpaceMD","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"N-(3,4-Dichlorophenyl)-N-methylpropanamide","moa":"CYP1A2\/CYP2B6","graph1":"Immunology","graph2":"Preclinical","graph3":"ExesaLibero Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExesaLibero Pharma \/ SpaceMD","highestDevelopmentStatusID":"4","companyTruncated":"ExesaLibero Pharma \/ SpaceMD"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Amsterdam UMC, VUmc","sponsor":"ZonMw | Academisch Medisch Centrum - Universiteit van Amsterdam | Tergooi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxygen","moa":"Cytochrome c oxidase subunit 1; NADPH oxidase 1","graph1":"Immunology","graph2":"Phase IV","graph3":"Amsterdam UMC, VUmc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amsterdam UMC, VUmc \/ ZonMw | Academisch Medisch Centrum - Universiteit van Amsterdam | Tergooi Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Amsterdam UMC, VUmc \/ ZonMw | Academisch Medisch Centrum - Universiteit van Amsterdam | Tergooi Hospital"},{"orgOrder":0,"company":"Samsung Medical Center","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Immunology","graph2":"Phase IV","graph3":"Samsung Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Samsung Medical Center \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Samsung Medical Center \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Posaconazole","moa":"Cytochrome P450 51","graph1":"Immunology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Spermidine","moa":"Cytoplasmic thioredoxin reductase (TXNRD1)||TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Momenta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Momenta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Trethera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ National Institutes of Health"},{"orgOrder":0,"company":"Trethera","sponsor":"Small Business Innovation Research","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Small Business Innovation Research","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ Small Business Innovation Research"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institutes of Health"},{"orgOrder":0,"company":"UMC Utrecht","sponsor":"Radboud University Medical Center | Utrecht University | Trajectum Pharma B.V. | Dutch Arthritis Association | ZonMw | Health Holland","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TolDCB29","moa":"Dendritic cell","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"UMC Utrecht","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UMC Utrecht \/ Radboud University Medical Center | Utrecht University | Trajectum Pharma B.V. | Dutch Arthritis Association | ZonMw | Health Holland","highestDevelopmentStatusID":"7","companyTruncated":"UMC Utrecht \/ Radboud University Medical Center | Utrecht University | Trajectum Pharma B.V. | Dutch Arthritis Association | ZonMw | Health Holland"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Public Offering","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Cowen"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ University of Pennsylvania"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Hofseth BioCare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Partnership","leadProduct":"DHA","moa":"||DHA level","graph1":"Immunology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Catalent Pharma Solutions \/ Hofseth BioCare","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Hofseth BioCare"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Immunology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Immunology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tufts University","sponsor":"Prevention Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tufts University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tufts University \/ Prevention Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Tufts University \/ Prevention Pharmaceuticals"},{"orgOrder":0,"company":"University of Florida","sponsor":"National Institute on Aging | Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Omega-3 Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Immunology","graph2":"Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Florida \/ National Institute on Aging | Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"University of Florida \/ National Institute on Aging | Abbott Laboratories"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Patient-Centered Outcomes Research Institute | ImproveCareNow | Helmsley Charitable Trust | Children's Hospital Medical Center, Cincinnati | Grifols Diagnostics Solutions, Inc | National Institutes of Health | National Institute of Arthritis and Musculosk","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Patient-Centered Outcomes Research Institute | ImproveCareNow | Helmsley Charitable Trust | Children's Hospital Medical Center, Cincinnati | Grifols Diagnostics Solutions, Inc | National Institutes of Health | National Institute of Arthritis and Musculosk","highestDevelopmentStatusID":"10","companyTruncated":"University of North Carolina \/ Patient-Centered Outcomes Research Institute | ImproveCareNow | Helmsley Charitable Trust | Children's Hospital Medical Center, Cincinnati | Grifols Diagnostics Solutions, Inc | National Institutes of Health | National Institute of Arthritis and Musculosk"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Sun Yat-sen University \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Keio University","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"Keio University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keio University \/ Eisai","highestDevelopmentStatusID":"11","companyTruncated":"Keio University \/ Eisai"},{"orgOrder":0,"company":"Keio University","sponsor":"Eisai | Mebix","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"Keio University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keio University \/ Eisai | Mebix","highestDevelopmentStatusID":"11","companyTruncated":"Keio University \/ Eisai | Mebix"},{"orgOrder":0,"company":"Eisai","sponsor":"Nippon Medac","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Nippon Medac","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Nippon Medac"},{"orgOrder":0,"company":"Eisai","sponsor":"Nippon Medac","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Nippon Medac","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Nippon Medac"},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"Mycenax Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mycenax Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mycenax Biotech \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"The Research Council of Norway | South-Eastern Norway Regional Health Authority | Remedy","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ The Research Council of Norway | South-Eastern Norway Regional Health Authority | Remedy","highestDevelopmentStatusID":"11","companyTruncated":"Oslo University Hospital \/ The Research Council of Norway | South-Eastern Norway Regional Health Authority | Remedy"},{"orgOrder":0,"company":"SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase II","graph3":"SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd \/ Undisclosed"},{"orgOrder":0,"company":"SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase II","graph3":"SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"medac \/ PPD","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ PPD"},{"orgOrder":0,"company":"medac","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"medac \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Eisai"},{"orgOrder":0,"company":"Therakind","sponsor":"Shorla Oncology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Acquisition","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Therakind","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Therakind \/ Shorla Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Therakind \/ Shorla Oncology"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Biogen","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Biogen"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"The Arthritis Society, Canada | University of Calgary | The Hospital for Sick Children | McGill University Health Centre Research Institute | London Health Sciences Centre | University of Manitoba | Alberta Children's Hospital | McMaster University | McMa","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ The Arthritis Society, Canada | University of Calgary | The Hospital for Sick Children | McGill University Health Centre Research Institute | London Health Sciences Centre | University of Manitoba | Alberta Children's Hospital | McMaster University | McMa","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ The Arthritis Society, Canada | University of Calgary | The Hospital for Sick Children | McGill University Health Centre Research Institute | London Health Sciences Centre | University of Manitoba | Alberta Children's Hospital | McMaster University | McMa"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antares Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Acquisition","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Antares Pharma \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase II","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Alimentiv \/ Abbott Laboratories"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antares Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Flinders University","sponsor":"University of South Australia | medac","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase IV","graph3":"Flinders University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flinders University \/ University of South Australia | medac","highestDevelopmentStatusID":"11","companyTruncated":"Flinders University \/ University of South Australia | medac"},{"orgOrder":0,"company":"University of S\u00e3o Paulo General Hospital","sponsor":"Libbs Farmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"University of S\u00e3o Paulo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of S\u00e3o Paulo General Hospital \/ Libbs Farmaceutica","highestDevelopmentStatusID":"7","companyTruncated":"University of S\u00e3o Paulo General Hospital \/ Libbs Farmaceutica"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Farudodstat","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ASLAN Pharmaceuticals \/ K2 HealthVentures","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ K2 HealthVentures"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Farudodstat","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Farudodstat","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"IMU-838","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | ","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Leflunomide","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | ","highestDevelopmentStatusID":"1","companyTruncated":"Chinese SLE Treatment And Research Group \/ Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | "},{"orgOrder":0,"company":"Fosun Wanbang Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fosun Wanbang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Fosun Wanbang Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Wanbang Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Leflunomide","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Peking University Health Science Center | Cisen Pharmaceutical Co. - Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University People's Hospital \/ Peking University Health Science Center | Cisen Pharmaceutical Co. - Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Peking University People's Hospital \/ Peking University Health Science Center | Cisen Pharmaceutical Co. - Ltd"},{"orgOrder":0,"company":"Adienne","sponsor":"Adienne","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Begelomab","moa":"Dipeptidyl peptidase IV","graph1":"Immunology","graph2":"Phase III","graph3":"Adienne","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Adienne \/ Adienne","highestDevelopmentStatusID":"10","companyTruncated":"Adienne \/ Adienne"},{"orgOrder":0,"company":"Shanghai GeneChem","sponsor":"RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Immunology","graph2":"Phase I","graph3":"Shanghai GeneChem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai GeneChem \/ RenJi Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai GeneChem \/ RenJi Hospital"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Preclinical","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Chord Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ EMD Serono","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ EMD Serono"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"DKMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"DKMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DKMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DKMS \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Dimitrios Tzachanis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"Dimitrios Tzachanis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dimitrios Tzachanis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dimitrios Tzachanis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Genentech | National Eye Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Illinois, Chicago \/ Genentech | National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"University of Illinois, Chicago \/ Genentech | National Eye Institute"},{"orgOrder":0,"company":"Universit\u00e4tsklinikum Hamburg-Eppendorf","sponsor":"Therakos | University Medical Center Regensburg | Arbeitskreis Klinische Forschung PD Dr. med. Seiler GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"Universit\u00e4tsklinikum Hamburg-Eppendorf","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Therakos | University Medical Center Regensburg | Arbeitskreis Klinische Forschung PD Dr. med. Seiler GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Therakos | University Medical Center Regensburg | Arbeitskreis Klinische Forschung PD Dr. med. Seiler GmbH"},{"orgOrder":0,"company":"CVC Capital Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"CVC Capital Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CVC Capital Partners \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CVC Capital Partners \/ Undisclosed"},{"orgOrder":0,"company":"CVC Capital Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"CVC Capital Partners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CVC Capital Partners \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CVC Capital Partners \/ Undisclosed"},{"orgOrder":0,"company":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","sponsor":"Effice Servicios Para la Investigacion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa \/ Effice Servicios Para la Investigacion","highestDevelopmentStatusID":"10","companyTruncated":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa \/ Effice Servicios Para la Investigacion"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Hamilton Academic Health Sciences Organization","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Hamilton Academic Health Sciences Organization","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Hamilton Academic Health Sciences Organization"},{"orgOrder":0,"company":"Entero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Entero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Entero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Entero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Niclosamide","moa":"DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Niclosamide","moa":"DNA","graph1":"Immunology","graph2":"IND Enabling","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"PPD \/ First Wave BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"PPD \/ First Wave BioPharma"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azathioprine","moa":"DNA | Amidophosphoribosyltransferase","graph1":"Immunology","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinese SLE Treatment And Research Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Kyungpook National University Hospital","sponsor":"Celltrion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Azathioprine","moa":"DNA | Amidophosphoribosyltransferase","graph1":"Immunology","graph2":"Phase IV","graph3":"Kyungpook National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyungpook National University Hospital \/ Celltrion","highestDevelopmentStatusID":"11","companyTruncated":"Kyungpook National University Hospital \/ Celltrion"},{"orgOrder":0,"company":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Azathioprine","moa":"DNA | Amidophosphoribosyltransferase","graph1":"Immunology","graph2":"Phase IV","graph3":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Azathioprine","moa":"DNA | Amidophosphoribosyltransferase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","highestDevelopmentStatusID":"1","companyTruncated":"Nantes University Hospital \/ Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Azathioprine","moa":"DNA | Amidophosphoribosyltransferase","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"RenJi Hospital","sponsor":"Shanghai Simnova Biotechnology Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Immunology","graph2":"Phase I","graph3":"RenJi Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RenJi Hospital \/ Shanghai Simnova Biotechnology Co.,Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"RenJi Hospital \/ Shanghai Simnova Biotechnology Co.,Ltd."},{"orgOrder":0,"company":"CellSight Technologies","sponsor":"Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"18-F AraG","moa":"DNA synthesis","graph1":"Immunology","graph2":"Phase I","graph3":"CellSight Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellSight Technologies \/ Stanford University","highestDevelopmentStatusID":"6","companyTruncated":"CellSight Technologies \/ Stanford University"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Immunology","graph2":"Phase III","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Virginia Commonwealth University \/ Merck & Co"},{"orgOrder":0,"company":"K-PAX Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Immunology","graph2":"Phase II","graph3":"K-PAX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"K-PAX Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"K-PAX Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Immunology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Undisclosed"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MetaBlok","moa":"DPEP1","graph1":"Immunology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Undisclosed"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Private Placement","leadProduct":"SL-325","moa":"DR3","graph1":"Immunology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ OrbiMed"},{"orgOrder":0,"company":"Theraly Fibrosis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TLY012","moa":"DR5","graph1":"Immunology","graph2":"Preclinical","graph3":"Theraly Fibrosis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theraly Fibrosis \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Theraly Fibrosis \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sibofimloc","moa":"Bacterial Fimbrin D-mannose adhesin (Bact FimH)||E.coli fimH protein","graph1":"Immunology","graph2":"Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sibofimloc","moa":"E.coli fimH protein","graph1":"Immunology","graph2":"Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sibofimloc","moa":"E.coli fimH protein","graph1":"Immunology","graph2":"Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TAK-018","moa":"E.coli fimH protein","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Iguratimod","moa":"E3 ubiquitin ligase TRAF3IP2 | Cyclooxygenase-2 | Macrophage migration inhibitory factor","graph1":"Immunology","graph2":"Phase IV","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Iguratimod","moa":"E3 ubiquitin ligase TRAF3IP2 | Cyclooxygenase-2 | Macrophage migration inhibitory factor","graph1":"Immunology","graph2":"Phase IV","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Iguratimod","moa":"E3 ubiquitin ligase TRAF3IP2 | Cyclooxygenase-2 | Macrophage migration inhibitory factor","graph1":"Immunology","graph2":"Phase IV","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Iguratimod","moa":"E3 ubiquitin ligase TRAF3IP2 | Cyclooxygenase-2 | Macrophage migration inhibitory factor","graph1":"Immunology","graph2":"Phase IV","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Iguratimod","moa":"E3 ubiquitin ligase TRAF3IP2 | Cyclooxygenase-2 | Macrophage migration inhibitory factor","graph1":"Immunology","graph2":"Phase IV","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iguratimod","moa":"E3 ubiquitin ligase TRAF3IP2 | Cyclooxygenase-2 | Macrophage migration inhibitory factor","graph1":"Immunology","graph2":"Phase II","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Partnership","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Atara Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Atara Biotherapeutics"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0.37,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Partnership","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0.67000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.67000000000000004,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0.37,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Fujifilm Diosynth Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Partnership","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Fujifilm Diosynth Biotechnologies","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Fujifilm Diosynth Biotechnologies"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biotherapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hebei Yanda Ludaopei Hospital","sponsor":"China Immunotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"EBV-TCR-T Cell","moa":"EBV antigens","graph1":"Immunology","graph2":"Phase I","graph3":"Hebei Yanda Ludaopei Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hebei Yanda Ludaopei Hospital \/ China Immunotech","highestDevelopmentStatusID":"6","companyTruncated":"Hebei Yanda Ludaopei Hospital \/ China Immunotech"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"F8IL10","moa":"EDB-fibronectin \/ IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"F8IL10","moa":"EDB-fibronectin \/ IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"F8IL10","moa":"EDB-fibronectin \/ IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Immunology","graph2":"Phase II","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Edinburgh \/ Travere Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"University of Edinburgh \/ Travere Therapeutics"},{"orgOrder":0,"company":"Heidelberg University","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"Phase II","graph3":"Heidelberg University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heidelberg University \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Heidelberg University \/ GSK"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Gilead Sciences"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Pennsylvania \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Gilead Sciences"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"Phase IV","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Groningen \/ Johnson & Johnson"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Macitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sitaxentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"IND Enabling","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Enavate Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Enavate Sciences"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Hercules Capital","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Alladapt Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Altasciences Company Inc \/ Alladapt Immunotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Altasciences Company Inc \/ Alladapt Immunotherapeutics"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series C Financing","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Gurnet Point Capital","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Gurnet Point Capital"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Immunology","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0.40999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"JPEO-CBRND","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Immunology","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"SIGA Technologies \/ JPEO-CBRND","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ JPEO-CBRND"},{"orgOrder":0,"company":"Italfarmaco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"enzyme inhibitors: inhibitors of histone deacetylase; vinca alkaloids","graph1":"Immunology","graph2":"Phase II","graph3":"Italfarmaco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Italfarmaco \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Italfarmaco \/ Undisclosed"},{"orgOrder":0,"company":"Italfarmaco","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"enzyme inhibitors: inhibitors of histone deacetylase; vinca alkaloids","graph1":"Immunology","graph2":"Phase II","graph3":"Italfarmaco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Italfarmaco \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Italfarmaco \/ Parexel"},{"orgOrder":0,"company":"Immune Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Bertilimumab","moa":"Eotaxin","graph1":"Immunology","graph2":"Phase II","graph3":"Immune Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immune Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immune Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Immune Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Bertilimumab","moa":"Eotaxin","graph1":"Immunology","graph2":"Phase II","graph3":"Immune Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immune Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immune Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HTL0033744","moa":"EP4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Olmutinib","moa":"Epidermal growth factor receptor erbB1||Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GRWD0715","moa":"ERAP1","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hanyang University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bazedoxifene","moa":"Estrogen receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Hanyang University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanyang University \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Hanyang University \/ Pfizer Inc"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ethinyl Estradiol","moa":"Estrogen receptor alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"University College, London","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Calcium Ion","moa":"Factor XIII","graph1":"Immunology","graph2":"Phase II","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University College, London \/ CSL Behring","highestDevelopmentStatusID":"8","companyTruncated":"University College, London \/ CSL Behring"},{"orgOrder":0,"company":"Bnai Zion Medical Center","sponsor":"Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Disodium Pamidronate Pentahydrate","moa":"Farnesyl diphosphate synthase","graph1":"Immunology","graph2":"Phase IV","graph3":"Bnai Zion Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bnai Zion Medical Center \/ Janssen-Cilag","highestDevelopmentStatusID":"11","companyTruncated":"Bnai Zion Medical Center \/ Janssen-Cilag"},{"orgOrder":0,"company":"PinCell","sponsor":"Scinai Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"PC111","moa":"FasL","graph1":"Immunology","graph2":"Preclinical","graph3":"PinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PinCell \/ Scinai Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PinCell \/ Scinai Immunotherapeutics"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal troponin complex","graph1":"Immunology","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cytokinetics \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AllerQuest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2013","type":"Inapplicable","leadProduct":"Benzylpenicilloyl G Polylysine","moa":"FCER1A","graph1":"Immunology","graph2":"Phase III","graph3":"AllerQuest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AllerQuest \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AllerQuest \/ Undisclosed"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NVG-2089","moa":"Fc-gamma receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Nuvig Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvig Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nuvig Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":1.27,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.75,"dosageForm":"Injection","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":1.27,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.75,"dosageForm":"Injection","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"||FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Efgartigimod","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Injection","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Argenx"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Argenx"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Halozyme Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zai Lab \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Argenx","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0.75,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.75,"dosageForm":"Infusion","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Medison Pharma"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soleo Health \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Argenx"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Argenx"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Argenx"},{"orgOrder":0,"company":"Elektrofi","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Elektrofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elektrofi \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Elektrofi \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod PH20","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Immunovant","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Preclinical","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanall Biopharma \/ Immunovant","highestDevelopmentStatusID":"4","companyTruncated":"Hanall Biopharma \/ Immunovant"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Private Placement","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.45000000000000001,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"REGN1908","moa":"Fel d 1 (cat allergen)","graph1":"Immunology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"REGN1908","moa":"Fel d 1 (cat allergen)","graph1":"Immunology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"REGN1908","moa":"Fel d 1 (cat allergen)","graph1":"Immunology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"REGN5713","moa":"Fel d 1 (cat allergen)","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"REGN5713","moa":"Fel d 1 (cat allergen)","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"REGN5713","moa":"Fel d 1 (cat allergen)","graph1":"Immunology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kunming Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Immunology","graph2":"Phase II","graph3":"Kunming Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kunming Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kunming Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor | Stem cell growth factor receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor | Stem cell growth factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Seoul St. Mary's Hospital","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Seoul St. Mary's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul St. Mary's Hospital \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Seoul St. Mary's Hospital \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","sponsor":"Deutsche Klinik f\u00fcr Diagnostik | ClinAssess","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Serum","sponsorNew":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH \/ Deutsche Klinik f\u00fcr Diagnostik | ClinAssess","highestDevelopmentStatusID":"8","companyTruncated":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH \/ Deutsche Klinik f\u00fcr Diagnostik | ClinAssess"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Colorado, Denver \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of South Carolina \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Medical University of South Carolina \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Hospital do Rim e Hipertens\u00e3o","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Hospital do Rim e Hipertens\u00e3o","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital do Rim e Hipertens\u00e3o \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Hospital do Rim e Hipertens\u00e3o \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Andre Barreto Pereira","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Andre Barreto Pereira","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andre Barreto Pereira \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Andre Barreto Pereira \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Peking University First Hospital","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Peking University First Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Peking University First Hospital \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Peking University First Hospital \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Beijing Municipal Science & Technology Commission | North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Beijing Municipal Science & Technology Commission | North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Chinese SLE Treatment And Research Group \/ Beijing Municipal Science & Technology Commission | North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"PALADIN LABS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Paladin Labs","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Paladin Labs"},{"orgOrder":0,"company":"Chang Gung Memorial Hospital","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chang Gung Memorial Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chang Gung Memorial Hospital \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Chang Gung Memorial Hospital \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Nantes University Hospital \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"Nantes University Hospital \/ Chiesi Group"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Cromsource","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Cromsource","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Cromsource"},{"orgOrder":0,"company":"Auritec Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"Auritec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Auritec Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Auritec Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Davis \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Davis \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University of Southern California","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Southern California \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"University of Colorado, Denver \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"University of Colorado, Denver \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Undisclosed","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Northwestern University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"PALADIN LABS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"University of British Columbia \/ Paladin Labs","highestDevelopmentStatusID":"11","companyTruncated":"University of British Columbia \/ Paladin Labs"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ Astellas Pharma"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Vanderbilt University Medical Center \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Vanderbilt University Medical Center \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Sentara Norfolk General Hospital","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Sentara Norfolk General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sentara Norfolk General Hospital \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sentara Norfolk General Hospital \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medical College of Wisconsin \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Medical College of Wisconsin \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Columbia University","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Columbia University \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Columbia University \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Novotech"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"8","companyTruncated":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Cedars-Sinai \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Linical","sponsor":"Astellas Pharma | National Cancer Center, Korea","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Linical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linical \/ Astellas Pharma | National Cancer Center, Korea","highestDevelopmentStatusID":"11","companyTruncated":"Linical \/ Astellas Pharma | National Cancer Center, Korea"},{"orgOrder":0,"company":"Klemens Budde","sponsor":"Charite University, Berlin, Germany | European Renal Association - European Dialysis and Transplant Association | European Kidney Transplant Association | DESCARTES Working Group On Transplantation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Klemens Budde","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Klemens Budde \/ Charite University, Berlin, Germany | European Renal Association - European Dialysis and Transplant Association | European Kidney Transplant Association | DESCARTES Working Group On Transplantation","highestDevelopmentStatusID":"11","companyTruncated":"Klemens Budde \/ Charite University, Berlin, Germany | European Renal Association - European Dialysis and Transplant Association | European Kidney Transplant Association | DESCARTES Working Group On Transplantation"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase I","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"HZN-1116","moa":"Flt3L","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"E6011","moa":"Fractalkine","graph1":"Immunology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"E6011","moa":"Fractalkine","graph1":"Immunology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"E6011","moa":"Fractalkine","graph1":"Immunology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"E6011","moa":"Fractalkine","graph1":"Immunology","graph2":"Phase II","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EA Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EA Pharma \/ Undisclosed"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"E6011","moa":"Fractalkine","graph1":"Immunology","graph2":"Phase II","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EA Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EA Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"E6011","moa":"Fractalkine","graph1":"Immunology","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kancera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KAND567","moa":"Fractalkine receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Kancera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kancera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kancera \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"GLPG0974","moa":"Free fatty acid receptor 2","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Rozibafusp Alfa","moa":"fusion proteins","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Rozibafusp Alfa","moa":"fusion proteins","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Carbohydrate","year":"2020","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ACT-129968","moa":"G protein-coupled receptor 44","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ACT-129968","moa":"G protein-coupled receptor 44","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"AZD1981","moa":"G protein-coupled receptor 44","graph1":"Immunology","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ AstraZeneca"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fevipiprant","moa":"G protein-coupled receptor 44","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Oxagen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"OC000459","moa":"G protein-coupled receptor 44","graph1":"Immunology","graph2":"Phase II","graph3":"Oxagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxagen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxagen \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"QAV680","moa":"G protein-coupled receptor 44","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Magnesium","moa":"GABA-B receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Ghent \/ Astellas Pharma"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ UCB Pharma S.A","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Ghent \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Froniglutide","moa":"GLP-1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunoforge \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunoforge \/ Undisclosed"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Froniglutide","moa":"GLP-1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunoforge \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunoforge \/ Undisclosed"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AgelessRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AgelessRx \/ Undisclosed"},{"orgOrder":0,"company":"VectivBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Undisclosed"},{"orgOrder":0,"company":"VectivBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Undisclosed"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"VectivBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Undisclosed"},{"orgOrder":0,"company":"VectivBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP2R","graph1":"Immunology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Novo Nordisk"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Luoxin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Marinomed Biotech","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"Marinomed Biotech \/ Luoxin Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Marinomed Biotech \/ Luoxin Pharmaceutical"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Prednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tongren Hospital","sponsor":"Beijing Institute of Otolaryngology | Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Beijing Tongren Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beijing Tongren Hospital \/ Beijing Institute of Otolaryngology | Johnson & Johnson","highestDevelopmentStatusID":"1","companyTruncated":"Beijing Tongren Hospital \/ Beijing Institute of Otolaryngology | Johnson & Johnson"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Reig Jofre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Reig Jofre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reig Jofre \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Reig Jofre \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Cosmo Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Cosmo Technologies","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Cosmo Technologies"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"HANDOK","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HANDOK \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"HANDOK \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apotex Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apotex Inc \/ Undisclosed"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Formosa Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Formosa Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sosei Group Corporation \/ Formosa Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Formosa Laboratories"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2025","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Formosa Pharmaceuticals \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Adalvo"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2025","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Formosa Pharmaceuticals \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Harrow"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Formosa Pharmaceuticals \/ Apotex Inc","highestDevelopmentStatusID":"10","companyTruncated":"Formosa Pharmaceuticals \/ Apotex Inc"},{"orgOrder":0,"company":"Dermtreat","sponsor":"Proinnovera | X-act Cologne Clinical Research GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Dermtreat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Dermtreat \/ Proinnovera | X-act Cologne Clinical Research GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Dermtreat \/ Proinnovera | X-act Cologne Clinical Research GmbH"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"AFYX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"AFYX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"AFYX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NovaBay Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Alliance Global Partners","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Alliance Global Partners"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Undisclosed"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Casa Sollievo della Sofferenza IRCCS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Dex 21-P","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Quince Therapeutics \/ Casa Sollievo della Sofferenza IRCCS","highestDevelopmentStatusID":"8","companyTruncated":"Quince Therapeutics \/ Casa Sollievo della Sofferenza IRCCS"},{"orgOrder":0,"company":"Icon Bioscience Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Icon Bioscience Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Bioscience Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Icon Bioscience Inc \/ Undisclosed"},{"orgOrder":0,"company":"Icon Bioscience Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Icon Bioscience Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Bioscience Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Icon Bioscience Inc \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AcuCort","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AcuCort","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"AcuCort \/ Kamada","highestDevelopmentStatusID":"15","companyTruncated":"AcuCort \/ Kamada"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"QATAR","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts Eye and Ear Infirmary","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Massachusetts Eye and Ear Infirmary","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Massachusetts Eye and Ear Infirmary \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts Eye and Ear Infirmary \/ Ocular Therapeutix"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Pfizer Inc | Minnesota Medical Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ Pfizer Inc | Minnesota Medical Foundation","highestDevelopmentStatusID":"9","companyTruncated":"University of Minnesota \/ Pfizer Inc | Minnesota Medical Foundation"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"ImprimisRx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Collaboration","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ ImprimisRx","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ ImprimisRx"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Public Offering","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Guggenheim Securities","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ Guggenheim Securities"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Vantage Outsourcing","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Vantage Outsourcing","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ Vantage Outsourcing"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Vision Center Network Of America","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Vision Center Network Of America","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ Vision Center Network Of America"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quince Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PIF Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"PIF Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIF Partners \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PIF Partners \/ Undisclosed"},{"orgOrder":0,"company":"National University of Malaysia","sponsor":"HOE Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"MALAYSIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"National University of Malaysia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"National University of Malaysia \/ HOE Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"National University of Malaysia \/ HOE Pharmaceuticals"},{"orgOrder":0,"company":"Noah Rosenberg, MD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Noah Rosenberg, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Noah Rosenberg, MD \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Noah Rosenberg, MD \/ Undisclosed"},{"orgOrder":0,"company":"Creighton University","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Creighton University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Creighton University \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Creighton University \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"University of Aarhus \/ GSK"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ora, Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ora, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"1","companyTruncated":"University of Rochester \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mapracorat","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Oklahoma Medical Research Foundation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Oklahoma Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oklahoma Medical Research Foundation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Oklahoma Medical Research Foundation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Biogen","sponsor":"Perrigo Company plc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Perrigo Company plc","highestDevelopmentStatusID":"11","companyTruncated":"Biogen \/ Perrigo Company plc"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Methylprednisolone Sodium Succinate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Mizacorat Monohydrate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Mizacorat Monohydrate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Actavis Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Actavis Inc \/ Actavis Inc","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Actavis Inc"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2020","type":"Divestment","leadProduct":"Mometasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aurobindo Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Perrigo Company plc \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Organon"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"University of Florida","sponsor":"Food and Drug Administration | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"University of Florida \/ Food and Drug Administration | GSK","highestDevelopmentStatusID":"6","companyTruncated":"University of Florida \/ Food and Drug Administration | GSK"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Amneal Pharmaceuticals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pharmaceuticals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Alkahest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkahest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Zheng Liu ENT","sponsor":"Zhejiang Xianju Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Zheng Liu ENT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Zheng Liu ENT \/ Zhejiang Xianju Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Zheng Liu ENT \/ Zhejiang Xianju Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PF-04171327","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"QATAR","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Zalicus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Zalicus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zalicus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zalicus \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Qilu Stem Cells Engineering Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shandong Qilu Stem Cells Engineering Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Qilu Stem Cells Engineering Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shandong Qilu Stem Cells Engineering Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"McMaster University","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"11","companyTruncated":"McMaster University \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ampel BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Ampel BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ampel BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ampel BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Tom Appleton","sponsor":"Canadian Research Group in Immuno-Oncology | Western University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Tom Appleton","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tom Appleton \/ Canadian Research Group in Immuno-Oncology | Western University","highestDevelopmentStatusID":"8","companyTruncated":"Tom Appleton \/ Canadian Research Group in Immuno-Oncology | Western University"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Allermi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Allermi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Undisclosed"},{"orgOrder":0,"company":"Allermi","sponsor":"Lucas Venture Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Financing","leadProduct":"Triamcinolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Allermi \/ Lucas Venture Group","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Lucas Venture Group"},{"orgOrder":0,"company":"Allermi","sponsor":"Nelstone Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Financing","leadProduct":"Triamcinolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Allermi \/ Nelstone Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Nelstone Ventures"},{"orgOrder":0,"company":"Ethypharm","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ethypharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ethypharm \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ethypharm \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medexus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medexus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AZD9567","moa":"Glucocorticoid receptor messenger RNA (GCR mRNA)","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Agility Life Sciences","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"CDT1656","moa":"Glucokinase","graph1":"Immunology","graph2":"Phase I","graph3":"Agility Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agility Life Sciences \/ Conduit Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Agility Life Sciences \/ Conduit Pharma"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Evergreen Therapeutics | University of Texas Health Science Center at Houston | Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University Medical Center \/ Evergreen Therapeutics | University of Texas Health Science Center at Houston | Cleveland Clinic","highestDevelopmentStatusID":"8","companyTruncated":"Vanderbilt University Medical Center \/ Evergreen Therapeutics | University of Texas Health Science Center at Houston | Cleveland Clinic"},{"orgOrder":0,"company":"Taichung Veterans General Hospital","sponsor":"TSH Biopharm Corporation Limited","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Taichung Veterans General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taichung Veterans General Hospital \/ TSH Biopharm Corporation Limited","highestDevelopmentStatusID":"1","companyTruncated":"Taichung Veterans General Hospital \/ TSH Biopharm Corporation Limited"},{"orgOrder":0,"company":"Immunoflex Therapeutics Inc.","sponsor":"Dicentra Inc. | University of British Columbia","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase||Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Immunology","graph2":"Undisclosed","graph3":"Immunoflex Therapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunoflex Therapeutics Inc. \/ Dicentra Inc. | University of British Columbia","highestDevelopmentStatusID":"1","companyTruncated":"Immunoflex Therapeutics Inc. \/ Dicentra Inc. | University of British Columbia"},{"orgOrder":0,"company":"ImmunoFlex","sponsor":"Chemistree","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Immunology","graph2":"Approved FDF","graph3":"ImmunoFlex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ImmunoFlex \/ Chemistree","highestDevelopmentStatusID":"15","companyTruncated":"ImmunoFlex \/ Chemistree"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"ASP1707","moa":"Gonadotropin-releasing hormone receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"ASP1707","moa":"Gonadotropin-releasing hormone receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Novotech"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Richard King Mellon Foundation"},{"orgOrder":0,"company":"CytoAgents","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ National Institutes of Health"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"GLPG1205","moa":"G-protein coupled receptor 84","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fezagepras","moa":"G-protein coupled receptor 84 | Free fatty acid receptor 1","graph1":"Immunology","graph2":"Phase II","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Liminal BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Liminal BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"GSK3196165","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Morphotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"MORAb-022","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase I","graph3":"Morphotek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Morphotek \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Morphotek \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Izana Bioscience","sponsor":"IQVIA | Innovate UK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase II","graph3":"Izana Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Izana Bioscience \/ IQVIA | Innovate UK","highestDevelopmentStatusID":"8","companyTruncated":"Izana Bioscience \/ IQVIA | Innovate UK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Parexel"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Otilimab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"MorphoSys \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TJ003234","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ MedImmune"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ MedImmune"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tilpisertib Fosmecarbil","moa":"GSK-3","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avenciguat","moa":"GUCY1A","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"FIN-524","moa":"Gut microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Finch Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Finch Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KB295","moa":"Gut microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"KB295","moa":"Gut microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KB295","moa":"Gut microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Connecticut Children's Medical Center","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Lactobacillus Acidophilus","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Connecticut Children's Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Connecticut Children's Medical Center \/ International Flavors and Fragrances","highestDevelopmentStatusID":"8","companyTruncated":"Connecticut Children's Medical Center \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Skyepharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Skyepharma","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Skyepharma"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Bpifrance"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"INRAE","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ INRAE","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ INRAE"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"MaaT013","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Clinigen Group","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Clinigen Group"},{"orgOrder":0,"company":"Skyepharma","sponsor":"MaaT Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"Skyepharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Skyepharma \/ MaaT Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Skyepharma \/ MaaT Pharma"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"EIB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Financing","leadProduct":"MaaT013","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ EIB","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ EIB"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"MB310","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbiotica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Microbiotica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Microbiotica \/ Undisclosed"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MB310","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbiotica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Microbiotica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Microbiotica \/ Undisclosed"},{"orgOrder":0,"company":"MRM Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRM Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Undisclosed"},{"orgOrder":0,"company":"MRM Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRM Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Undisclosed"},{"orgOrder":0,"company":"MRM Health","sponsor":"Biocodex","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Probiotic","year":"2025","type":"Series B Financing","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"MRM Health \/ Biocodex","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Biocodex"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Microbio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Immunology","graph2":"Undisclosed","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"National Taiwan University Hospital \/ Microbio","highestDevelopmentStatusID":"1","companyTruncated":"National Taiwan University Hospital \/ Microbio"},{"orgOrder":0,"company":"Microbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MS-20","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Microbio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Microbio \/ Undisclosed"},{"orgOrder":0,"company":"Emergo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Norketotifen","moa":"H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Emergo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Emergo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Emergo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Citryll","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"89-Zr CIT-013","moa":"H2A | Histone H4","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citryll \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Undisclosed"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Immunology","graph2":"Phase I","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"aTyr Pharma \/ Undisclosed"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Immunology","graph2":"Phase I","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"aTyr Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CKD-506","moa":"HDAC-6","graph1":"Immunology","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"IPP-201101","moa":"Heat shock cognate 71 kDa protein","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"IPP-201101","moa":"Heat shock cognate 71 kDa protein","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Forigerimod","moa":"Heat shock cognate 71 kDa protein","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Forigerimod","moa":"Heat shock cognate 71 kDa protein","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Undisclosed"},{"orgOrder":0,"company":"ZevraDenmark","sponsor":"University of Kansas Medical Center | University College, London","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"heat-shock protein inducers","graph1":"Immunology","graph2":"Phase III","graph3":"ZevraDenmark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZevraDenmark \/ University of Kansas Medical Center | University College, London","highestDevelopmentStatusID":"10","companyTruncated":"ZevraDenmark \/ University of Kansas Medical Center | University College, London"},{"orgOrder":0,"company":"ZevraDenmark","sponsor":"University of Kansas Medical Center | University College, London","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"heat-shock protein inducers","graph1":"Immunology","graph2":"Phase III","graph3":"ZevraDenmark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZevraDenmark \/ University of Kansas Medical Center | University College, London","highestDevelopmentStatusID":"10","companyTruncated":"ZevraDenmark \/ University of Kansas Medical Center | University College, London"},{"orgOrder":0,"company":"Tunitas Therapeutics","sponsor":"Tunitas Therapeutics Australia Pty Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Epsi-Gam","moa":"Hepatitis B virus","graph1":"Immunology","graph2":"Phase I","graph3":"Tunitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tunitas Therapeutics \/ Tunitas Therapeutics Australia Pty Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Tunitas Therapeutics \/ Tunitas Therapeutics Australia Pty Ltd"},{"orgOrder":0,"company":"Indiana University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Boceprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Immunology","graph2":"Phase I","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indiana University \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Indiana University \/ Merck & Co"},{"orgOrder":0,"company":"CorMedix","sponsor":"ARC Dialysis, LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ ARC Dialysis, LLC","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ ARC Dialysis, LLC"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"New Jersey Economic Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Taurolidine","moa":"Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"CorMedix \/ New Jersey Economic Development Authority","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ New Jersey Economic Development Authority"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Suntrust Robinson Humphrey","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Suntrust Robinson Humphrey","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Suntrust Robinson Humphrey"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"ClinConnect","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"AZD1656","moa":"Hexokinase type IV","graph1":"Immunology","graph2":"Phase II","graph3":"ClinConnect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ClinConnect \/ Conduit Pharma","highestDevelopmentStatusID":"8","companyTruncated":"ClinConnect \/ Conduit Pharma"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AZD1656","moa":"Hexokinase type IV","graph1":"Immunology","graph2":"Preclinical","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conduit Pharma \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Conduit Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Creative Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Amniotic Fluid Derived Stem Cell","moa":"HGF-1","graph1":"Immunology","graph2":"Preclinical","graph3":"Creative Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Creative Medical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"GB004","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"GB004","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GB004 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GB004 \/ Undisclosed"},{"orgOrder":0,"company":"University of Alberta","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Human Immunoglobulin G","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Alberta \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"University of Alberta \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Human Immunoglobulin G","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"University of Washington","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Human Normal Immunoglobulin","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ Grifols International"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Immunology","graph2":"Phase IV","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Efprezimod Alfa","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ohio State University | University of Michigan Rogel Cancer Center | Indiana University School of Medicine | Barbara Ann Karmanos Cancer Institute | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Efprezimod Alfa","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Ohio State University | University of Michigan Rogel Cancer Center | Indiana University School of Medicine | Barbara Ann Karmanos Cancer Institute | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Ohio State University | University of Michigan Rogel Cancer Center | Indiana University School of Medicine | Barbara Ann Karmanos Cancer Institute | National Cancer Institute"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"||High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"MEXICO","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laboratorios Silanes \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Silanes \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Loratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Synmosa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Synmosa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Synmosa \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Synmosa \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"ClinResearch | Prolytic GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Viatris \/ ClinResearch | Prolytic GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Viatris \/ ClinResearch | Prolytic GmbH"},{"orgOrder":0,"company":"Viatris","sponsor":"ClinResearch | Prolytic GmbH | pharm-analyt Labor","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Viatris \/ ClinResearch | Prolytic GmbH | pharm-analyt Labor","highestDevelopmentStatusID":"6","companyTruncated":"Viatris \/ ClinResearch | Prolytic GmbH | pharm-analyt Labor"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TURKEY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TURKEY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Novella Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Viatris \/ Novella Clinical","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Novella Clinical"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Apotex Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apotex Inc \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Vivimed Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Vivimed Labs","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivimed Labs \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vivimed Labs \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Faes Farma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Undisclosed"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Faes Farma \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Faes Farma \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Undisclosed"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Tiefenbacher Group \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Undisclosed"},{"orgOrder":0,"company":"Aralez Pharmaceuticals","sponsor":"Miravo Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aralez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aralez Pharmaceuticals \/ Miravo Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Aralez Pharmaceuticals \/ Miravo Healthcare"},{"orgOrder":0,"company":"Nora Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nora Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nora Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nora Pharma \/ Undisclosed"},{"orgOrder":0,"company":"McNeil AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"McNeil AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McNeil AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"McNeil AB \/ Undisclosed"},{"orgOrder":0,"company":"California Allergy and Asthma Medical Group","sponsor":"McNeil Consumer Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"California Allergy and Asthma Medical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"California Allergy and Asthma Medical Group \/ McNeil Consumer Health","highestDevelopmentStatusID":"11","companyTruncated":"California Allergy and Asthma Medical Group \/ McNeil Consumer Health"},{"orgOrder":0,"company":"Queen's University","sponsor":"Biogenics Research Chamber, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Queen's University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Queen's University \/ Biogenics Research Chamber, LLC","highestDevelopmentStatusID":"11","companyTruncated":"Queen's University \/ Biogenics Research Chamber, LLC"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Johnson & Johnson \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Pfizer Inc"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indoco Remedies Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Undisclosed"},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seattle Gummy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gummy \/ Undisclosed"},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seattle Gummy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gummy \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Chlorpheniramine Maleate","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diphenhydramine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Epinastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Opella Healthcare Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Opella Healthcare Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Opella Healthcare Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opella Healthcare Group \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Ltl Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Fexofenadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Ltl Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Ltl Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adelia Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Adelia Therapeutics \/ Cybin","highestDevelopmentStatusID":"15","companyTruncated":"Adelia Therapeutics \/ Cybin"},{"orgOrder":0,"company":"Anergis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Histamine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Anergis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anergis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Anergis \/ Undisclosed"},{"orgOrder":0,"company":"Gordon Sussman Clinical Research","sponsor":"Mast Cell Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Gordon Sussman Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gordon Sussman Clinical Research \/ Mast Cell Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Gordon Sussman Clinical Research \/ Mast Cell Pharmaceuticals"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Levocabastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Association Asthma, Bulgaria","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BULGARIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Association Asthma, Bulgaria","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Association Asthma, Bulgaria \/ UCB Pharma S.A","highestDevelopmentStatusID":"11","companyTruncated":"Association Asthma, Bulgaria \/ UCB Pharma S.A"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Zensei Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Zensei Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Zensei Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Nanhua University","sponsor":"Buddhist Tzu Chi General Hospital | Solano Semiconductor Technology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nanhua University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanhua University \/ Buddhist Tzu Chi General Hospital | Solano Semiconductor Technology","highestDevelopmentStatusID":"1","companyTruncated":"Nanhua University \/ Buddhist Tzu Chi General Hospital | Solano Semiconductor Technology"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Athena Pharmaceutiques \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athena Pharmaceutiques \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Loratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"J.B.Chemicals & Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Loratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"J.B.Chemicals & Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"J.B.Chemicals & Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"J.B.Chemicals & Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Loratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marksans Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Loratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Loratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Loratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ora, Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ora, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Olopatadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Olopatadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Menarini"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hikma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bausch Health \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"GSP 301-2","moa":"Histamine H1 receptor\/Muscarinic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"GSP301","moa":"Histamine H1 receptor\/Muscarinic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"JNJ-38518168","moa":"Histamine H4 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"JNJ-38518168","moa":"Histamine H4 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JNJ-38518168","moa":"Histamine H4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Palau Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"UR-63325","moa":"Histamine H4 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palau Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palau Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palau Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Immunology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Moffitt Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Immunology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK3117391","moa":"Histone deacetylase (HDAC)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"TX200","moa":"HLA-A2 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"TX200","moa":"HLA-A2 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Milatuzumab","moa":"HLA-DR antigens-associated invariant chain","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Ohio State University","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Ohio State University"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Milatuzumab","moa":"HLA-DR antigens-associated invariant chain","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ US Department of Defense"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"VIB","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ VIB","highestDevelopmentStatusID":"9","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ VIB"},{"orgOrder":0,"company":"Prolong Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Pegylated Carboxyhemoglobin Bovine","moa":"Homeostasis","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Prolong Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prolong Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Prolong Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Prolong Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Pegylated Carboxyhemoglobin Bovine","moa":"Homeostasis","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Prolong Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prolong Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Prolong Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Perfluorobutane","moa":"Homeostasis","graph1":"Immunology","graph2":"Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Brigham and Women's Hospital \/ GE Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Brigham and Women's Hospital \/ GE Healthcare"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"RLYB212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"RLYB212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"RLYB212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme \/ Undisclosed"},{"orgOrder":0,"company":"Nippon Kayaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Gusperimus","moa":"Hsp70","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nippon Kayaku","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nippon Kayaku \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nippon Kayaku \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Viracor Eurofins","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Valganciclovir Hydrochloride","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Immunology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Insert","sponsorNew":"NYU Langone Health \/ Viracor Eurofins","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Viracor Eurofins"},{"orgOrder":0,"company":"Northwell Health","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Nelfinavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Immunology","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Northwell Health \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | National Human Genome Research Institute | Gilead Sciences | Emerson Resources | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Gansu Provincial Maternal and Child Health Care Hospital | National Human Genome Research Institute | Gilead Sciences | Emerson Resources | National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Children's Hospital of Philadelphia \/ Gansu Provincial Maternal and Child Health Care Hospital | National Human Genome Research Institute | Gilead Sciences | Emerson Resources | National Institutes of Health"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Hyaluronidase","moa":"Hyaluronic acid","graph1":"Immunology","graph2":"Phase II","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"ICOS","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Acazicolcept","moa":"ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.87,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.87,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Immune Sciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Acazicolcept","moa":"ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Immune Sciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Private Placement","leadProduct":"Acazicolcept","moa":"ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Immune Sciences \/ Omega Funds"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"ICOS","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"ICOS","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"ICOS","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AMG557","moa":"ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AMG557","moa":"ICOS","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AMG557","moa":"ICOS","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AMG557","moa":"ICOS","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AMG570","moa":"ICOSL\/BAFF","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Neovacs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Interferon Alpha Kinoid","moa":"IFN-?","graph1":"Immunology","graph2":"Phase II","graph3":"Neovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neovacs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neovacs \/ Undisclosed"},{"orgOrder":0,"company":"Neovacs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Interferon Alpha Kinoid","moa":"IFN-?","graph1":"Immunology","graph2":"Phase II","graph3":"Neovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neovacs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neovacs \/ Undisclosed"},{"orgOrder":0,"company":"Neovacs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Ifn-Kinoid","moa":"IFN-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Neovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neovacs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neovacs \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"JNJ-55920839","moa":"IFN-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Ainos","sponsor":"Taiwan Tanabe Seiyaku","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Partnership","leadProduct":"Interferon Alpha","moa":"IFNAR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Taiwan Tanabe Seiyaku","highestDevelopmentStatusID":"15","companyTruncated":"Ainos \/ Taiwan Tanabe Seiyaku"},{"orgOrder":0,"company":"Ainos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"IFNAR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ainos \/ Undisclosed"},{"orgOrder":0,"company":"Ainos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"IFNAR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ainos \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interferon Beta","moa":"IFNAR1","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AMG811","moa":"IFN-gamma","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"AMG811","moa":"IFN-gamma","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Immunology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Immunology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Immunology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P39","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"MEMP1972A","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"Adverse Drug Reactions, Advice and Consulting ADR-AC | University of Bern | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ Adverse Drug Reactions, Advice and Consulting ADR-AC | University of Bern | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"9","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ Adverse Drug Reactions, Advice and Consulting ADR-AC | University of Bern | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ Genentech"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Genentech"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Wisconsin, Madison \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of Wisconsin, Madison \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Jewish Health \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"National Jewish Health \/ Genentech"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"COD Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ COD Research","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ COD Research"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Genentech | Novartis Pharmaceuticals Corporation | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Genentech | Novartis Pharmaceuticals Corporation | Rho, Inc","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Genentech | Novartis Pharmaceuticals Corporation | Rho, Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"QGE031","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"QGE031","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"QGE031","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"QGE031","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Baike","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SYN008","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase III","graph3":"CSPC Baike","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC Baike \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Baike \/ Undisclosed"},{"orgOrder":0,"company":"Desentum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DM-101","moa":"IgE","graph1":"Immunology","graph2":"Phase I","graph3":"Desentum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Desentum \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Desentum \/ Undisclosed"},{"orgOrder":0,"company":"Desentum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"DM-101","moa":"IgE","graph1":"Immunology","graph2":"Phase I","graph3":"Desentum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Desentum \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Desentum \/ Undisclosed"},{"orgOrder":0,"company":"Desentum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DM-101PX","moa":"IgE","graph1":"Immunology","graph2":"Phase I","graph3":"Desentum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Desentum \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Desentum \/ Undisclosed"},{"orgOrder":0,"company":"Probelte Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"House Dust Mite Allergoid","moa":"IgE","graph1":"Immunology","graph2":"Phase III","graph3":"Probelte Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probelte Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Probelte Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"JYB1904","moa":"IgE","graph1":"Immunology","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ADL-018","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S\u20118484","moa":"IgE receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Seismic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"UBP Greater China (Shanghai) Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase I","graph3":"UBP Greater China (Shanghai) Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UBP Greater China (Shanghai) Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"UBP Greater China (Shanghai) Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Xencor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"XmAb7195","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xencor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Undisclosed"},{"orgOrder":0,"company":"Xencor","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"XmAb7195","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Aimmune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Aimmune Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lonigutamab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lonigutamab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lonigutamab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"ValenzaBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lonigutamab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"ValenzaBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ValenzaBio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ValenzaBio \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Teprotumumab N01","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Miragen Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Miragen Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"5","companyTruncated":"Miragen Therapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Viridian Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Viridian Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Sciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Viridian Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Sciences","sponsor":"Miragen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Viridian Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Sciences \/ Miragen Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Viridian Sciences \/ Miragen Therapeutics"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VRDN-002","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VRDN-002","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VelaVigo","sponsor":"Ollin Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"VBS-102","moa":"IGF-1 receptor\/TSHR","graph1":"Immunology","graph2":"Preclinical","graph3":"VelaVigo","amount2":0.44,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.44,"dosageForm":"Undisclosed","sponsorNew":"VelaVigo \/ Ollin Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"VelaVigo \/ Ollin Biosciences"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1|IGF-2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BHV-1300","moa":"IgG","graph1":"Immunology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BHV-1300","moa":"IgG","graph1":"Immunology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Rho D Immune Globulin","moa":"IgG","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Octanorm","moa":"IgG","graph1":"Immunology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"CSL Behring | Association ASLUMARE","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Privigen","moa":"IgG","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ CSL Behring | Association ASLUMARE","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ CSL Behring | Association ASLUMARE"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"S-1117","moa":"IgG","graph1":"Immunology","graph2":"Preclinical","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Seismic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S\u20111117","moa":"IgG","graph1":"Immunology","graph2":"Phase I","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seismic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seismic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Cyrus Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CYR212","moa":"IgG level","graph1":"Immunology","graph2":"Preclinical","graph3":"Cyrus Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cyrus Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cyrus Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"ALXN1830","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ALXN1830","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Nona Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanall Biopharma \/ Nona Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Nona Biosciences"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanall Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Immunovant \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ SVB Securities"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"CSPC Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ CSPC Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ CSPC Pharmaceutical Group"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Financing","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Roivant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Roivant Sciences"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Hudson Bay Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series C Financing","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Hudson Bay Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Hudson Bay Capital"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BlackRock Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ BlackRock Fund","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ BlackRock Fund"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Immunovant \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ SVB Leerink"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Quintiles Inc","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Quintiles Inc"},{"orgOrder":0,"company":"Argenx","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Quintiles Inc","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Quintiles Inc"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ IQVIA"},{"orgOrder":0,"company":"Argenx","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ IQVIA"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Argenx","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ Argenx"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Colorado, Denver \/ Argenx","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ Argenx"},{"orgOrder":0,"company":"Clinique Neuro-Outaouais","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Clinique Neuro-Outaouais","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clinique Neuro-Outaouais \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Clinique Neuro-Outaouais \/ Argenx"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme Therapeutics \/ Argenx"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"HBM9161","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"HBM9161","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HBM9161","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"HBM9161","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"HBM9161","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"M281","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"M281","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Momenta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":6.5,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":6.5,"dosageForm":"Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Pharmaceuticals \/ Johnson & Johnson"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":6.5,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":6.5,"dosageForm":"Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Pharmaceuticals \/ Johnson & Johnson"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Momenta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Momenta Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Momenta Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"RVT-1401","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"RVT-1401","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"RVT-1401","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"UCB7665","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"GlycoEra","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Series B Financing","leadProduct":"GE8820","moa":"IgG4","graph1":"Immunology","graph2":"Preclinical","graph3":"GlycoEra","amount2":0.13,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"GlycoEra \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"GlycoEra \/ Novo Holdings"},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PN-1007","moa":"IgM","graph1":"Immunology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polyneuron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PN-1007","moa":"IgM","graph1":"Immunology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polyneuron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Cantargia AB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Cantargia AB","highestDevelopmentStatusID":"4","companyTruncated":"BioInvent \/ Cantargia AB"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"West China Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GenSci048","moa":"IL-1?","graph1":"Immunology","graph2":"Phase II","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ West China Hospital","highestDevelopmentStatusID":"8","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ West China Hospital"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ BofA Securities"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"BT063","moa":"IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biotest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ Undisclosed"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10R","graph1":"Immunology","graph2":"Phase II","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xalud Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xalud Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Series B Financing","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Lassen Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Lassen Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Lassen Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lassen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"ASLAN004","moa":"IL-13-alpha-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASLAN Pharmaceuticals \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ IQVIA"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Gumokimab","moa":"IL-17","graph1":"Immunology","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"LY3114062","moa":"IL-17\/TNF-?","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Genakumab","moa":"IL-17A","graph1":"Immunology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Genakumab","moa":"IL-17A","graph1":"Immunology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK111","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK111","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CEL-4000","moa":"IL-17-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEL-SCI \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"CEL-SCI \/ National Institutes of Health"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"GSK | University Hospital Birmingham","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"GSK1070806","moa":"IL-18","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Birmingham \/ GSK | University Hospital Birmingham","highestDevelopmentStatusID":"7","companyTruncated":"University of Birmingham \/ GSK | University Hospital Birmingham"},{"orgOrder":0,"company":"AprilBio","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"EVO301","moa":"IL-18 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AprilBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AprilBio \/ Evommune","highestDevelopmentStatusID":"6","companyTruncated":"AprilBio \/ Evommune"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AB2 Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Tadekinig Alpha","moa":"IL-18 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ AB2 Bio","highestDevelopmentStatusID":"10","companyTruncated":"WuXi Biologics \/ AB2 Bio"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vilamakitug","moa":"IL1A","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vilamakitug","moa":"IL1A","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"ISB 880","moa":"IL-1RAP","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ichnos Sciences \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Ichnos Sciences \/ Almirall"},{"orgOrder":0,"company":"Cugene","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"CUG252","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cugene \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Cugene \/ AbbVie Inc"},{"orgOrder":0,"company":"Cugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUG252","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cugene \/ Undisclosed"},{"orgOrder":0,"company":"Cugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CUG252","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cugene \/ Undisclosed"},{"orgOrder":0,"company":"Cyrus Biotechnology","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"IL-2 Mutein","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cyrus Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyrus Biotechnology \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Cyrus Biotechnology \/ Selecta Biosciences"},{"orgOrder":0,"company":"Slate Bio","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Financing","leadProduct":"IL233","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Slate Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Slate Bio \/ Epidarex Capital","highestDevelopmentStatusID":"4","companyTruncated":"Slate Bio \/ Epidarex Capital"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NEO-TRA1","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neoleukin Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Neoleukin Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-652","moa":"IL22 Receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Evive Biotech \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Evive Biotech \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AMG139","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PN-232","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI112","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0.98999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.98999999999999999,"dosageForm":"Tablet","sponsorNew":"Protagonist Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Xencor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"XmAb564","moa":"IL-2-beta-receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xencor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Undisclosed"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-401","moa":"IL-2R\/TGF-?","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"CUE-401","moa":"IL-2R\/TGF-?","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"CUE-401","moa":"IL-2R\/TGF-?","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"CUE-401","moa":"IL-2R\/TGF-?","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0.22,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.22,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"IGE025","moa":"IL-36 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMG-008","moa":"IL-36 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gachon University Gil Medical Center","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Gachon University Gil Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gachon University Gil Medical Center \/ Thermo Fisher Scientific","highestDevelopmentStatusID":"6","companyTruncated":"Gachon University Gil Medical Center \/ Thermo Fisher Scientific"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"United Allergy Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Allergy Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Allergy Services \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Allergy Services \/ Undisclosed"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Orange County Research Center | Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2017","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Orange County Research Center | Integrium","highestDevelopmentStatusID":"7","companyTruncated":"AOBiome Therapeutics \/ Orange County Research Center | Integrium"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GR1802","moa":"IL-4R?","graph1":"Immunology","graph2":"Phase II","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mabgeek Biotech.Co.Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MG-K10","moa":"IL-4R?","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Mabgeek Biotech.Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R?","graph1":"Immunology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R?","graph1":"Immunology","graph2":"Approved FDF","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AP1189","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"SynAct Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SynAct Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SynAct Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AP1189","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"SynAct Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SynAct Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SynAct Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"NBCD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AP1189","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"SynAct Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SynAct Pharma \/ NBCD","highestDevelopmentStatusID":"8","companyTruncated":"SynAct Pharma \/ NBCD"},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"NBCD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AP1189","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"SynAct Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SynAct Pharma \/ NBCD","highestDevelopmentStatusID":"8","companyTruncated":"SynAct Pharma \/ NBCD"},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"NBCD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AP1189","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"SynAct Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SynAct Pharma \/ NBCD","highestDevelopmentStatusID":"8","companyTruncated":"SynAct Pharma \/ NBCD"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BCD-085","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BCD-085","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BCD-085","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Beijing VDJBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IL-6R Monoclonal Antibody","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Beijing VDJBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing VDJBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing VDJBio \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Olamkicept","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ferring Pharmaceuticals \/ I-Mab Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ I-Mab Biopharma"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TJ301","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Tourmaline Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Merger","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Talaris Therapeutics \/ Tourmaline Bio","highestDevelopmentStatusID":"8","companyTruncated":"Talaris Therapeutics \/ Tourmaline Bio"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Acuta Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Acuta Capital Partners"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Jefferies"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Jefferies"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Talaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Merger","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Talaris Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Talaris Therapeutics"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CT-P47","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AMG592","moa":"IL-7 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AMG592","moa":"IL-7 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series A Financing","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.69999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.69999999999999996,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series B Financing","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Eurofins CDMO","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"PL-14","moa":"IL-8 secretion","graph1":"Immunology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Polyrizon \/ Eurofins CDMO","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Eurofins CDMO"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PL-14","moa":"IL-8 secretion","graph1":"Immunology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Polyrizon \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Undisclosed"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PL-14","moa":"IL-8 secretion","graph1":"Immunology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Polyrizon \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Undisclosed"},{"orgOrder":0,"company":"Protalix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"OPRX-106","moa":"Immune","graph1":"Immunology","graph2":"Phase II","graph3":"Protalix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protalix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Protalix \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Probi AB","sponsor":"Lund University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Probi AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probi AB \/ Lund University","highestDevelopmentStatusID":"1","companyTruncated":"Probi AB \/ Lund University"},{"orgOrder":0,"company":"\u00d6rebro University","sponsor":"University of Hohenheim | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"\u00d6rebro University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"\u00d6rebro University \/ University of Hohenheim | Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"\u00d6rebro University \/ University of Hohenheim | Pfizer Inc"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Qbeco SSI","moa":"Immune","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qu Biologics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Qbeco SSI","moa":"Immune","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qu Biologics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Undisclosed"},{"orgOrder":0,"company":"RenJi Hospital","sponsor":"Jiangsu ZuoYou Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SM934","moa":"Immune","graph1":"Immunology","graph2":"Phase II","graph3":"RenJi Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RenJi Hospital \/ Jiangsu ZuoYou Medicine","highestDevelopmentStatusID":"8","companyTruncated":"RenJi Hospital \/ Jiangsu ZuoYou Medicine"},{"orgOrder":0,"company":"ParaTech A\/S","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"Trichuris Suis Ova","moa":"Immune","graph1":"Immunology","graph2":"Phase II","graph3":"ParaTech A\/S","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ParaTech A\/S \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ParaTech A\/S \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Microorganism","year":"2011","type":"Inapplicable","leadProduct":"Trichuris Suis Ova","moa":"Immune","graph1":"Immunology","graph2":"Phase II","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Dr. Falk Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Falk Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Coronado Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2012","type":"Inapplicable","leadProduct":"Trichuris Suis Ova","moa":"Immune","graph1":"Immunology","graph2":"Phase II","graph3":"Coronado Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coronado Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Coronado Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Coronado Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2011","type":"Inapplicable","leadProduct":"Trichuris Suis Ova","moa":"Immune","graph1":"Immunology","graph2":"Phase II","graph3":"Coronado Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coronado Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Coronado Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Coronado Biosciences | Autoimmunity Centers of Excellence","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2013","type":"Inapplicable","leadProduct":"Trichuris Suis Ova","moa":"Immune","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Coronado Biosciences | Autoimmunity Centers of Excellence","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Coronado Biosciences | Autoimmunity Centers of Excellence"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2011","type":"Inapplicable","leadProduct":"Trichuris Suis Ova","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Fuda Cancer Hospital, Guangzhou","sponsor":"Four-Leaf Clover HealthTech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Very Small Embryonic-Like Stem Cell","moa":"Immune","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Fuda Cancer Hospital, Guangzhou","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fuda Cancer Hospital, Guangzhou \/ Four-Leaf Clover HealthTech","highestDevelopmentStatusID":"7","companyTruncated":"Fuda Cancer Hospital, Guangzhou \/ Four-Leaf Clover HealthTech"},{"orgOrder":0,"company":"Fuda Cancer Hospital, Guangzhou","sponsor":"Four-Leaf Clover HealthTech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Very Small Embryonic-Like Stem Cell","moa":"Immune","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Fuda Cancer Hospital, Guangzhou","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fuda Cancer Hospital, Guangzhou \/ Four-Leaf Clover HealthTech","highestDevelopmentStatusID":"7","companyTruncated":"Fuda Cancer Hospital, Guangzhou \/ Four-Leaf Clover HealthTech"},{"orgOrder":0,"company":"Fuda Cancer Hospital, Guangzhou","sponsor":"Four-Leaf Clover HealthTech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Very Small Embryonic-Like Stem Cell","moa":"Immune","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Fuda Cancer Hospital, Guangzhou","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuda Cancer Hospital, Guangzhou \/ Four-Leaf Clover HealthTech","highestDevelopmentStatusID":"7","companyTruncated":"Fuda Cancer Hospital, Guangzhou \/ Four-Leaf Clover HealthTech"},{"orgOrder":0,"company":"Nuvo Research GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"WF10","moa":"Immune","graph1":"Immunology","graph2":"Phase II","graph3":"Nuvo Research GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvo Research GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nuvo Research GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Epithelium Allergenic Extract","moa":"Immune system","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"Central Adelaide Local Health Network","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Jack Jumper Venom","moa":"Immune system","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Central Adelaide Local Health Network","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Central Adelaide Local Health Network \/ Vaxine","highestDevelopmentStatusID":"7","companyTruncated":"Central Adelaide Local Health Network \/ Vaxine"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Surveyor Capital"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Rigerimod","moa":"Immuno","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"ImmuPharma \/ Avion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Avion Pharmaceuticals"},{"orgOrder":0,"company":"SK Plasma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Liv-Gamma SN","moa":"Immunoglobulins","graph1":"Immunology","graph2":"Phase III","graph3":"SK Plasma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Plasma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SK Plasma \/ Undisclosed"},{"orgOrder":0,"company":"SK Plasma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Liv-Gamma SN","moa":"Immunoglobulins","graph1":"Immunology","graph2":"Phase III","graph3":"SK Plasma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Plasma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SK Plasma \/ Undisclosed"},{"orgOrder":0,"company":"SK Plasma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Liv-Gamma SN","moa":"Immunoglobulins","graph1":"Immunology","graph2":"Phase II","graph3":"SK Plasma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Plasma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SK Plasma \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"IPP-201101","moa":"immunomodulators","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"IPP-201101","moa":"immunomodulators","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Laquinimod","moa":"immunomodulators","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Paquinimod","moa":"immunomodulators","graph1":"Immunology","graph2":"Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Active Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Protalex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PRTX-100","moa":"immunomodulators","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Protalex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Protalex \/ Undisclosed"},{"orgOrder":0,"company":"Protalex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PRTX-100","moa":"immunomodulators","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Protalex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Protalex \/ Undisclosed"},{"orgOrder":0,"company":"Protalex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PRTX-100","moa":"immunomodulators","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Protalex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Protalex \/ Undisclosed"},{"orgOrder":0,"company":"Protalex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PRTX-100","moa":"immunomodulators","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Protalex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Protalex \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ubenimex","moa":"immunostimulants","graph1":"Immunology","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Miycophenolate Sodium","moa":"IMPDH","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"MEDI-570","moa":"Inducible T-cell costimulator","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ AstraZeneca"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"REGN2477","moa":"Inhibin beta A chain","graph1":"Immunology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mycophenolic Acid","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)||Inosine-5\\'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase IV","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Georgetown University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mycophenolic Acid","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"University of Wisconsin, Madison \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"East Carolina University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mycophenolic Acid","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase IV","graph3":"East Carolina University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"East Carolina University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"East Carolina University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Santa Casa de Porto Alegre","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mycophenolic Acid","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase IV","graph3":"Santa Casa de Porto Alegre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santa Casa de Porto Alegre \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Santa Casa de Porto Alegre \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Concord Biotech","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Concord Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concord Biotech \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Concord Biotech \/ Lupin Ltd"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Transplant Genomics, Inc. | Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Transplant Genomics, Inc. | Eurofins CDMO","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Transplant Genomics, Inc. | Eurofins CDMO"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Autoimmunity Centers of Excellence | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mizoribine","moa":"GMP synthase [glutamine-hydrolyzing] | Inosine-5'-monophosphate dehydrogenase (IMPDH)||Inosine-5\\'-monophosphate dehydrogenase (IMPDH) | GMP synthase [glutamine-hydrolyzing]","graph1":"Immunology","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Linsitinib","moa":"Insulin receptor | Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sling Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sling Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Linsitinib","moa":"Insulin receptor | Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sling Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sling Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Linsitinib","moa":"Insulin receptor | Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sling Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sling Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Linsitinib","moa":"Insulin receptor | Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sling Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sling Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":27.800000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":27.800000000000001,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EirGen Pharma","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EirGen Pharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"EirGen Pharma \/ Horizon Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EirGen Pharma \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":2.7799999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":2.7799999999999998,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AGC Biologics \/ Horizon Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"AGC Biologics \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Teprotumumab","moa":"||Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Halozyme Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0.19,"dosageForm":"Injection","sponsorNew":"Halozyme Therapeutics \/ Horizon Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Halozyme Therapeutics \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ypsomed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ypsomed \/ Viridian Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ypsomed \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Viridian Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Zenas BioPharma \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Viridian Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Zenas BioPharma \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Financing","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Veligrotug","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"E6007","moa":"Integrin ?4","graph1":"Immunology","graph2":"Phase II","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EA Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EA Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"San-300","moa":"Integrin alpha-1 (VLA-1)","graph1":"Immunology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"SAR339658","moa":"Integrin alpha-2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"SAR339658","moa":"Integrin alpha-2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"PTG-100","moa":"Integrin alpha-4 (ITGA4)","graph1":"Immunology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"TRK-170","moa":"Integrin alpha-4\/beta-1 (ITGA4\/B1)","graph1":"Immunology","graph2":"Phase II","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Phoenix Neurological Associates, LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase I","graph3":"Phoenix Neurological Associates, LTD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Neurological Associates, LTD \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Phoenix Neurological Associates, LTD \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Biogen"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Abrilumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Abrilumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"MEDI7183","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Takeda Pharmaceutical | Mauna Kea Technologies | INSERM","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nantes University Hospital \/ Takeda Pharmaceutical | Mauna Kea Technologies | INSERM","highestDevelopmentStatusID":"1","companyTruncated":"Nantes University Hospital \/ Takeda Pharmaceutical | Mauna Kea Technologies | INSERM"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Theradiag | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase IV","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Theradiag | Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Theradiag | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Guy's and St Thomas' NHS Foundation Trust","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase IV","graph3":"Guy's and St Thomas' NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guy's and St Thomas' NHS Foundation Trust \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Guy's and St Thomas' NHS Foundation Trust \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polpharma Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Preclinical","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Fuji Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Alvotech \/ Fuji Pharma"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polpharma Biologics \/ Fresenius Kabi AG","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"MS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polpharma Biologics \/ MS Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ MS Pharma"},{"orgOrder":0,"company":"University of Miami","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase I","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"University of Miami \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Takeda Pharmaceutical | Corporal Michael J. Crescenz VA Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Takeda Pharmaceutical | Corporal Michael J. Crescenz VA Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Takeda Pharmaceutical | Corporal Michael J. Crescenz VA Medical Center"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase IV","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Alimentiv \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Massachusetts General Hospital","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Massachusetts General Hospital \/ Royalty Pharma"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GS-1427","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":3.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":3.2000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Eli Lilly"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PN-943","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Protagonist Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PN-943","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Immunology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Protagonist Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Etrolizumab","moa":"Integrin beta-7","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AMG181","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AMG181","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AVT16","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Ensho Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NSHO-101","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase I","graph3":"Ensho Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensho Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ensho Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PB016","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polpharma Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Sifalimumab","moa":"Interferon alpha","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dazukibart","moa":"Interferon beta","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PF-06823859","moa":"Interferon beta","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"PF-06823859","moa":"Interferon beta","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"PRA Health Sciences | Cytel | Q2 Solutions | ABF Pharmaceutical Services | Cromsource | Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase II","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ PRA Health Sciences | Cytel | Q2 Solutions | ABF Pharmaceutical Services | Cromsource | Biomerieux","highestDevelopmentStatusID":"8","companyTruncated":"Swedish Orphan Biovitrum AB \/ PRA Health Sciences | Cytel | Q2 Solutions | ABF Pharmaceutical Services | Cromsource | Biomerieux"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Immunology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Medical Center Groningen \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University Medical Center Groningen \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ PRA Health Sciences","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ PRA Health Sciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ PPD","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ PPD"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Clinigen Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Clinigen Group"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ PRA Health Sciences","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ PRA Health Sciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ PRA Health Sciences","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ PRA Health Sciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Oklahoma Medical Research Foundation","sponsor":"NYU Langone Health | Yale University | Piedmont Heart Institute | Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase I","graph3":"Oklahoma Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oklahoma Medical Research Foundation \/ NYU Langone Health | Yale University | Piedmont Heart Institute | Columbia University","highestDevelopmentStatusID":"6","companyTruncated":"Oklahoma Medical Research Foundation \/ NYU Langone Health | Yale University | Piedmont Heart Institute | Columbia University"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MEDI-546","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ IQVIA"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"MEDI-546","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ MedImmune"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ABY-035","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Affibody","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ABY-035","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inmagene Biopharmaceuticals \/ Affibody","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Affibody"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mayo Clinic \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Affibody","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Affibody \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Undisclosed"},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Affibody \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Affibody","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Affibody","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Affibody"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Affibody","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inmagene Biopharmaceuticals \/ Affibody","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Affibody"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Series C Financing","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.29999999999999999,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Access Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Access Biotechnology"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2439821","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2439821","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"RO5310074","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"University of Liverpool","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"University of Liverpool","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Liverpool \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Liverpool \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"||Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"||Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts General Hospital \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Vunakizumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase I","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chinese SLE Treatment And Research Group \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ PRA Health Sciences","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ PRA Health Sciences"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parexel | MAC Clinical Research | Comac Medical | ARENSIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"UCB4940","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Parexel | MAC Clinical Research | Comac Medical | ARENSIA","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Parexel | MAC Clinical Research | Comac Medical | ARENSIA"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"LY3090106","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"LY3090106","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Undisclosed"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Undisclosed"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Zura Bio","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Access Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Access Biotechnology"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Zura Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Undisclosed"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zura Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Zura Bio"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Natrunix","moa":"Interleukin-1 alpha (IL1A)","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Natrunix","moa":"Interleukin-1 alpha (IL1A)","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Natrunix","moa":"Interleukin-1 alpha (IL1A)","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Natrunix","moa":"Interleukin-1 alpha (IL1A)","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lutikizumab","moa":"Interleukin-1 alpha | Interleukin-1 beta","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lutikizumab","moa":"Interleukin-1 alpha | Interleukin-1 beta","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"PRINTO\/PRCSG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ PRINTO\/PRCSG","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ PRINTO\/PRCSG"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Boston University","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Rilonacept","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Boston University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston University \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Boston University \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Rilonacept","moa":"Interleukin-1 beta","graph1":"Immunology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"CMIC Co, Ltd. Japan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ CMIC Co, Ltd. Japan","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ CMIC Co, Ltd. Japan"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"PF-06650833","moa":"Interleukin-1 receptor-associated kinase 4","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PF-06650833","moa":"Interleukin-1 receptor-associated kinase 4","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Gedeon Richter","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Gedeon Richter"},{"orgOrder":0,"company":"Belgian Inflammatory Bowel Disease Research and Development","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Belgian Inflammatory Bowel Disease Research and Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belgian Inflammatory Bowel Disease Research and Development \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Belgian Inflammatory Bowel Disease Research and Development \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Belgian Inflammatory Bowel Disease Research and Development","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Belgian Inflammatory Bowel Disease Research and Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belgian Inflammatory Bowel Disease Research and Development \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Belgian Inflammatory Bowel Disease Research and Development \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase IV","graph3":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"STADA Arzneimittel \/ Alvotech","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Alvotech"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"STADA Arzneimittel \/ Alvotech","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase I","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Rochester \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"University of Rochester \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"NeuClone","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Phase I","graph3":"NeuClone","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeuClone \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeuClone \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Anrukinzumab","moa":"Interleukin-13","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"QAX576","moa":"Interleukin-13","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ MedImmune"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"SAR156597","moa":"Interleukin-13 | Interleukin-4","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"ABBV-257","moa":"Interleukin-17 (IL17)","graph1":"Immunology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A||Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SHL Medical AG","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Adalimumab","moa":"||Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"SHL Medical AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHL Medical AG \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SHL Medical AG \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"Merck Group","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Cerecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AEVI-007","moa":"Interleukin-18","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Undisclosed"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Camoteskimab","moa":"Interleukin-18","graph1":"Immunology","graph2":"Phase I","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apollo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apollo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AB2 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Tadekinig Alfa","moa":"Interleukin-18","graph1":"Immunology","graph2":"Phase III","graph3":"AB2 Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AB2 Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB2 Bio \/ Undisclosed"},{"orgOrder":0,"company":"AB2 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Tadekinig Alfa","moa":"Interleukin-18","graph1":"Immunology","graph2":"Phase II","graph3":"AB2 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB2 Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB2 Bio \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Toulouse","sponsor":"Neovii | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Basiliximab","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"University Hospital, Toulouse","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Toulouse \/ Neovii | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Toulouse \/ Neovii | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Basiliximab","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Cerimon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Basiliximab","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Cerimon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerimon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerimon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Basiliximab","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Iltoo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"ILT-101","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Iltoo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iltoo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Iltoo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Iltoo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Iltoo Pharma"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"PROMETHEUS LABS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ PROMETHEUS LABS","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ PROMETHEUS LABS"},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Inolimomab","moa":"Interleukin-2 receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"ElsaLys Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ElsaLys Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ElsaLys Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Inolimomab","moa":"Interleukin-2 receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"ElsaLys Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ElsaLys Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ElsaLys Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Mediolanum Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Inolimomab","moa":"Interleukin-2 receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"ElsaLys Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ElsaLys Biotech \/ Mediolanum Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"ElsaLys Biotech \/ Mediolanum Farmaceutici"},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Funding","leadProduct":"Inolimomab","moa":"Interleukin-2 receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"ElsaLys Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ElsaLys Biotech \/ Bpifrance","highestDevelopmentStatusID":"15","companyTruncated":"ElsaLys Biotech \/ Bpifrance"},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Inolimomab","moa":"Interleukin-2 receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"ElsaLys Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ElsaLys Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ElsaLys Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Inolimomab","moa":"Interleukin-2 receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"ElsaLys Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ElsaLys Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ElsaLys Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"NNC0109-0012","moa":"Interleukin-20","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"NNC0109-0012","moa":"Interleukin-20","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"NNC0109-0012","moa":"Interleukin-20","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NNC0114-0006","moa":"Interleukin-21","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NNC0114-0006","moa":"Interleukin-21","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NNC0114-0006","moa":"Interleukin-21","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NNC0114-0006","moa":"Interleukin-21","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ AbbVie Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Termination","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AstraZeneca"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":63,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":63,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Divestment","leadProduct":"Brazikumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AstraZeneca"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":2.0299999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":2.0299999999999998,"dosageForm":"Injection","sponsorNew":"MorphoSys \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Royalty Pharma"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Diego \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Pennsylvania \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"University of Pennsylvania \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"||Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"||Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ AbbVie Inc"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"MEDI2070","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ MedImmune"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase IV","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alimentiv \/ Undisclosed"},{"orgOrder":0,"company":"Rubix LS","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase IV","graph3":"Rubix LS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubix LS \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Rubix LS \/ Eli Lilly"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Pennsylvania University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Pennsylvania University","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Pennsylvania University"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK101","moa":"Interleukin-23 | Interleukin-12","graph1":"Immunology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"JNJ-56022473","moa":"Interleukin-3 receptor subunit alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Etokimab","moa":"Interleukin-33","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Sanofi | Proinnovera","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Sanofi | Proinnovera","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Sanofi | Proinnovera"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Michigan \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi | Aimmune Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi | Aimmune Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi | Aimmune Therapeutics"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"Interleukin-5","graph1":"Immunology","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mayo Clinic \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ GSK"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Hospital, Lille \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Lille \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ IQVIA"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"ALD518","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"BMS-945429","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"BMS-945429","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"BMS-945429","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"CDP6038","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Vienna","sponsor":"CSL Behring | University of Alberta | Charite University, Berlin, Germany","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Clazakizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"Medical University of Vienna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medical University of Vienna \/ CSL Behring | University of Alberta | Charite University, Berlin, Germany","highestDevelopmentStatusID":"8","companyTruncated":"Medical University of Vienna \/ CSL Behring | University of Alberta | Charite University, Berlin, Germany"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Clazakizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Icon Plc"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Clazakizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Vitaeris","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Clazakizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Vitaeris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitaeris \/ CSL","highestDevelopmentStatusID":"10","companyTruncated":"Vitaeris \/ CSL"},{"orgOrder":0,"company":"Centocor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"CNTO 136","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase I","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Centocor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Centocor \/ Undisclosed"},{"orgOrder":0,"company":"R-Pharm","sponsor":"IQVIA | Thermo Fisher Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"R-Pharm \/ IQVIA | Thermo Fisher Scientific","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ IQVIA | Thermo Fisher Scientific"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Quintiles Inc | OCT Clinical Trials | Mene Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials | Mene Research","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials | Mene Research"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Quintiles Inc | OCT Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Quintiles Inc | OCT Clinical Trials | Mene Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials | Mene Research","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Quintiles Inc | OCT Clinical Trials | Mene Research"},{"orgOrder":0,"company":"R-Pharm","sponsor":"IQVIA | OCT Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"R-Pharm \/ IQVIA | OCT Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ IQVIA | OCT Clinical Trials"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"R-Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ R-Pharm","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ R-Pharm"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"R-Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ R-Pharm","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ R-Pharm"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"PF-04236921","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"PF-04236921","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"PF-04236921","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Techtrials Pesquisa e Tecnologia Ltda | Pharmagenix","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Gerilimzumab","moa":"Interleukin-6 (IL6)","graph1":"Immunology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skye Bioscience \/ Techtrials Pesquisa e Tecnologia Ltda | Pharmagenix","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Techtrials Pesquisa e Tecnologia Ltda | Pharmagenix"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MEDI5117","moa":"Interleukin-6 (IL6)","graph1":"Immunology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"ALX-0061","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"ALX-0061","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"ALX-0061","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"ALX-0061","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"ALX-0061","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"ALX-0061","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"BAT1806","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BAT1806","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BCD-089","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BCD-089","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Levilimab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MSB11456","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"SAR153191","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"SAR153191","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SAR153191","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Biogen"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Mycenax Biotech","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Mycenax Biotech \/ Gedeon Richter","highestDevelopmentStatusID":"6","companyTruncated":"Mycenax Biotech \/ Gedeon Richter"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"||Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Undisclosed","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Enzene Biosciences \/ Theramex","highestDevelopmentStatusID":"1","companyTruncated":"Enzene Biosciences \/ Theramex"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Chugai Pharmaceutical | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Chugai Pharmaceutical | F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Chugai Pharmaceutical | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Spanish Foundation of Rheumatology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Spanish Foundation of Rheumatology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Foundation of Rheumatology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"11","companyTruncated":"Spanish Foundation of Rheumatology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"University of Bern | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ University of Bern | F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ University of Bern | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University of Leeds","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Leeds","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leeds \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"11","companyTruncated":"University of Leeds \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius SE & Co. KGaA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Clalit","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Clalit","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Clalit"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Genentech"},{"orgOrder":0,"company":"Reade Rheumatology Research Institute","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Reade Rheumatology Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reade Rheumatology Research Institute \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Reade Rheumatology Research Institute \/ ZonMw"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Bio-Thera Solutions"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Bio-Thera Solutions"},{"orgOrder":0,"company":"Biogen","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Organon"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Bio-Thera Solutions"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Brigham and Women's Hospital | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Brigham and Women's Hospital | Genentech","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ Brigham and Women's Hospital | Genentech"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ Genentech"},{"orgOrder":0,"company":"SURPRISE Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase IV","graph3":"SURPRISE Study Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SURPRISE Study Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SURPRISE Study Group \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"GSK2618960","moa":"Interleukin-7 (IL7)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"GSK2618960","moa":"Interleukin-7 (IL7)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Reparixin","moa":"Interleukin-8 receptor A | Interleukin-8 receptor B","graph1":"Immunology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ladarixin","moa":"Interleukin-8 receptor A | Interleukin-8 receptor B||Interleukin-8 receptor B | Interleukin-8 receptor A","graph1":"Immunology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efavaleukin Alfa","moa":"interleukins: interleukin-2 analogues and derivatives; Fc fusion protein","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efavaleukin Alfa","moa":"interleukins: interleukin-2 analogues and derivatives; Fc fusion protein","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efavaleukin Alfa","moa":"interleukins: interleukin-2 analogues and derivatives; Fc fusion protein","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Efavaleukin Alfa","moa":"interleukins: interleukin-2 analogues and derivatives; Fc fusion protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Efavaleukin Alfa","moa":"interleukins: interleukin-2 analogues and derivatives; Fc fusion protein","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efavaleukin Alfa","moa":"interleukins: interleukin-2 analogues and derivatives; Fc fusion protein","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Efavaleukin Alfa","moa":"interleukins: interleukin-2 analogues and derivatives; Fc fusion protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efmarodocokin Alfa","moa":"interleukins; Fc fusion protein","graph1":"Immunology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Alloksys Life Sciences","sponsor":"Aix Scientifics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Bovine Intestinal Alkaline Phosphatase","moa":"Intestinal alkaline phosphatase","graph1":"Immunology","graph2":"Phase III","graph3":"Alloksys Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alloksys Life Sciences \/ Aix Scientifics","highestDevelopmentStatusID":"10","companyTruncated":"Alloksys Life Sciences \/ Aix Scientifics"},{"orgOrder":0,"company":"Alloksys Life Sciences","sponsor":"Aix Scientifics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Bovine Intestinal Alkaline Phosphatase","moa":"Intestinal alkaline phosphatase","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alloksys Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alloksys Life Sciences \/ Aix Scientifics","highestDevelopmentStatusID":"7","companyTruncated":"Alloksys Life Sciences \/ Aix Scientifics"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Immunology","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Theriva Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Massachusetts General Hospital \/ Theriva Biologics"},{"orgOrder":0,"company":"PharmaLundensis AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"3-Iodo-2-propynyl butylcarbamate","moa":"iodine-containing contrast media","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"PharmaLundensis AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"PharmaLundensis AB \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PharmaLundensis AB \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BAY1830839","moa":"IRAK4","graph1":"Immunology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"BGB-45035","moa":"IRAK4","graph1":"Immunology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"BGB-45035","moa":"IRAK4","graph1":"Immunology","graph2":"Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"BIIB142","moa":"IRAK4","graph1":"Immunology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Biogen","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Immunology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"NX-0479","moa":"IRAK4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Nurix Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Nurix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"NX-0479","moa":"IRAK4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Nurix Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.45000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Nurix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NX-0479","moa":"IRAK4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Nurix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"DESF","moa":"Iron","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Carotegrast Methyl","moa":"Alpha-4 integrin||ITGA4\/ITGB1","graph1":"Immunology","graph2":"Phase III","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"EA Pharma \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"EA Pharma \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Carotegrast Methyl","moa":"ITGA4\/ITGB1","graph1":"Immunology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ EA Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ EA Pharma"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Immunology","graph2":"Preclinical","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Vitalli Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"DWP213388","moa":"ITK\/BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0.47999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.47999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Vitalli Bio","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Vitalli Bio"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DWP213388","moa":"ITK\/BTK","graph1":"Immunology","graph2":"IND Enabling","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Vitalli Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"VIT-801","moa":"ITK\/BTK","graph1":"Immunology","graph2":"IND Enabling","graph3":"Vitalli Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitalli Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Vitalli Bio \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LNK01003","moa":"JAK","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01003","moa":"JAK","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"China Grand Prosperity Investment","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"China Grand Prosperity Investment","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Prime Gene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pumecitinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Prime Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Prime Gene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prime Gene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rovadicitinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VC005","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VC005","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Jaktinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Jaktinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Jaktinib HCl","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Jaktinib HCl","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TLL018","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase I","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"TLL Pharmaceutical, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TLL018","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase II","graph3":"TLL Pharmaceutical, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TLL Pharmaceutical, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TLL Pharmaceutical, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Topivert Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TOP1288","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"Topivert Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Topivert Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Topivert Pharma Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Topivert Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"TOP1288","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"Topivert Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Topivert Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Topivert Pharma Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Topivert Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"TOP1288","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"Topivert Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Topivert Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Topivert Pharma Ltd \/ Undisclosed"},{"orgOrder":0,"company":"TRB CHEMEDICA INTERNATIONAL SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diacerein","moa":"IL-1?","graph1":"Immunology","graph2":"Phase II","graph3":"TRB CHEMEDICA INTERNATIONAL SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRB CHEMEDICA INTERNATIONAL SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TRB CHEMEDICA INTERNATIONAL SA \/ Undisclosed"},{"orgOrder":0,"company":"Sareum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SDC-1802","moa":"JAK1\/TYK2","graph1":"Immunology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sareum \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ Undisclosed"},{"orgOrder":0,"company":"Sareum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SDC-1802","moa":"JAK1\/TYK2","graph1":"Immunology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sareum \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ Undisclosed"},{"orgOrder":0,"company":"VivaVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VVN461","moa":"JAK1\/TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"VivaVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Undisclosed"},{"orgOrder":0,"company":"VivaVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VVN461","moa":"JAK1\/TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"VivaVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Undisclosed"},{"orgOrder":0,"company":"VivaVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VVN461","moa":"JAK1\/TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VivaVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CS12192","moa":"JAK3\/JAK1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"JNJ-54781532","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TD-1473","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Globe Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BANGLADESH","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Globe Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Globe Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Globe Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","sponsor":"Incepta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BANGLADESH","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh \/ Incepta Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh \/ Incepta Pharmaceuticals"},{"orgOrder":0,"company":"Globe Pharmaceuticals","sponsor":"Globe Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BANGLADESH","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Globe Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Globe Pharmaceuticals \/ Globe Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Globe Pharmaceuticals \/ Globe Pharmaceuticals"},{"orgOrder":0,"company":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","sponsor":"Aristopharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BANGLADESH","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II","graph3":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh \/ Aristopharma","highestDevelopmentStatusID":"8","companyTruncated":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh \/ Aristopharma"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Charite University, Berlin, Germany \/ Pfizer Inc"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johns Hopkins University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University \/ Pfizer Inc"},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Tufts Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tufts Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Tufts Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Michigan \/ Pfizer Inc"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)||Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Progenity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Undisclosed"},{"orgOrder":0,"company":"Progenity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GSK2586184","moa":"Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"GSK2586184","moa":"Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GSK2586184","moa":"Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Prof Geert D'Haens, AMC, Amsterdam","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GSK2586184","moa":"Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Prof Geert D'Haens, AMC, Amsterdam","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Prof Geert D'Haens, AMC, Amsterdam"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ABC008","moa":"Killer cell lectin-like receptor subfamily G member 1 (KLRG1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Syneos Health","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Syneos Health"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ABC008","moa":"Killer cell lectin-like receptor subfamily G member 1 (KLRG1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Jasper Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ RBC Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"Jasper Therapeutics \/ RBC Capital Markets"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series A Financing","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Jasper Therapeutics \/ Abingworth","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Abingworth"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Mass General Brigham Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Series A Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Mass General Brigham Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Mass General Brigham Ventures"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Series B Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.16,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Redmile Group","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Redmile Group"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series C Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ RA Capital Management","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ RA Capital Management"},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KNS366","moa":"KMO","graph1":"Immunology","graph2":"Phase I","graph3":"Kynos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kynos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kynos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Kansas Medical Center","sponsor":"Terra Biological LLC","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Oxaloacetate","moa":"Krebs cycle","graph1":"Immunology","graph2":"Phase I","graph3":"University of Kansas Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kansas Medical Center \/ Terra Biological LLC","highestDevelopmentStatusID":"6","companyTruncated":"University of Kansas Medical Center \/ Terra Biological LLC"},{"orgOrder":0,"company":"D. E. Shaw Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"DES-7114","moa":"KV1.3 potassium ion channel","graph1":"Immunology","graph2":"Phase I","graph3":"D. E. Shaw Research","amount2":0.54000000000000004,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.54000000000000004,"dosageForm":"Undisclosed","sponsorNew":"D. E. Shaw Research \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"D. E. Shaw Research \/ Eli Lilly"},{"orgOrder":0,"company":"GSK","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IMP731","moa":"LAG3 cell","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"IMP731","moa":"LAG3 cell","graph1":"Immunology","graph2":"Phase II","graph3":"Immutep","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Immutep \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ GSK"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"LITHUANIA","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northway Biotechpharma \/ Immutep","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Immutep \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"NImmune Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase II","graph3":"NImmune Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NImmune Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NImmune Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"NImmune Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase II","graph3":"NImmune Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NImmune Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NImmune Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"NImmune Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase II","graph3":"NImmune Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NImmune Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NImmune Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"LianBio","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LianBio \/ NImmune Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ NImmune Biopharma"},{"orgOrder":0,"company":"NIMML Institute","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase II","graph3":"NIMML Institute","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"NIMML Institute \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"NIMML Institute \/ NImmune Biopharma"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ LianBio","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ LianBio"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"NImmune Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ NImmune Biopharma"},{"orgOrder":0,"company":"NImmune Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase II","graph3":"NImmune Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NImmune Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NImmune Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2\/MAP2K6","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Icahn School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LABP-104","moa":"LanC-like protein 2 (LANCL2)","graph1":"Immunology","graph2":"Phase I","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"CSL Behring | Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Alpha 1-Antitrypsin","moa":"Leukocyte elastase","graph1":"Immunology","graph2":"Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ CSL Behring | Leukemia and Lymphoma Society","highestDevelopmentStatusID":"8","companyTruncated":"University of Michigan Rogel Cancer Center \/ CSL Behring | Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Alpha 1-Antitrypsin","moa":"Leukocyte elastase","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Alpha1-proteinase Inhibitor","moa":"Leukocyte elastase","graph1":"Immunology","graph2":"Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Baxalta Pharmaceutical","sponsor":"Kamada","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Alpha1-proteinase Inhibitor","moa":"Leukocyte elastase","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Baxalta Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxalta Pharmaceutical \/ Kamada","highestDevelopmentStatusID":"9","companyTruncated":"Baxalta Pharmaceutical \/ Kamada"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"MEDI7734","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ MedImmune","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ MedImmune"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"VIB7734","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"VIB7734","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIB7734","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Immunology","graph2":"Phase I","graph3":"Viela Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viela Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viela Bio \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Celltaxis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Acebilustat","moa":"Leukotriene A4 hydrolase","graph1":"Immunology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Stanford University \/ Celltaxis","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Celltaxis"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LYS006","moa":"Leukotriene A-4 hydrolase (LTA4H)","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"||Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BIIL 284 BS","moa":"Leukotriene B4 receptor 1","graph1":"Immunology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BIIL-284","moa":"Leukotriene B4 receptor 1","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GSK3050002","moa":"Liver and activation-regulated chemokine (CCL20)","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"GSK \/ Eisai Inc","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Eisai Inc"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"GSK3050002","moa":"Liver and activation-regulated chemokine (CCL20)","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Lolium Allergen Extract","moa":"Lolium perenne allergen","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Series B Financing","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Enavate Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Enavate Sciences"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.26000000000000001,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series C Financing","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ SR One Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ SR One Capital Management"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.26000000000000001,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Xencor","sponsor":"Zenas BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Xencor","amount2":0.47999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.47999999999999998,"dosageForm":"Infusion","sponsorNew":"Xencor \/ Zenas BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Zenas BioPharma"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Financing","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.29999999999999999,"dosageForm":"Injection","sponsorNew":"Zenas BioPharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Xencor","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"XmAb5871","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xencor \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Xencor","sponsor":"PPD | Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"XmAb5871","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xencor \/ PPD | Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ PPD | Icon Plc"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"SAR100842","moa":"LPA1","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BI706321","moa":"LRRK2","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"IMP731","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"TJ Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TJ202","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase I","graph3":"TJ Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TJ Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TJ Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Janssen-Cilag | Labor Berlin-Charit\u00e9 Vivantes | German Cancer Research Center | Charit\u00e9 CTO","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Charite University, Berlin, Germany \/ Janssen-Cilag | Labor Berlin-Charit\u00e9 Vivantes | German Cancer Research Center | Charit\u00e9 CTO","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Janssen-Cilag | Labor Berlin-Charit\u00e9 Vivantes | German Cancer Research Center | Charit\u00e9 CTO"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"BioInvent \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"BioInvent","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"BioInvent","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"BioInvent \/ XOMA","highestDevelopmentStatusID":"10","companyTruncated":"BioInvent \/ XOMA"},{"orgOrder":0,"company":"XOMA","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase II","graph3":"XOMA","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"TAK-079","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"TAK-079","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TAK-079","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"TAK-079","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BMS-986020","moa":"Lysophosphatidic acid receptor Edg-2","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Yingu Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bencycloquidium Bromide","moa":"M1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Yingu Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Yingu Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yingu Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Riptide Bioscience","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"AUR300","moa":"M2 macrophages dysregulation","graph1":"Immunology","graph2":"IND Enabling","graph3":"Riptide Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Riptide Bioscience \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Riptide Bioscience \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Cresence","sponsor":"Bioasis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"CRES101","moa":"M2 polarization","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cresence","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cresence \/ Bioasis","highestDevelopmentStatusID":"5","companyTruncated":"Cresence \/ Bioasis"},{"orgOrder":0,"company":"MetrioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MP1032","moa":"Macrophage","graph1":"Immunology","graph2":"Preclinical","graph3":"MetrioPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MetrioPharm \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"MetrioPharm \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.59999999999999998,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Specialised Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Specialised Therapeutics"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.59999999999999998,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"FPA008","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Five Prime Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Five Prime Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"JNJ-40346527","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PLX5622","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Plexxikon \/ Undisclosed"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Plexxikon \/ Undisclosed"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ABSK021","moa":"Macrophage colony-stimulating factor 1 receptor (CSF1R)","graph1":"Immunology","graph2":"Phase II","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Abbisko Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Calgary","sponsor":"University of Alberta | Alberta Health services","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Rabbit Antithymocyte Globulin","moa":"Major histocompatibility complex class I-related gene protein; Integrin alpha-L; T-lymphocyte activation antigen CD86; Low affinity immunoglobulin gamma Fc region receptor II-b; T-cell surface glycoprotein CD4; Integrin beta-1; Integrin alpha-V; Integrin beta-3; T-cell surface glycoprotein CD1a","graph1":"Immunology","graph2":"Phase II","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ University of Alberta | Alberta Health services","highestDevelopmentStatusID":"8","companyTruncated":"University of Calgary \/ University of Alberta | Alberta Health services"},{"orgOrder":0,"company":"Cryostem","sponsor":"Rheos Medicines","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cryostem","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cryostem \/ Rheos Medicines","highestDevelopmentStatusID":"5","companyTruncated":"Cryostem \/ Rheos Medicines"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Impatients N.V. trading as myTomorrows","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Undisclosed","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeros \/ Impatients N.V. trading as myTomorrows","highestDevelopmentStatusID":"1","companyTruncated":"Omeros \/ Impatients N.V. trading as myTomorrows"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"GLPG0259","moa":"MAP kinase-activated protein kinase 5","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD0120","moa":"MAPK pathway","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATI-450","moa":"MAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATI-450","moa":"MAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moerae Matrix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"MMI-0100","moa":"MAPK-activated protein kinase 2 (MAPKAPK2)","graph1":"Immunology","graph2":"Phase I","graph3":"Moerae Matrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moerae Matrix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Moerae Matrix \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPKAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPKAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPKAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"The Task Force for Global Health","sponsor":"United States Agency for International Development","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Immunology","graph2":"Phase III","graph3":"The Task Force for Global Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Task Force for Global Health \/ United States Agency for International Development","highestDevelopmentStatusID":"10","companyTruncated":"The Task Force for Global Health \/ United States Agency for International Development"},{"orgOrder":0,"company":"The Task Force for Global Health","sponsor":"United States Agency for International Development","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Immunology","graph2":"Phase III","graph3":"The Task Force for Global Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Task Force for Global Health \/ United States Agency for International Development","highestDevelopmentStatusID":"10","companyTruncated":"The Task Force for Global Health \/ United States Agency for International Development"},{"orgOrder":0,"company":"The Task Force for Global Health","sponsor":"United States Agency for International Development","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Immunology","graph2":"Phase III","graph3":"The Task Force for Global Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Task Force for Global Health \/ United States Agency for International Development","highestDevelopmentStatusID":"10","companyTruncated":"The Task Force for Global Health \/ United States Agency for International Development"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases | Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases | Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases | Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Andecaliximab","moa":"Matrix metalloproteinase 9","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Andecaliximab","moa":"Matrix metalloproteinase 9","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Andecaliximab","moa":"Matrix metalloproteinase 9","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Andecaliximab","moa":"Matrix metalloproteinase 9","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Andecaliximab","moa":"Matrix metalloproteinase 9","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Andecaliximab","moa":"Matrix metalloproteinase 9","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dersimelagon","moa":"Melanocortin receptor 1","graph1":"Immunology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dersimelagon","moa":"Melanocortin receptor 1","graph1":"Immunology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PL8177","moa":"Melanocortin receptor 1 (MC1R)","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PL8177","moa":"Melanocortin receptor 1 (MC1R)","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PL8177","moa":"Melanocortin receptor 1 (MC1R)","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"PL8177","moa":"Melanocortin receptor 1 (MC1R)","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PL8177","moa":"Melanocortin receptor 1 (MC1R)","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"PL8177","moa":"Melanocortin receptor 1 (MC1R)","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase IV","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cleveland Clinic \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Cleveland Clinic \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase IV","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Iraj Sabahi Research Inc.","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase IV","graph3":"Iraj Sabahi Research Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Iraj Sabahi Research Inc. \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Iraj Sabahi Research Inc. \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"IRIS Research and Development, LLC","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase IV","graph3":"IRIS Research and Development, LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRIS Research and Development, LLC \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"IRIS Research and Development, LLC \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Dartmouth-Hitchcock Medical Center","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase II","graph3":"Dartmouth-Hitchcock Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dartmouth-Hitchcock Medical Center \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dartmouth-Hitchcock Medical Center \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase IV","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase IV","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Attune Health Research","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase III","graph3":"Attune Health Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attune Health Research \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Attune Health Research \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Laboratorios Vi\u00f1as, S.A.","sponsor":"Hospital Vall d'Hebron | Laboratorio Echevarne","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laboratorios Vi\u00f1as, S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Vi\u00f1as, S.A. \/ Hospital Vall d'Hebron | Laboratorio Echevarne","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Vi\u00f1as, S.A. \/ Hospital Vall d'Hebron | Laboratorio Echevarne"},{"orgOrder":0,"company":"Laboratorios Vi\u00f1as, S.A.","sponsor":"Laboratorio Echevarne | Hospital Vall d'Hebron","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laboratorios Vi\u00f1as, S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Vi\u00f1as, S.A. \/ Laboratorio Echevarne | Hospital Vall d'Hebron","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Vi\u00f1as, S.A. \/ Laboratorio Echevarne | Hospital Vall d'Hebron"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Membrane","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Membrane","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Membrane","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Membrane","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Immunology","graph2":"Phase I","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Cx601","moa":"Mesenchymal stem cells","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Cx601","moa":"Mesenchymal stem cells","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Hope Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hope Biosciences \/ Hope Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Hope Biosciences \/ Hope Biosciences"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hope Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Series B Financing","leadProduct":"AGMB-101","moa":"MET receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"AgomAb Therapeutics N.V","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"AgomAb Therapeutics N.V \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"AgomAb Therapeutics N.V \/ Redmile Group"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of North Carolina \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Bayer AG"},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"ReveraGen BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ReveraGen BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ReveraGen BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AXA1125","moa":"Mitochondrial dysfunction","graph1":"Immunology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcella Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"Vitae Health Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ Vitae Health Innovation","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ Vitae Health Innovation"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tilpisertib","moa":"Mitogen-activated protein kinase kinase kinase 8","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CC-99677","moa":"MK2 kinase","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Reprocell","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"HT-003","moa":"MNK1\/MNK2","graph1":"Immunology","graph2":"Preclinical","graph3":"Reprocell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reprocell \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Reprocell \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"BMS-986004","moa":"monoclonal antibodies: humanized","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BMS-986004","moa":"monoclonal antibodies: humanized","graph1":"Immunology","graph2":"Phase I","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Moffitt Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"JNJ-64304500","moa":"monoclonal antibodies: immunomodulating","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"JNJ-64304500","moa":"monoclonal antibodies: immunomodulating","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BOS161721","moa":"monoclonal antibodies: interleukins","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boston Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Lusvertikimab","moa":"monoclonal antibodies: interleukins","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Servier"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lusvertikimab","moa":"monoclonal antibodies: interleukins","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Undisclosed"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lusvertikimab","moa":"monoclonal antibodies: interleukins","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Undisclosed"},{"orgOrder":0,"company":"OSE Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"OSE-127","moa":"monoclonal antibodies: interleukins","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Sinocelltech Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ripertamab","moa":"monoclonal antibodies: tumors","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Union Hospital \/ Sinocelltech Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Wuhan Union Hospital \/ Sinocelltech Ltd."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"VB-201","moa":"Monocyte differentiation antigen CD14 | Toll-like receptor 2","graph1":"Immunology","graph2":"Phase II","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VB-601","moa":"MOSPD2","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VB-601","moa":"MOSPD2","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Ergomed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GS-248","moa":"mPGES-1","graph1":"Immunology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gesynta Pharma \/ Ergomed","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Pharma \/ Ergomed"},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GS-248","moa":"mPGES-1","graph1":"Immunology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gesynta Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Hadean Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"GS-248","moa":"mPGES-1","graph1":"Immunology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Gesynta Pharma \/ Hadean Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Pharma \/ Hadean Ventures"},{"orgOrder":0,"company":"KYORIN PHARMACEUTICAL CO LTD","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"KRP-M223","moa":"MRGPRX2","graph1":"Immunology","graph2":"Preclinical","graph3":"KYORIN PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KYORIN PHARMACEUTICAL CO LTD \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"KYORIN PHARMACEUTICAL CO LTD \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"CYTO-201","moa":"Mu opioid receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytocom \/ Cleveland Clinic","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland Clinic"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"PF-00547659","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"PF-00547659","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"PF-00547659","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"SHP647","moa":"Mucosal addressin cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Renovion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Mucous clearance","graph1":"Immunology","graph2":"Phase I","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Renovion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Renovion \/ Undisclosed"},{"orgOrder":0,"company":"Baylx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"hUC-MSC","moa":"Multiple","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Baylx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Baylx \/ Undisclosed"},{"orgOrder":0,"company":"Baylx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"hUC-MSC","moa":"Multiple","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Baylx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Baylx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Baylx \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Iberogast","moa":"Multiple (motility, inflammation)","graph1":"Immunology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Magna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Atropine","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Immunology","graph2":"Phase III","graph3":"Magna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Magna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Magna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Magna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Atropine","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Immunology","graph2":"Phase III","graph3":"Magna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Magna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Magna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CNP-106","moa":"nAChR?1\/?1\/?\/?","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Umira Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"CNP-106","moa":"nAChR?1\/?1\/?\/?","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Umira Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Umira Ventures"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CNP-106","moa":"nAChR?1\/?1\/?\/?","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CNP-106","moa":"nAChR?1\/?1\/?\/?","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Niagen Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ ChromaDex, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Oslo University Hospital \/ ChromaDex, Inc"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"SRT2104","moa":"NAD-dependent deacetylase sirtuin 1","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ Pharma Nord","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ Pharma Nord"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Simbec-Orion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Simbec-Orion","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Simbec-Orion"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Columbus Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Preclinical","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Li Ka Shing Knowledge Institute | University of Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oseltamivir Phosphate","moa":"Neuraminidase","graph1":"Immunology","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Unity Health Toronto \/ Li Ka Shing Knowledge Institute | University of Toronto","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ Li Ka Shing Knowledge Institute | University of Toronto"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Oyster Point Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"University of Pennsylvania \/ Oyster Point Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Oyster Point Pharma"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adiso Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bacainn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bacainn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adiso Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adiso Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University at Buffalo","sponsor":"Kaleida Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ezetimibe","moa":"Niemann-Pick C1-like protein 1","graph1":"Immunology","graph2":"Undisclosed","graph3":"University at Buffalo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University at Buffalo \/ Kaleida Health","highestDevelopmentStatusID":"1","companyTruncated":"University at Buffalo \/ Kaleida Health"},{"orgOrder":0,"company":"Topadur Pharma","sponsor":"Bioskin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TOP-N53","moa":"Nitric oxide synthase","graph1":"Immunology","graph2":"Phase II","graph3":"Topadur Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Topadur Pharma \/ Bioskin","highestDevelopmentStatusID":"8","companyTruncated":"Topadur Pharma \/ Bioskin"},{"orgOrder":0,"company":"Shanghai Simnova Biotechnology Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CAR+NK Cell","moa":"NK cell","graph1":"Immunology","graph2":"Phase I","graph3":"Shanghai Simnova Biotechnology Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Simnova Biotechnology Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Simnova Biotechnology Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"ST Phi Therapeutics Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Chimeric NK Receptor Universal T-cell","moa":"NK cell receptor","graph1":"Immunology","graph2":"Phase I","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ ST Phi Therapeutics Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ ST Phi Therapeutics Co., Ltd"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NX-13","moa":"NLR family member X1 (NLRX1)","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NX-13","moa":"NLR family member X1 (NLRX1)","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NX-13","moa":"NLR family member X1 (NLRX1)","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NX-13","moa":"NLR family member X1 (NLRX1)","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NX-13","moa":"NLR family member X1 (NLRX1)","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"NX-13","moa":"NLR family member X1 (NLRX1)","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"NX-13","moa":"NLR family member X1 (NLRX1)","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"KU Leuven","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"NX-13","moa":"NLR family member X1 (NLRX1)","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ KU Leuven","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ KU Leuven"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"KCRN Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BBT-401","moa":"NLRP3","graph1":"Immunology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ KCRN Research","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ KCRN Research"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"KCRN Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BBT-401","moa":"NLRP3","graph1":"Immunology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ KCRN Research","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ KCRN Research"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BBT-401","moa":"NLRP3","graph1":"Immunology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Covance","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Covance"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BBT-401","moa":"NLRP3","graph1":"Immunology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Covance","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Covance"},{"orgOrder":0,"company":"NodThera","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"NT-0167","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I","graph3":"NodThera","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"NodThera \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/ Organovo Holdings"},{"orgOrder":0,"company":"NodThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NT-0796","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NodThera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NodThera \/ Undisclosed"},{"orgOrder":0,"company":"Inflazome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Somalix","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inflazome \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ Undisclosed"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ventus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Ventus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"SoftBank Vision Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series C Financing","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ SoftBank Vision Fund","highestDevelopmentStatusID":"4","companyTruncated":"Ventus Therapeutics \/ SoftBank Vision Fund"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Guaifenesin","moa":"NMDA receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Virginia Commonwealth University \/ Pfizer Inc"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Immunology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Immunology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Brigham and Women's Hospital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Collaboration","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Immunology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Brigham and Women's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Finch Therapeutics \/ Brigham and Women's Hospital"},{"orgOrder":0,"company":"HoHo Biotech","sponsor":"Tri-Service General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Hydrogen","moa":"None","graph1":"Immunology","graph2":"Phase I","graph3":"HoHo Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HoHo Biotech \/ Tri-Service General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"HoHo Biotech \/ Tri-Service General Hospital"},{"orgOrder":0,"company":"HoHo Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Hydrogen","moa":"None","graph1":"Immunology","graph2":"Phase I","graph3":"HoHo Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HoHo Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HoHo Biotech \/ Undisclosed"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Aarhus \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Novo Nordisk"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"National Institutes of Health | OnLume | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ National Institutes of Health | OnLume | National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"University of Wisconsin, Madison \/ National Institutes of Health | OnLume | National Cancer Institute"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Forest Laboratories"},{"orgOrder":0,"company":"Loma Linda University","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase IV","graph3":"Loma Linda University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loma Linda University \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Loma Linda University \/ Forest Laboratories"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Forest Laboratories | National Institute of Arthritis and Musculoskeletal and Skin Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase IV","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Brigham and Women's Hospital \/ Forest Laboratories | National Institute of Arthritis and Musculoskeletal and Skin Diseases","highestDevelopmentStatusID":"11","companyTruncated":"Brigham and Women's Hospital \/ Forest Laboratories | National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pseudoephedrine","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Magna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pseudoephedrine","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase II","graph3":"Magna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Magna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Magna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GSK2330811","moa":"Oncostatin-M (OSM)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"GSK2330811","moa":"Oncostatin-M (OSM)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"GSK2330811","moa":"Oncostatin-M (OSM)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Kiniksa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"KPL-716","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Kiniksa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Kiniksa Pharmaceuticals"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"STAT-201","moa":"Opioid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Statera Biopharma \/ EF Hutton","highestDevelopmentStatusID":"10","companyTruncated":"Statera Biopharma \/ EF Hutton"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"STAT-201","moa":"Opioid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Statera Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Statera Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"TaiwanJ Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"JKB-122","moa":"Opioid receptor (OPR)","graph1":"Immunology","graph2":"Phase II","graph3":"TaiwanJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiwanJ Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TaiwanJ Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TaiwanJ Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JKB-122","moa":"Opioid receptor (OPR)","graph1":"Immunology","graph2":"Phase II","graph3":"TaiwanJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiwanJ Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TaiwanJ Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TaiwanJ Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JKB-122","moa":"Opioid receptor (OPR)","graph1":"Immunology","graph2":"Phase II","graph3":"TaiwanJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiwanJ Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TaiwanJ Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Avalotcagene Ontaparvovec","moa":"Ornithine transcarbamylase (OTC)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fountain Biopharma","sponsor":"Oneness Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"FB704A","moa":"OX40","graph1":"Immunology","graph2":"Phase I","graph3":"Fountain Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fountain Biopharma \/ Oneness Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Fountain Biopharma \/ Oneness Biotech"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"4","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BIRB 796","moa":"p38 MAPK","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lu AG09222","moa":"PACAP38","graph1":"Immunology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"JBI-589","moa":"PAD4","graph1":"Immunology","graph2":"Preclinical","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jubilant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Brigham and Women's Hospital \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Brigham and Women's Hospital \/ Eli Lilly"},{"orgOrder":0,"company":"University Hospital Schleswig-Holstein","sponsor":"Ced Service | Gesellschaft f\u00fcr Therapieforschung mbH | German Federal Ministry of Education and Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nicotinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"University Hospital Schleswig-Holstein","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Schleswig-Holstein \/ Ced Service | Gesellschaft f\u00fcr Therapieforschung mbH | German Federal Ministry of Education and Research","highestDevelopmentStatusID":"9","companyTruncated":"University Hospital Schleswig-Holstein \/ Ced Service | Gesellschaft f\u00fcr Therapieforschung mbH | German Federal Ministry of Education and Research"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BAT1406","moa":"PCSK9","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"S-4321","moa":"PD?1\/c?RIIb","graph1":"Immunology","graph2":"Phase I","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seismic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seismic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JNJ-67484703","moa":"PD-1","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JS005","moa":"PD-1","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Sponsor GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Junshi Biosciences \/ Sponsor GmbH"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JS005","moa":"PD-1","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Sponsor GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Junshi Biosciences \/ Sponsor GmbH"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"PT627","moa":"PD-1","graph1":"Immunology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBI Biopharma \/ Pandion Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Peresolimab","moa":"PDCD1","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"PDCD1","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"PDCD1","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"PDCD1","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"PDCD1","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BenevolentAI \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Undisclosed"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BenevolentAI \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Undisclosed"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BenevolentAI \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Undisclosed"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Palisade Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Giiant pharma \/ Palisade Bio","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Palisade Bio"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Giiant pharma \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Amplitude Ventures"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Giiant pharma \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Amplitude Ventures"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Immunology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"IRIS Research and Development, LLC","sponsor":"Artiva Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AB-101","moa":"PD-L1","graph1":"Immunology","graph2":"Phase I","graph3":"IRIS Research and Development, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IRIS Research and Development, LLC \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"IRIS Research and Development, LLC \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"mRNA-6231","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DBV1605","moa":"Peanut allergen","graph1":"Immunology","graph2":"Phase II","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Immunology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Immunology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BaseLaunch","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Partnership","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Immunology","graph2":"Phase II","graph3":"BaseLaunch","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BaseLaunch \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BaseLaunch \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"Apeptico","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Solnatide","moa":"peptides","graph1":"Immunology","graph2":"Phase II","graph3":"Apeptico","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Apeptico \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apeptico \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Vedanta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Vedanta Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Vedanta Biosciences"},{"orgOrder":0,"company":"Walter Reed National Military Medical Center","sponsor":"National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Walter Reed National Military Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walter Reed National Military Medical Center \/ National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"1","companyTruncated":"Walter Reed National Military Medical Center \/ National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"University at Buffalo","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Immunology","graph2":"Phase IV","graph3":"University at Buffalo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University at Buffalo \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University at Buffalo \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"PPM Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GED-0507-34-Levo","moa":"Peroxisome proliferator-activated receptor gamma (PPAR-gamma)","graph1":"Immunology","graph2":"Phase II","graph3":"PPM Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPM Services \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PPM Services \/ Undisclosed"},{"orgOrder":0,"company":"Holy Stone Healthcare","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase II","graph3":"Holy Stone Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Holy Stone Healthcare \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Holy Stone Healthcare \/ Syneos Health"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Zeria Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Zeria Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Zeria Pharmaceutical"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Zeria Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tillotts Pharma AG \/ Zeria Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Tillotts Pharma AG \/ Zeria Pharmaceutical"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"VSL Pharmaceuticals","sponsor":"Actial Farmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Undisclosed","graph3":"VSL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VSL Pharmaceuticals \/ Actial Farmaceutica","highestDevelopmentStatusID":"1","companyTruncated":"VSL Pharmaceuticals \/ Actial Farmaceutica"},{"orgOrder":0,"company":"EMET Pharmaceuticals, LLC","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"EMET Pharmaceuticals, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMET Pharmaceuticals, LLC \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"EMET Pharmaceuticals, LLC \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Altheus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase II","graph3":"Altheus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altheus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altheus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Aarhus University Hospital | PRONOVA BIOPHARMA NORGE AS | South-Eastern Norway Regional Health Authority | Aalborg University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Immunology","graph2":"Phase IV","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oslo University Hospital \/ Aarhus University Hospital | PRONOVA BIOPHARMA NORGE AS | South-Eastern Norway Regional Health Authority | Aalborg University","highestDevelopmentStatusID":"11","companyTruncated":"Oslo University Hospital \/ Aarhus University Hospital | PRONOVA BIOPHARMA NORGE AS | South-Eastern Norway Regional Health Authority | Aalborg University"},{"orgOrder":0,"company":"University of Memphis","sponsor":"Nordic Naturals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Memphis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Memphis \/ Nordic Naturals","highestDevelopmentStatusID":"1","companyTruncated":"University of Memphis \/ Nordic Naturals"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Radboud University Medical Center \/ ZonMw"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shilpa Medicare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase III","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ Celgene Corporation"},{"orgOrder":0,"company":"Medical University of Graz","sponsor":"Celgene Corporation | Medical University of Vienna | Medical University Innsbruck","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase IV","graph3":"Medical University of Graz","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Graz \/ Celgene Corporation | Medical University of Vienna | Medical University Innsbruck","highestDevelopmentStatusID":"11","companyTruncated":"Medical University of Graz \/ Celgene Corporation | Medical University of Vienna | Medical University Innsbruck"},{"orgOrder":0,"company":"Stanford University","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Celgene Corporation"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Bristol Myers Squibb | Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunnybrook Health Sciences Centre \/ Bristol Myers Squibb | Sunnybrook Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Bristol Myers Squibb | Sunnybrook Research Institute"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2012","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"CC-11050","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Revamilast","moa":"Phosphodiesterase 4","graph1":"Immunology","graph2":"Phase II","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Glenmark Pharmaceuticals \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Kerckhoff Heart Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Immunology","graph2":"Phase IV","graph3":"Kerckhoff Heart Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kerckhoff Heart Center \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Kerckhoff Heart Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"CDZ173","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CDZ173","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Pharming","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CDZ173","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharming \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/ Undisclosed"},{"orgOrder":0,"company":"Pharming","sponsor":"Lahey Hospital & Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharming \/ Lahey Hospital & Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Lahey Hospital & Medical Center"},{"orgOrder":0,"company":"Pharming","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nemiralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"UCB5857","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"UCB Pharma S.A \/ PRA Health Sciences","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ PRA Health Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CAL-263","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-gamma subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"SecuraBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II","graph3":"SecuraBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SecuraBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SecuraBio \/ Undisclosed"},{"orgOrder":0,"company":"Exscientia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EXS4318","moa":"PKC theta","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Immunology","graph2":"Phase III","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Ecallantide","moa":"Plasma kallikrein","graph1":"Immunology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHIRE PLC \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"C1 Esterase Inhibitor","moa":"Plasma protease C1 inhibitor","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"C1 Esterase Inhibitor","moa":"Plasma protease C1 inhibitor","graph1":"Immunology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"C1 Esterase Inhibitor","moa":"Plasma protease C1 inhibitor","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"Defibrotide","moa":"Plasminogen","graph1":"Immunology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Defibrotide","moa":"Plasminogen","graph1":"Immunology","graph2":"Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Francisco \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Jiangsu Kanion Pharmaceutical","sponsor":"Beijing Bionovo Medicine Development","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Ginkgolides","moa":"Platelet Activating Factor receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Jiangsu Kanion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Kanion Pharmaceutical \/ Beijing Bionovo Medicine Development","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Kanion Pharmaceutical \/ Beijing Bionovo Medicine Development"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor | Fibroblast growth factor receptor | Vascular endothelial growth factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Aminopterin","moa":"Polypeptide deformylase (PDF)","graph1":"Immunology","graph2":"Phase II","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntrix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syntrix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EHP-101","moa":"PPA-gamma receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emerald Health Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Emerald Health Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lubris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Recombinant Human Proteoglycan 4","moa":"PRG4","graph1":"Immunology","graph2":"Phase II","graph3":"Lubris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lubris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lubris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Lubris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Recombinant Human Proteoglycan 4","moa":"PRG4","graph1":"Immunology","graph2":"Phase II","graph3":"Lubris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lubris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lubris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell","graph1":"Immunology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell","graph1":"Immunology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell","graph1":"Immunology","graph2":"Undisclosed","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Cenplacel-L","moa":"Progenitor cell","graph1":"Immunology","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Celgene Corporation"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Cenplacel-L","moa":"Progenitor cell","graph1":"Immunology","graph2":"Phase I","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Glia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Pro-Ocular","moa":"Progesterone receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Glia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Glia \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Glia \/ Undisclosed"},{"orgOrder":0,"company":"Glia","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Pro-Ocular","moa":"Progesterone receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Glia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Glia \/ Ora, Inc","highestDevelopmentStatusID":"9","companyTruncated":"Glia \/ Ora, Inc"},{"orgOrder":0,"company":"Alliance Foundation Trials","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Immunology","graph2":"Phase I","graph3":"Alliance Foundation Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alliance Foundation Trials \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Alliance Foundation Trials \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Aditxt","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-100","moa":"Pro-inflammatory cytokine","graph1":"Immunology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aditxt \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Undisclosed"},{"orgOrder":0,"company":"Laval University","sponsor":"Atrium Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Atrium Innovations","highestDevelopmentStatusID":"1","companyTruncated":"Laval University \/ Atrium Innovations"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ONO-4053","moa":"Prostaglandin D2 receptor (PTGDR)","graph1":"Immunology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Asapiprant","moa":"Prostanoid DP receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Rottapharm Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CR6086","moa":"Prostanoid EP4 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Rottapharm Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rottapharm Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rottapharm Biotech \/ Undisclosed"},{"orgOrder":0,"company":"CiVi Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Immunology","graph2":"Phase III","graph3":"CiVi Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CiVi Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CiVi Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"University of Pittsburgh Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ University of Pittsburgh Medical Center","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ University of Pittsburgh Medical Center"},{"orgOrder":0,"company":"Pharmathen SA","sponsor":"National Institute of Allergy and Infectious Diseases | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Valortim","moa":"Protective antigen","graph1":"Immunology","graph2":"Phase I","graph3":"Pharmathen SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmathen SA \/ National Institute of Allergy and Infectious Diseases | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Pharmathen SA \/ National Institute of Allergy and Infectious Diseases | National Institutes of Health"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sotrastaurin","moa":"Protein kinase C (PKC)","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sotrastaurin","moa":"Protein kinase C (PKC)","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AbGenomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"AbGn-168H","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AbGenomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbGenomics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbGenomics \/ Undisclosed"},{"orgOrder":0,"company":"AbGenomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"AbGn-168H","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase II","graph3":"AbGenomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbGenomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbGenomics \/ Undisclosed"},{"orgOrder":0,"company":"AbGenomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase II","graph3":"AbGenomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbGenomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbGenomics \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"AbGenomics B.V","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ AbGenomics B.V","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ AbGenomics B.V"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Series A Financing","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ aMoon","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ aMoon"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Organic Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palmitoleic Acid","moa":"Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of North Carolina \/ Organic Technologies","highestDevelopmentStatusID":"1","companyTruncated":"University of North Carolina \/ Organic Technologies"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"ALTB-168","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ALTB-268","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"AltruBio \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ BVF Partners"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Cowen"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"PSMB9","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Curexsys Gmbh","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Exosome","moa":"PTEN","graph1":"Immunology","graph2":"Undisclosed","graph3":"Curexsys Gmbh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curexsys Gmbh \/ Evotec","highestDevelopmentStatusID":"1","companyTruncated":"Curexsys Gmbh \/ Evotec"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nimesulide","moa":"PTGS2","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"DR-6MP","moa":"Purine synthesis pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Samjin pharm Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Immunology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Samjin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Samjin Pharmaceutical"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Immunology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Rabies Immune Globulin (Human)","moa":"Rabies Virus Proteins","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TAS5315","moa":"RANKL","graph1":"Immunology","graph2":"Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TAS5315","moa":"RANKL","graph1":"Immunology","graph2":"Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"OR-812","moa":"RAR-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orphagen Pharmaceuticals \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ NIDDK"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Immunology","graph2":"Phase I","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Exacte Labs | Ministry of Health, Russia | Scientific Center EFiS | Data Management 365","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"RPH-104","moa":"receptor molecules","graph1":"Immunology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"R-Pharm \/ Exacte Labs | Ministry of Health, Russia | Scientific Center EFiS | Data Management 365","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Exacte Labs | Ministry of Health, Russia | Scientific Center EFiS | Data Management 365"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"R552","moa":"Receptor-interacting protein 1 (RIPK1)","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0.95999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.95999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"GSK2982772","moa":"Receptor-interacting serine\/threonine-protein kinase 1","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"GSK2982772","moa":"Receptor-interacting serine\/threonine-protein kinase 1","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Quotient Sciences"},{"orgOrder":0,"company":"GSK","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"GSK2982772","moa":"Receptor-interacting serine\/threonine-protein kinase 1","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Quotient Sciences"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK2982772","moa":"Receptor-interacting serine\/threonine-protein kinase 1","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK2982772","moa":"Receptor-interacting serine\/threonine-protein kinase 1","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"GSK2982772","moa":"Receptor-interacting serine\/threonine-protein kinase 1","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Alloantigen-Reactive Regulatory T Cell","moa":"Regulatory T lymphocyte","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AZD6793","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BAY1834845","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Immunology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BAY1834845","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Immunology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GS-5718","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SPH3127","moa":"Renin","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Muenster","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alitretinoin","moa":"Retinoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"University Hospital Muenster","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University Hospital Muenster \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Muenster \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Transposon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TPN-101","moa":"Reverse transcriptase","graph1":"Immunology","graph2":"Phase II","graph3":"Transposon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transposon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Transposon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"BioNova Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"BioNova Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"BioNova Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"BioNova Pharma \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Quotient Sciences"},{"orgOrder":0,"company":"Sanofi","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Quotient Sciences"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.23999999999999999,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Meiji Seika Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":1.8999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":1.8999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Onco360","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AC-003","moa":"RIPK1","graph1":"Immunology","graph2":"Phase I","graph3":"Accro Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Accro Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Accro Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GDC-8264","moa":"RIPK1","graph1":"Immunology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LY3871801","moa":"RIPK1","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SAR443122","moa":"RIPK1","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SAR443122","moa":"RIPK1","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AC-101","moa":"RIPK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Accro Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Accro Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Accro Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AC-101","moa":"RIPK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Accro Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Accro Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Accro Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"OD-07656","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Odyssey Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odyssey Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Odyssey Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Affinity Asset Advisors","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series D Financing","leadProduct":"OD-07656","moa":"||RIPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Odyssey Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Odyssey Therapeutics \/ Affinity Asset Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Odyssey Therapeutics \/ Affinity Asset Advisors"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"University Hospital Birmingham | Newcastle NHS Trust","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Immunology","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Resolve Therapeutics \/ University Hospital Birmingham | Newcastle NHS Trust","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ University Hospital Birmingham | Newcastle NHS Trust"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Immunology","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Resolve Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Immunology","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Resolve Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Immunology","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resolve Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Immunology","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resolve Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BN101","moa":"ROCK1\/ROCK2","graph1":"Immunology","graph2":"Phase II","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNova Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioNova Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"GV101","moa":"ROCK2","graph1":"Immunology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Graviton Bioscience \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Graviton Bioscience \/ Sanofi"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TDI01","moa":"ROCK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Beijing Tide Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Beijing Tide Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Tide Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BI730357","moa":"ROR-gamma","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LX2931","moa":"S1P lyase","graph1":"Immunology","graph2":"Phase I","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"Oppilan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Oppilan Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oppilan Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oppilan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1||Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1||Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 S","graph1":"Immunology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Siena","sponsor":"IBSA Institut Biochimique","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Amino Acid","year":"2014","type":"Inapplicable","leadProduct":"Selenium Methionine","moa":"Selenoprotein","graph1":"Immunology","graph2":"Phase II","graph3":"University of Siena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Siena \/ IBSA Institut Biochimique","highestDevelopmentStatusID":"8","companyTruncated":"University of Siena \/ IBSA Institut Biochimique"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"aNRP2-14","moa":"Sema3F\/NRP2","graph1":"Immunology","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Immunology","graph2":"Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"University of Maryland","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||Serotonin 2a (5-HT2a) receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silo Pharma \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ University of Maryland"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Amilo-5MER","moa":"Serum amyloid A","graph1":"Immunology","graph2":"Phase I","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galmed Pharmaceuticals \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Galmed Pharmaceuticals \/ Quotient Sciences"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Hebrew University Of Jerusalem","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Amilo-5MER","moa":"Serum amyloid A","graph1":"Immunology","graph2":"Phase I","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galmed Pharmaceuticals \/ Hebrew University Of Jerusalem","highestDevelopmentStatusID":"6","companyTruncated":"Galmed Pharmaceuticals \/ Hebrew University Of Jerusalem"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aceneuramic Acid","moa":"Sialic acid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Aceneuramic Acid","moa":"Sialic acid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Aceneuramic Acid","moa":"Sialic acid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"N-Acetyl-D-neuraminate","moa":"Sialic acid receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"AK002","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Immunology","graph2":"Phase II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Immunology","graph2":"Phase II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Immunology","graph2":"Phase II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Concentra Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Concentra Biosciences"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Preclinical","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"11-C BMT-136088","moa":"Sigma-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MG01","moa":"Sigma-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MG01","moa":"Sigma-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Autoimmunity Centers of Excellence | Bristol Myers Squibb | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Bristol Myers Squibb | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Bristol Myers Squibb | Rho, Inc"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2016","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2016","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"GED-0301","moa":"SMAD-7 mRNA","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sonidegib Phosphate","moa":"Smoothened homolog","graph1":"Immunology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Immunology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuroversion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Neuroversion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuroversion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neuroversion \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Digoxin","moa":"Sodium\/potassium-transporting ATPase","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Mallinckrodt Pharmaceuticals | Clinical & Translational Science Institute of Southeast Wisconsin | Versiti","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical College of Wisconsin \/ Mallinckrodt Pharmaceuticals | Clinical & Translational Science Institute of Southeast Wisconsin | Versiti","highestDevelopmentStatusID":"9","companyTruncated":"Medical College of Wisconsin \/ Mallinckrodt Pharmaceuticals | Clinical & Translational Science Institute of Southeast Wisconsin | Versiti"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Immunology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amiselimod","moa":"Sphingosine 1-phosphate receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amiselimod","moa":"Sphingosine 1-phosphate receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amiselimod","moa":"Sphingosine 1-phosphate receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amiselimod","moa":"Sphingosine 1-phosphate receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amiselimod","moa":"Sphingosine 1-phosphate receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amiselimod HCl","moa":"Sphingosine 1-phosphate receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Viatris"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Cenerimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":6.7000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":6.7000000000000002,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":6.7000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":6.7000000000000002,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Everstar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Everstar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Everstar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Everstar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Geert D'Haens","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase IV","graph3":"Geert D'Haens","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Geert D'Haens \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Geert D'Haens \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Siponimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Everest Medicines"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SK1-I","moa":"Sphingosine kinase 1 (SPHK1)","graph1":"Immunology","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzo Biochem \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Biochem \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"AC BioScience","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"LX2931","moa":"Sphingosine-1-phosphate lyase 1 (SGPL1)","graph1":"Immunology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ AC BioScience","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ AC BioScience"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BMS-986104","moa":"Sphingosine-1-phosphate receptor 1 (S1PR1)","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CBP-307","moa":"Sphingosine-1-phosphate receptor 1 (S1PR1)","graph1":"Immunology","graph2":"Phase I","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CBP-307","moa":"Sphingosine-1-phosphate receptor 1 (S1PR1)","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CBP-307","moa":"Sphingosine-1-phosphate receptor 1 (S1PR1)","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CBP-307","moa":"Sphingosine-1-phosphate receptor 1 (S1PR1)","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CBP-307","moa":"Sphingosine-1-phosphate receptor 1 (S1PR1)","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CBP-307","moa":"Sphingosine-1-phosphate receptor 1 (S1PR1)","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharm","sponsor":"Tigermed | Nucleus Network","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"CBP-307","moa":"Sphingosine-1-phosphate receptor 1 (S1PR1)","graph1":"Immunology","graph2":"Phase I","graph3":"Connect Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connect Biopharm \/ Tigermed | Nucleus Network","highestDevelopmentStatusID":"6","companyTruncated":"Connect Biopharm \/ Tigermed | Nucleus Network"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Casirivimab","moa":"||Spike glycoprotein","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ US Government","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ US Government"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Autoimmunity Centers of Excellence | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1273","moa":"Spike glycoprotein","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Butenafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Butenafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Immunology","graph2":"Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Lille \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Immunology","graph2":"Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ossium Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"OSSM-001","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Phase I","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ossium Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ossium Health \/ Undisclosed"},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"ISD017","moa":"STING","graph1":"Immunology","graph2":"Preclinical","graph3":"ISD Immunotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISD Immunotech \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"ISD Immunotech \/ Biogen"},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ISD017","moa":"STING","graph1":"Immunology","graph2":"Preclinical","graph3":"ISD Immunotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISD Immunotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ISD Immunotech \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MHV370","moa":"STING","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"RS Umum Pusat Sanglah","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine","moa":"Surface antigen (HBsAg)","graph1":"Immunology","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ RS Umum Pusat Sanglah","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ RS Umum Pusat Sanglah"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"R788","moa":"Syk","graph1":"Immunology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Rochester Center for Behavioral Medicine","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Immunology","graph2":"Phase IV","graph3":"Rochester Center for Behavioral Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Rochester Center for Behavioral Medicine \/ SHIRE PLC","highestDevelopmentStatusID":"11","companyTruncated":"Rochester Center for Behavioral Medicine \/ SHIRE PLC"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Wake Forest University Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Daxibotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Immunology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Wake Forest University Health Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Wake Forest University Health Sciences"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Daxibotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Immunology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Foralumab","moa":"T cell surface glycoprotein CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Foralumab","moa":"T cell surface glycoprotein CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Foralumab","moa":"T cell surface glycoprotein CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Thinkequity"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"T cell surface glycoprotein CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Foralumab","moa":"T cell surface glycoprotein CD3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parexel Biotech \/ Tiziana Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Parexel Biotech \/ Tiziana Life Sciences"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SAR442970","moa":"TAX transcriptionally-activated glycoprotein 1 (OX40)","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SAR442970","moa":"TAX transcriptionally-activated glycoprotein 1 (OX40)","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"HCW9302","moa":"T-cell","graph1":"Immunology","graph2":"IND Enabling","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Healios K.K","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"T-cell","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Healios K.K","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Healios K.K"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rabbit Anti-Thymocyte Globulin","moa":"T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Rho, Inc","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Rho, Inc"},{"orgOrder":0,"company":"TRexBio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"TRB-051","moa":"T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"TRexBio","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.1599999999999999,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ Eli Lilly"},{"orgOrder":0,"company":"TRexBio","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series A Financing","leadProduct":"TRB-051","moa":"T-cell","graph1":"Immunology","graph2":"Discovery Platform","graph3":"TRexBio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Polaris Partners","highestDevelopmentStatusID":"3","companyTruncated":"TRexBio \/ Polaris Partners"},{"orgOrder":0,"company":"TRexBio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"TRB-051","moa":"T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"TRexBio","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.1599999999999999,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ Eli Lilly"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Shanghai Xiniao Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Ucar T-Cell","moa":"T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Shanghai Xiniao Biotech Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Shanghai Xiniao Biotech Co., Ltd."},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Shanghai Xiniao Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Ucar T-Cell","moa":"T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Shanghai Xiniao Biotech Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Shanghai Xiniao Biotech Co., Ltd."},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Shanghai Xiniao Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Ucar T-Cell","moa":"T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Shanghai Xiniao Biotech Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Shanghai Xiniao Biotech Co., Ltd."},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon \/ Equillium","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Equillium"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase I","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Equillium","highestDevelopmentStatusID":"6","companyTruncated":"Biocon \/ Equillium"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Decheng Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Decheng Capital","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Decheng Capital"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Termination","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Preclinical","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"Equillium \/ University of Oxford"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Biotech Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase I","graph3":"Biotech Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotech Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biotech Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Biotech Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase I","graph3":"Biotech Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotech Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biotech Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT115301","moa":"T-cell effector","graph1":"Immunology","graph2":"Phase I","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sonoma Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"R-2487","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-2487","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Regimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"RGI-2001","moa":"T-cell receptor (TCR)","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ Undisclosed"},{"orgOrder":0,"company":"Regimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"RGI-2001","moa":"T-cell receptor (TCR)","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ Undisclosed"},{"orgOrder":0,"company":"Regimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RGI-2001","moa":"T-cell receptor (TCR)","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ Undisclosed"},{"orgOrder":0,"company":"Regimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RGI-2001","moa":"T-cell receptor (TCR)","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ Undisclosed"},{"orgOrder":0,"company":"Regimmune","sponsor":"San Fu Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"RGI-2001","moa":"T-cell receptor (TCR)","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regimmune \/ San Fu Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ San Fu Biotech"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Alefacept","moa":"T-cell surface antigen CD2","graph1":"Immunology","graph2":"Phase I","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Astellas Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Northwestern University \/ Astellas Pharma"},{"orgOrder":0,"company":"University Hospitals Cleveland Medical Center","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Alefacept","moa":"T-cell surface antigen CD2","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Hospitals Cleveland Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals Cleveland Medical Center \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University Hospitals Cleveland Medical Center \/ Astellas Pharma"},{"orgOrder":0,"company":"T-Balance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tregalizumab","moa":"T-cell surface antigen CD4","graph1":"Immunology","graph2":"Phase II","graph3":"T-Balance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"T-Balance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"T-Balance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Tregalizumab","moa":"T-cell surface antigen CD4","graph1":"Immunology","graph2":"Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ AbbVie Inc"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Oxford University Hospitals NHS Trust | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Antithymocyte Globulin","moa":"T-cell surface glycoprotein CD1a (CD1A)","graph1":"Immunology","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Oxford University Hospitals NHS Trust | Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Oxford University Hospitals NHS Trust | Sanofi"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Otelixizumab","moa":"T-cell surface glycoprotein CD3 epsilon chain","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Otelixizumab","moa":"T-cell surface glycoprotein CD3 epsilon chain","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Neovii","sponsor":"Eurotrials Brasil | Recerca Cl\u00ednica | PsyConsult","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Atg-Fresenius S","moa":"T-cells (T-cells)","graph1":"Immunology","graph2":"Phase III","graph3":"Neovii","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neovii \/ Eurotrials Brasil | Recerca Cl\u00ednica | PsyConsult","highestDevelopmentStatusID":"10","companyTruncated":"Neovii \/ Eurotrials Brasil | Recerca Cl\u00ednica | PsyConsult"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"JTE-051","moa":"T-cell-specific kinase (ITK)","graph1":"Immunology","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BMS-931699","moa":"T-cell-specific surface glycoprotein CD28","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Theramab LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"TAB08","moa":"T-cell-specific surface glycoprotein CD28","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theramab LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theramab LLC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theramab LLC \/ Undisclosed"},{"orgOrder":0,"company":"Theramab LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"TAB08","moa":"T-cell-specific surface glycoprotein CD28","graph1":"Immunology","graph2":"Phase II","graph3":"Theramab LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theramab LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theramab LLC \/ Undisclosed"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Origo Biopharma","sponsor":"AgomAb Therapeutics N.V","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"ORG-129","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase I","graph3":"Origo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Origo Biopharma \/ AgomAb Therapeutics N.V","highestDevelopmentStatusID":"6","companyTruncated":"Origo Biopharma \/ AgomAb Therapeutics N.V"},{"orgOrder":0,"company":"A.T. Resolve","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"RX-10045","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"A.T. Resolve","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A.T. Resolve \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"A.T. Resolve \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"UTTR1147A","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"UTTR1147A","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"UTTR1147A","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Medsenic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nantes University Hospital \/ Medsenic","highestDevelopmentStatusID":"8","companyTruncated":"Nantes University Hospital \/ Medsenic"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"BioSenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Undisclosed"},{"orgOrder":0,"company":"BioSenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Phebra","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Phebra"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Medsenic","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Medsenic"},{"orgOrder":0,"company":"Medsenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Undisclosed"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"BioSenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Undisclosed"},{"orgOrder":0,"company":"BioSenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Undisclosed"},{"orgOrder":0,"company":"BioSenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"BioSenic","sponsor":"Gestys Sant\u00e9 Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Gestys Sant\u00e9 Biotech","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Gestys Sant\u00e9 Biotech"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Preclinical","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phebra \/ BioSenic","highestDevelopmentStatusID":"4","companyTruncated":"Phebra \/ BioSenic"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"E5501","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"E5501","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"E5501","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"E5501","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Blood and Marrow Transplant, Pakistan","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"PAKISTAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"National Institute of Blood and Marrow Transplant, Pakistan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Blood and Marrow Transplant, Pakistan \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Blood and Marrow Transplant, Pakistan \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Renata Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BANGLADESH","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Renata Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renata Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Renata Limited \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"McMaster University","sponsor":"GSK | Hamilton Health Sciences | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"McMaster University \/ GSK | Hamilton Health Sciences | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ GSK | Hamilton Health Sciences | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Weill Medical College of Cornell University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Humanity & Health Medical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Humanity & Health Medical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Humanity & Health Medical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Humanity & Health Medical Group \/ Undisclosed"},{"orgOrder":0,"company":"University Children's Hospital Basel","sponsor":"Stiftung zur F\u00f6rderung medizinischer und biologischer Forschung | Novartis Pharmaceuticals Corporation | University of Erlangen-N\u00fcrnberg, Department of Biology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase II","graph3":"University Children's Hospital Basel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Children's Hospital Basel \/ Stiftung zur F\u00f6rderung medizinischer und biologischer Forschung | Novartis Pharmaceuticals Corporation | University of Erlangen-N\u00fcrnberg, Department of Biology","highestDevelopmentStatusID":"8","companyTruncated":"University Children's Hospital Basel \/ Stiftung zur F\u00f6rderung medizinischer und biologischer Forschung | Novartis Pharmaceuticals Corporation | University of Erlangen-N\u00fcrnberg, Department of Biology"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hetrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Union Hospital \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Wuhan Union Hospital \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hetrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lusutrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lusutrombopag","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"Thymic stromal lymphopoietin","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"Thymic stromal lymphopoietin","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"NYU Langone Health | Duke University | University of Chicago | Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ NYU Langone Health | Duke University | University of Chicago | Stanford University","highestDevelopmentStatusID":"11","companyTruncated":"Johns Hopkins University \/ NYU Langone Health | Duke University | University of Chicago | Stanford University"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methimazole","moa":"Thyroid peroxidase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ravaglimab","moa":"TIGIT","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Immunology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LAPIX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Immunology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LAPIX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Immunology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LAPIX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Health Resources and Services Administration","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Immunology","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cleveland Clinic \/ Health Resources and Services Administration","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Health Resources and Services Administration"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Telavant","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Telavant","amount2":7.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":7.25,"dosageForm":"Injection","sponsorNew":"Telavant \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Telavant","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Telavant","amount2":7.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":7.25,"dosageForm":"Injection","sponsorNew":"Telavant \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"GALE Therapeutics Inc.","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"XmAb942","moa":"TL1A","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"GALE Therapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GALE Therapeutics Inc. \/ Xencor","highestDevelopmentStatusID":"7","companyTruncated":"GALE Therapeutics Inc. \/ Xencor"},{"orgOrder":0,"company":"Xencor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"XmAb942","moa":"TL1A","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xencor \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xencor \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"PRV-300","moa":"TLR3","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Glucopyranosyl Lipid A","moa":"TLR4","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Afimetoran","moa":"TLR4 receptor antagonists","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"BL-7040","moa":"TLR9","graph1":"Immunology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"Longevity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Proximod","moa":"TLR9","graph1":"Immunology","graph2":"Phase I","graph3":"Longevity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Longevity \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Longevity \/ Undisclosed"},{"orgOrder":0,"company":"Longevity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Proximod","moa":"TLR9","graph1":"Immunology","graph2":"Phase I","graph3":"Longevity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Longevity \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Longevity \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Center Groningen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arthritis & Rheumatic Disease Specialties Research","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Arthritis & Rheumatic Disease Specialties Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arthritis & Rheumatic Disease Specialties Research \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Arthritis & Rheumatic Disease Specialties Research \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"University of California, Los Angeles \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arthritis & Rheumatism Associates, P.C.","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Arthritis & Rheumatism Associates, P.C.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arthritis & Rheumatism Associates, P.C. \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Arthritis & Rheumatism Associates, P.C. \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Children's Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Boston Children's Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Oklahoma Medical Research Foundation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Oklahoma Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oklahoma Medical Research Foundation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Oklahoma Medical Research Foundation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of Washington","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Washington \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"University of Washington \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"||T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Dartmouth-Hitchcock Medical Center | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Dartmouth-Hitchcock Medical Center | Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Dartmouth-Hitchcock Medical Center | Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Columbia University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Columbia University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cleveland Clinic \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Cleveland Clinic \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Thrasher Research Fund | Sickle Cell Transplant & Research Alliance | Aflac Cancer and Blood Disorders Center | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Thrasher Research Fund | Sickle Cell Transplant & Research Alliance | Aflac Cancer and Blood Disorders Center | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Gabrail Cancer Center Research \/ Thrasher Research Fund | Sickle Cell Transplant & Research Alliance | Aflac Cancer and Blood Disorders Center | Bristol Myers Squibb"},{"orgOrder":0,"company":"Orrin M Troum, M.D. and Medical Associates","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Orrin M Troum, M.D. and Medical Associates","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orrin M Troum, M.D. and Medical Associates \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Orrin M Troum, M.D. and Medical Associates \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"R\u00fcdiger B. M\u00fcller","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"R\u00fcdiger B. M\u00fcller","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"R\u00fcdiger B. M\u00fcller \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"R\u00fcdiger B. M\u00fcller \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Duke University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Duke University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Duke University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Transplant Genomics, Inc. | CareDx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Transplant Genomics, Inc. | CareDx","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ Transplant Genomics, Inc. | CareDx"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Heart, Lung, and Blood Institute | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Heart, Lung, and Blood Institute | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Heart, Lung, and Blood Institute | Bristol Myers Squibb"},{"orgOrder":0,"company":"Lorenzo Gallon","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Lorenzo Gallon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lorenzo Gallon \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Lorenzo Gallon \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Beijing Continent Pharmaceutical","sponsor":"Shanghai Genomics, Inc. | GNI Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Immunology","graph2":"Phase III","graph3":"Beijing Continent Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Continent Pharmaceutical \/ Shanghai Genomics, Inc. | GNI Group","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Continent Pharmaceutical \/ Shanghai Genomics, Inc. | GNI Group"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Immunology","graph2":"Phase II","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Michigan \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Michigan \/ Genentech"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BAT2506","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BAT2506","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"INmune Bio","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Immunology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INmune Bio \/ ALS Association","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ ALS Association"},{"orgOrder":0,"company":"William Harvey Research Institute","sponsor":"Cyxone AB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Rabeximod","moa":"TNF receptor","graph1":"Immunology","graph2":"Phase II","graph3":"William Harvey Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"William Harvey Research Institute \/ Cyxone AB","highestDevelopmentStatusID":"8","companyTruncated":"William Harvey Research Institute \/ Cyxone AB"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cyxone AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Undisclosed"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cyxone AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Undisclosed"},{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Danuo Science Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"EN1001","moa":"TNF1 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Enosi Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Enosi Therapeutics \/ Danuo Science Group","highestDevelopmentStatusID":"4","companyTruncated":"Enosi Therapeutics \/ Danuo Science Group"},{"orgOrder":0,"company":"Dualyx","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"DT-001","moa":"TNF2 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Dualyx","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Dualyx \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"5","companyTruncated":"Dualyx \/ Fountain Healthcare Partners"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Hershey Medical Center","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Hershey Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hershey Medical Center \/ UCB Pharma S.A","highestDevelopmentStatusID":"11","companyTruncated":"Hershey Medical Center \/ UCB Pharma S.A"},{"orgOrder":0,"company":"University of Washington","sponsor":"UCB Pharma S.A | University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Washington \/ UCB Pharma S.A | University of Pennsylvania","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ UCB Pharma S.A | University of Pennsylvania"},{"orgOrder":0,"company":"Highmark","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Highmark","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highmark \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Highmark \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Korea Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Korea Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Korea Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2011","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2011","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"PPD | Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2013","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ PPD | Parexel","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ PPD | Parexel"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2011","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2011","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Parexel","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Parexel"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ PRA Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ PRA Health Sciences"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Parexel","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Parexel"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Parexel","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Parexel"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Parexel","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Parexel"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2025","type":"Acquisition","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Xbrane Biopharma \/ Alvotech","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Biopharma \/ Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody-drug Conjugate","year":"2025","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Alvotech \/ Advanz Pharma"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"PPD | Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ PPD | Parexel","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ PPD | Parexel"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Xbrane Biopharma \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Biopharma \/ Biogen"},{"orgOrder":0,"company":"Shafran Gastroenterology Center","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Shafran Gastroenterology Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shafran Gastroenterology Center \/ UCB Pharma S.A","highestDevelopmentStatusID":"11","companyTruncated":"Shafran Gastroenterology Center \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Shafran Gastroenterology Center","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Shafran Gastroenterology Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shafran Gastroenterology Center \/ UCB Pharma S.A","highestDevelopmentStatusID":"11","companyTruncated":"Shafran Gastroenterology Center \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Gastroenterology Research of America","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2013","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Gastroenterology Research of America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gastroenterology Research of America \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Gastroenterology Research of America \/ UCB Pharma S.A"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Illinois, Chicago \/ UCB Pharma S.A","highestDevelopmentStatusID":"11","companyTruncated":"University of Illinois, Chicago \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Oklahoma Medical Research Foundation","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Oklahoma Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oklahoma Medical Research Foundation \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Oklahoma Medical Research Foundation \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"ABP 710","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"ATN-103","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Avsola","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ National Institute of Diabetes and Digestive and Kidney Diseases | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ National Institute of Diabetes and Digestive and Kidney Diseases | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"BI695501","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"BI695501","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"BI695501","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BI695501","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BIBR 796 BS","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BIBR-796","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Epirus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BOW015","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Epirus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Epirus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Epirus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"CDP870","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"CHS-0214","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Daiichi Sankyo | SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"CHS-0214","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Daiichi Sankyo | SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Daiichi Sankyo | SHIRE PLC"},{"orgOrder":0,"company":"Shanghai Biomabs Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CMAB008","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Biomabs Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Biomabs Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Biomabs Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"CT-P13","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Pfizer Inc"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"CT-P13","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"CT-P13","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"CT-P13","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Hanwha Chemical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Hanwha Chemical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanwha Chemical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanwha Chemical \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Sandoz B2B"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"LG Life Sciences \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Giannina Gaslini Institute","sponsor":"Agenzia Italiana del Farmaco | Compagnia di San Paolo | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Giannina Gaslini Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Giannina Gaslini Institute \/ Agenzia Italiana del Farmaco | Compagnia di San Paolo | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Giannina Gaslini Institute \/ Agenzia Italiana del Farmaco | Compagnia di San Paolo | Pfizer Inc"},{"orgOrder":0,"company":"University of Leeds","sponsor":"National Institute for Health Research, UK | Pfizer Inc | Clinical Trials Research Unit, Leeds","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"University of Leeds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Leeds \/ National Institute for Health Research, UK | Pfizer Inc | Clinical Trials Research Unit, Leeds","highestDevelopmentStatusID":"8","companyTruncated":"University of Leeds \/ National Institute for Health Research, UK | Pfizer Inc | Clinical Trials Research Unit, Leeds"},{"orgOrder":0,"company":"University of Leeds","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Leeds","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leeds \/ Samsung Bioepis","highestDevelopmentStatusID":"11","companyTruncated":"University of Leeds \/ Samsung Bioepis"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Sunshine Guojian Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CZECH REPUBLIC","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"FARMAK, a.s \/ Sunshine Guojian Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"FARMAK, a.s \/ Sunshine Guojian Pharmaceutical"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"4P Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ 4P Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ 4P Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Gema Biotech","sponsor":"QUID Quality in Drugs and Devices LA Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Gema Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gema Biotech \/ QUID Quality in Drugs and Devices LA Consulting","highestDevelopmentStatusID":"10","companyTruncated":"Gema Biotech \/ QUID Quality in Drugs and Devices LA Consulting"},{"orgOrder":0,"company":"Gema Biotech","sponsor":"QUID Quality in Drugs and Devices LA Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Gema Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gema Biotech \/ QUID Quality in Drugs and Devices LA Consulting","highestDevelopmentStatusID":"10","companyTruncated":"Gema Biotech \/ QUID Quality in Drugs and Devices LA Consulting"},{"orgOrder":0,"company":"P. Verschueren","sponsor":"Belgium Health Care Knowledge Centre","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"P. Verschueren","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"P. Verschueren \/ Belgium Health Care Knowledge Centre","highestDevelopmentStatusID":"11","companyTruncated":"P. Verschueren \/ Belgium Health Care Knowledge Centre"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Dutch Arthritis Association","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Dutch Arthritis Association","highestDevelopmentStatusID":"11","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Dutch Arthritis Association"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"FKB327","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"FKB327","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Accord BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Accord BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Accord BioPharma"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"University Ghent","sponsor":"Merck & Co | the Flanders Institute for Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"University Ghent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Ghent \/ Merck & Co | the Flanders Institute for Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"University Ghent \/ Merck & Co | the Flanders Institute for Biotechnology"},{"orgOrder":0,"company":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Merck & Co"},{"orgOrder":0,"company":"IMM Jo\u00e3o Lobo Antunes","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"PORTUGAL","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"IMM Jo\u00e3o Lobo Antunes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IMM Jo\u00e3o Lobo Antunes \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"IMM Jo\u00e3o Lobo Antunes \/ Merck & Co"},{"orgOrder":0,"company":"Hospital de Manises","sponsor":"General University Hospital of Valencia | Hospital Cl\u00ednico Universitario de Valencia | Hospital de Sagunto | Hospital Universitario La Fe | Hospital General Universitario de Alicante | Hospital Universitario Doctor Peset | Hospital Arnau de Vilanova | Hos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Hospital de Manises","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital de Manises \/ General University Hospital of Valencia | Hospital Cl\u00ednico Universitario de Valencia | Hospital de Sagunto | Hospital Universitario La Fe | Hospital General Universitario de Alicante | Hospital Universitario Doctor Peset | Hospital Arnau de Vilanova | Hos","highestDevelopmentStatusID":"11","companyTruncated":"Hospital de Manises \/ General University Hospital of Valencia | Hospital Cl\u00ednico Universitario de Valencia | Hospital de Sagunto | Hospital Universitario La Fe | Hospital General Universitario de Alicante | Hospital Universitario Doctor Peset | Hospital Arnau de Vilanova | Hos"},{"orgOrder":0,"company":"Guy's and St Thomas' NHS Foundation Trust","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Guy's and St Thomas' NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guy's and St Thomas' NHS Foundation Trust \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Guy's and St Thomas' NHS Foundation Trust \/ Merck & Co"},{"orgOrder":0,"company":"The Leeds Teaching Hospitals NHS Trust","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"The Leeds Teaching Hospitals NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Leeds Teaching Hospitals NHS Trust \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"The Leeds Teaching Hospitals NHS Trust \/ Janssen Pharmaceutica"},{"orgOrder":0,"company":"Imperial College Healthcare NHS Trust","sponsor":"Merck & Co | Imperial College London","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Imperial College Healthcare NHS Trust","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College Healthcare NHS Trust \/ Merck & Co | Imperial College London","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College Healthcare NHS Trust \/ Merck & Co | Imperial College London"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Financing","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.34000000000000002,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Advanz Pharma"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Pharmapark","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaMar \/ Pharmapark","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Pharmapark"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Centocor","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centocor \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Centocor \/ Merck & Co"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Centocor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centocor \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Centocor \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Johnson & Johnson"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Centocor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centocor \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Centocor \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"GP2015","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"HLX03","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Mabpharm Limitied","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Mabpharm Limitied","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabpharm Limitied \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mabpharm Limitied \/ Undisclosed"},{"orgOrder":0,"company":"Mabpharm Limitied","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Mabpharm Limitied","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabpharm Limitied \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabpharm Limitied \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Nichi-Iko Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Nichi-Iko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nichi-Iko Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nichi-Iko Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Klinikum Westbrandenburg","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Klinikum Westbrandenburg","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Klinikum Westbrandenburg \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Klinikum Westbrandenburg \/ Undisclosed"},{"orgOrder":0,"company":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Undisclosed"},{"orgOrder":0,"company":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","sponsor":"Saint-Louis Hospital, Paris","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Saint-Louis Hospital, Paris","highestDevelopmentStatusID":"11","companyTruncated":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Saint-Louis Hospital, Paris"},{"orgOrder":0,"company":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","sponsor":"Celltrion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Celltrion","highestDevelopmentStatusID":"11","companyTruncated":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Celltrion"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Pfizer Inc"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Celltrion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Celltrion","highestDevelopmentStatusID":"10","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Celltrion"},{"orgOrder":0,"company":"Diakonhjemmet Hospital","sponsor":"South-Eastern Norway Regional Health Authority","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Diakonhjemmet Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diakonhjemmet Hospital \/ South-Eastern Norway Regional Health Authority","highestDevelopmentStatusID":"11","companyTruncated":"Diakonhjemmet Hospital \/ South-Eastern Norway Regional Health Authority"},{"orgOrder":0,"company":"Intract Pharma","sponsor":"SGS Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Intract Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intract Pharma \/ SGS Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Intract Pharma \/ SGS Life Sciences"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Alimentiv","highestDevelopmentStatusID":"11","companyTruncated":"University of Calgary \/ Alimentiv"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Centocor","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oregon Health and Science University \/ Centocor","highestDevelopmentStatusID":"1","companyTruncated":"Oregon Health and Science University \/ Centocor"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hospital Universitario Reina Sofia de Cordoba | Dr. Jose Mar\u00eda Martos Becerra (Central Radiological Assessment) - Hospital de Alta Resoluci\u00f3n","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Hospital Universitario Reina Sofia de Cordoba | Dr. Jose Mar\u00eda Martos Becerra (Central Radiological Assessment) - Hospital de Alta Resoluci\u00f3n","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Hospital Universitario Reina Sofia de Cordoba | Dr. Jose Mar\u00eda Martos Becerra (Central Radiological Assessment) - Hospital de Alta Resoluci\u00f3n"},{"orgOrder":0,"company":"Austin Health","sponsor":"University of Melbourne","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Austin Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Austin Health \/ University of Melbourne","highestDevelopmentStatusID":"11","companyTruncated":"Austin Health \/ University of Melbourne"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"ZonMw | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw | Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw | Pfizer Inc"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"MSB11022","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fresenius Kabi AG \/ PRA Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ PRA Health Sciences"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"MSB11022","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Nichi-Iko Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"NI-071","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Nichi-Iko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nichi-Iko Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nichi-Iko Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nichi-Iko Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"NI-071","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Nichi-Iko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nichi-Iko Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nichi-Iko Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"PF-06410293","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PF-06410293","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"PF-06438179","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"TA-650","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"TA-650","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Neovacs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"TNF Kinoid","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Neovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neovacs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neovacs \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"ABBV-3373","moa":"TNF-alpha | Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ABBV-3373","moa":"TNF-alpha | Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"ABT-122","moa":"TNF-alpha | Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"ABT-122","moa":"TNF-alpha | Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"ABT-122","moa":"TNF-alpha | Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"ABT-122","moa":"TNF-alpha | Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"ABT-122","moa":"TNF-alpha | Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Institute for Developing Science and Health Initiatives, Bangladesh","sponsor":"Universal Medical College Hospital | Green Life Center for Rheumatic Care & Research, Bangladesh | Incepta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BANGLADESH","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Institute for Developing Science and Health Initiatives, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institute for Developing Science and Health Initiatives, Bangladesh \/ Universal Medical College Hospital | Green Life Center for Rheumatic Care & Research, Bangladesh | Incepta Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Institute for Developing Science and Health Initiatives, Bangladesh \/ Universal Medical College Hospital | Green Life Center for Rheumatic Care & Research, Bangladesh | Incepta Pharmaceuticals"},{"orgOrder":0,"company":"Hanyang University Seoul Hospital","sponsor":"Linical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Hanyang University Seoul Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanyang University Seoul Hospital \/ Linical","highestDevelopmentStatusID":"11","companyTruncated":"Hanyang University Seoul Hospital \/ Linical"},{"orgOrder":0,"company":"Celltrion","sponsor":"Rani Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celltrion \/ Rani Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Celltrion \/ Rani Therapeutics"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ PPD","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ PPD"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Biogen"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enzene Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Enzene Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cadila Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cadila Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"LG Life Sciences \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"University of Erlangen-N\u00fcrnberg Medical School","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"University of Erlangen-N\u00fcrnberg Medical School","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Erlangen-N\u00fcrnberg Medical School \/ Abbott Laboratories","highestDevelopmentStatusID":"7","companyTruncated":"University of Erlangen-N\u00fcrnberg Medical School \/ Abbott Laboratories"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"University of Southern Denmark | Hvidovre University Hospital | Aarhus University Hospital | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odense University Hospital \/ University of Southern Denmark | Hvidovre University Hospital | Aarhus University Hospital | AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Odense University Hospital \/ University of Southern Denmark | Hvidovre University Hospital | Aarhus University Hospital | AbbVie Inc"},{"orgOrder":0,"company":"The Rheumatological Center of Helsinki","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"The Rheumatological Center of Helsinki","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Rheumatological Center of Helsinki \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"The Rheumatological Center of Helsinki \/ Abbott Laboratories"},{"orgOrder":0,"company":"University of Helsinki","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Helsinki","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Helsinki \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Helsinki \/ AbbVie Inc"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ AbbVie Inc"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Maastricht University | ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Maastricht University | ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Maastricht University Medical Center \/ Maastricht University | ZonMw"},{"orgOrder":0,"company":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","sponsor":"Abbott Laboratories | TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa \/ Abbott Laboratories | TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa \/ Abbott Laboratories | TFS Trial Form Support"},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Abbott Laboratories | Swedish Foundation for Strategic Research | The Swedish Research Council","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Institutet \/ Abbott Laboratories | Swedish Foundation for Strategic Research | The Swedish Research Council","highestDevelopmentStatusID":"1","companyTruncated":"Karolinska Institutet \/ Abbott Laboratories | Swedish Foundation for Strategic Research | The Swedish Research Council"},{"orgOrder":0,"company":"Skane University Hospital","sponsor":"Abbott Laboratories | The Swedish Research Council | The Swedish Rheumatism Ass | Crafoord Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Skane University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skane University Hospital \/ Abbott Laboratories | The Swedish Research Council | The Swedish Rheumatism Ass | Crafoord Foundation","highestDevelopmentStatusID":"11","companyTruncated":"Skane University Hospital \/ Abbott Laboratories | The Swedish Research Council | The Swedish Rheumatism Ass | Crafoord Foundation"},{"orgOrder":0,"company":"University of Leeds","sponsor":"AbbVie Inc | Theorem","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Leeds","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leeds \/ AbbVie Inc | Theorem","highestDevelopmentStatusID":"11","companyTruncated":"University of Leeds \/ AbbVie Inc | Theorem"},{"orgOrder":0,"company":"University of Leeds","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"University of Leeds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leeds \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"University of Leeds \/ Abbott Laboratories"},{"orgOrder":0,"company":"Heinrich-Heine University, Duesseldorf","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Heinrich-Heine University, Duesseldorf","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heinrich-Heine University, Duesseldorf \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Heinrich-Heine University, Duesseldorf \/ Abbott Laboratories"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Hexal AG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Hexal AG","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Hexal AG"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Bioventure Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Quallent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Quallent Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Quallent Pharmaceuticals"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Samsung Bioepis"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Mabwell","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Binnopharm Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binnopharm Group \/ Mabwell","highestDevelopmentStatusID":"15","companyTruncated":"Binnopharm Group \/ Mabwell"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Fresenius Kabi","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Fresenius Kabi"},{"orgOrder":0,"company":"Alvotech","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ DKSH"},{"orgOrder":0,"company":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ Abbott Laboratories"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabin Medical Center \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Rabin Medical Center \/ Abbott Laboratories"},{"orgOrder":0,"company":"Clalit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Clalit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clalit \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clalit \/ Undisclosed"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinnaGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Universit\u00e9 de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e9 de Sherbrooke \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Universit\u00e9 de Sherbrooke \/ AbbVie Inc"},{"orgOrder":0,"company":"Reade Rheumatology Research Institute","sponsor":"ZonMw | Sint Maartenskliniek","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Reade Rheumatology Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reade Rheumatology Research Institute \/ ZonMw | Sint Maartenskliniek","highestDevelopmentStatusID":"11","companyTruncated":"Reade Rheumatology Research Institute \/ ZonMw | Sint Maartenskliniek"},{"orgOrder":0,"company":"Reade Rheumatology Research Institute","sponsor":"ZonMw | Sint Maartenskliniek","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Reade Rheumatology Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reade Rheumatology Research Institute \/ ZonMw | Sint Maartenskliniek","highestDevelopmentStatusID":"11","companyTruncated":"Reade Rheumatology Research Institute \/ ZonMw | Sint Maartenskliniek"},{"orgOrder":0,"company":"Superior Biologics","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Superior Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Superior Biologics \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Superior Biologics \/ Coherus Biosciences"},{"orgOrder":0,"company":"Progenity","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Funding","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Progenity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Undisclosed"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Progenity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Undisclosed"},{"orgOrder":0,"company":"Progenity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Mount Sinai Hospital, Canada","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Mount Sinai Hospital, Canada","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Mount Sinai Hospital, Canada"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Laboratorio Echevarne | Pivotal S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Laboratorio Echevarne | Pivotal S.L.","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Laboratorio Echevarne | Pivotal S.L."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"IST GmbH | Hannover Medical School | Improvement by Movement","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ IST GmbH | Hannover Medical School | Improvement by Movement","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ IST GmbH | Hannover Medical School | Improvement by Movement"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Mark Cuban Cost Plus Drug Company"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Samsung Bioepis"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Hong Kong King-Friend Industrial Co. Ltd","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Divestment","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Hong Kong King-Friend Industrial Co. Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Hong Kong King-Friend Industrial Co. Ltd"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"St Vincent's Hospital Melbourne","sponsor":"Australasian Gastro Intestinal Research Foundation | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"St Vincent's Hospital Melbourne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"St Vincent's Hospital Melbourne \/ Australasian Gastro Intestinal Research Foundation | AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"St Vincent's Hospital Melbourne \/ Australasian Gastro Intestinal Research Foundation | AbbVie Inc"},{"orgOrder":0,"company":"Quallent Pharmaceuticals","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CAYMAN ISLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Quallent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Quallent Pharmaceuticals \/ Alvotech","highestDevelopmentStatusID":"15","companyTruncated":"Quallent Pharmaceuticals \/ Alvotech"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FSD201","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Quantum BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quantum BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TNF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TNF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Akers Biosciences","sponsor":"MyMD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Akers Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Akers Biosciences \/ MyMD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Akers Biosciences \/ MyMD Pharmaceuticals"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TNF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lucid Psycheceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Lucid Psycheceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lucid Psycheceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lucid Psycheceuticals \/ Undisclosed"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Ingenu","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum BioPharma \/ iNGENu","highestDevelopmentStatusID":"8","companyTruncated":"Quantum BioPharma \/ iNGENu"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"TNF alpha monoclonal antibody","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Neovacs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"TNF alpha monoclonal antibody","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Neovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neovacs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neovacs \/ Undisclosed"},{"orgOrder":0,"company":"Sorriso Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SOR102","moa":"TNF-alpha\/IL-23 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Sorriso Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorriso Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorriso Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sorriso Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SOR102","moa":"TNF-alpha\/IL-23 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Sorriso Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorriso Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorriso Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"MLTA3698A","moa":"TNF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Evotec","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Protein","year":"2022","type":"Expanded Collaboration","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Evotec \/ Alpine Immune Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ Alpine Immune Sciences"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Private Placement","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Frazier Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"TNFRSF17","graph1":"Immunology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Kiniksa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Abiprubart","moa":"TNFRSF5","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Kiniksa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Kiniksa Pharmaceuticals"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Abiprubart","moa":"TNFRSF5","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Abiprubart","moa":"TNFRSF5","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":10.800000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":10.800000000000001,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Thermo Fisher Scientific","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Thermo Fisher Scientific"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GLPG3970","moa":"TOL2\/TOL3","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GLPG3970","moa":"TOL2\/TOL3","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GLPG3970","moa":"TOL2\/TOL3","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GLPG3970","moa":"TOL2\/TOL3","graph1":"Immunology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||Toll-like receptor 3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"NI-0101","moa":"Toll-like receptor 4 (TLR4)","graph1":"Immunology","graph2":"Phase II","graph3":"Light Chain Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Light Chain Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Light Chain Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD8848","moa":"Toll-like receptor 7","graph1":"Immunology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SOF-SKN","moa":"Toll-like receptor 7 | Toll-like receptor 8","graph1":"Immunology","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enpatoran","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Immunology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"M5049","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Immunology","graph2":"Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"M5049","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Immunology","graph2":"Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"M5049","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Immunology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"IMO-8400","moa":"Toll-like receptor 8 | Toll-like receptor 7 | Toll-like receptor 9","graph1":"Immunology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Vinnova","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Vinnova","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Vinnova"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InDex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"InDex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Cobitolimod","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Parexel Biotech \/ InDex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Biotech \/ InDex Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"NYU Langone Health \/ National Institutes of Health"},{"orgOrder":0,"company":"Inimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INI-2004","moa":"Toll-like-4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Inimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inimmune \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inimmune \/ Undisclosed"},{"orgOrder":0,"company":"Inimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INI-2004","moa":"Toll-like-4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Inimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inimmune \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inimmune \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Carbohydrate","year":"2021","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Toll-like-4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Toll-like-4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Toll Biotech Co. Ltd. (Beijing)","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TollB-001","moa":"Toll-like-7 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Toll Biotech Co. Ltd. (Beijing)","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Toll Biotech Co. Ltd. (Beijing) \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toll Biotech Co. Ltd. (Beijing) \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Afimetoran","moa":"TLR4 receptor antagonists","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Afimetoran","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Undisclosed","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.29999999999999999,"dosageForm":"Capsule","sponsorNew":"Undisclosed \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Undisclosed \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"E6742","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"E6742","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Herombopag","moa":"TPO receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Herombopag Olamine","moa":"TPO receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Herombopag Olamine","moa":"TPO receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ACE-1334","moa":"Transforming growth factor beta 1 (TGFB1)","graph1":"Immunology","graph2":"Phase I","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tr1X Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Tr1X Bio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Series A Financing","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Tr1X Bio \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ The Column Group"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tr1X Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tr1X Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tr1X Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tr1X Bio \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BI 3032950","moa":"TREM1","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CEL383","moa":"TREM1","graph1":"Immunology","graph2":"Preclinical","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celsius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Celsius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Walloon Region","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"HY-083","moa":"TRPV1","graph1":"Immunology","graph2":"Preclinical","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hyloris Pharmaceuticals \/ Walloon Region","highestDevelopmentStatusID":"4","companyTruncated":"Hyloris Pharmaceuticals \/ Walloon Region"},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Kappa Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Vitamin K2","moa":"Trypanosoma Cruzipain (Trypano CYSP)","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Glasgow","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Glasgow \/ Kappa Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"University of Glasgow \/ Kappa Bioscience"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Immunology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AV7","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"K1-70","moa":"TSH receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AV7","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AV7 \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AV7 \/ Undisclosed"},{"orgOrder":0,"company":"Apitope International","sponsor":"Quintiles Inc | European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ATX-GD-59","moa":"TSHR","graph1":"Immunology","graph2":"Phase I","graph3":"Apitope International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apitope International \/ Quintiles Inc | European Commission","highestDevelopmentStatusID":"6","companyTruncated":"Apitope International \/ Quintiles Inc | European Commission"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ATI-052","moa":"TSLP\/IL-4 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"ATx201","moa":"Tubulin","graph1":"Immunology","graph2":"Phase I","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Funding","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Immunology","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Montreal Heart Institute \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ COVID-19 Therapeutics Accelerator"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ABBV-154","moa":"Tumor necrosis factor (TNF)","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ABBV-154","moa":"Tumor necrosis factor (TNF)","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"ILab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IA-14069","moa":"Tumor necrosis factor (TNF)","graph1":"Immunology","graph2":"Phase I","graph3":"ILab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ILab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ILab \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SAR441566","moa":"Tumor necrosis factor (TNF)","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SAR441566","moa":"Tumor necrosis factor (TNF)","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SAR441566","moa":"Tumor necrosis factor (TNF)","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SAR441566","moa":"Tumor necrosis factor (TNF)","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SAR441566","moa":"Tumor necrosis factor (TNF)","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"VHsquared Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"V565","moa":"Tumor necrosis factor alpha","graph1":"Immunology","graph2":"Phase I","graph3":"VHsquared Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VHsquared Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VHsquared Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"VHsquared Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"V565","moa":"Tumor necrosis factor alpha","graph1":"Immunology","graph2":"Phase II","graph3":"VHsquared Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VHsquared Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VHsquared Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"VHsquared Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"V565","moa":"Tumor necrosis factor alpha","graph1":"Immunology","graph2":"Phase II","graph3":"VHsquared Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VHsquared Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VHsquared Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Immunology","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Immunology","graph2":"Phase I","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Sibeprenlimab","moa":"Tumor necrosis factor ligand superfamily member 13","graph1":"Immunology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"A-623","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"A-623","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"National University Hospital, Singapore","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"National University Hospital, Singapore","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National University Hospital, Singapore \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"National University Hospital, Singapore \/ GSK"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Biologics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"Samsung Biologics \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Biologics \/ GSK"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Dutch Kidney Foundation | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leiden University Medical Center \/ Dutch Kidney Foundation | GSK","highestDevelopmentStatusID":"10","companyTruncated":"Leiden University Medical Center \/ Dutch Kidney Foundation | GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Health Network, Toronto \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ GSK"},{"orgOrder":0,"company":"Northwell Health","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwell Health \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"Northwell Health \/ GSK"},{"orgOrder":0,"company":"Hospital for Special Surgery, New York","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Hospital for Special Surgery, New York","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital for Special Surgery, New York \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Hospital for Special Surgery, New York \/ GSK"},{"orgOrder":0,"company":"Hospital for Special Surgery, New York","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"Hospital for Special Surgery, New York","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital for Special Surgery, New York \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Hospital for Special Surgery, New York \/ GSK"},{"orgOrder":0,"company":"Oklahoma Medical Research Foundation","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase IV","graph3":"Oklahoma Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oklahoma Medical Research Foundation \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"Oklahoma Medical Research Foundation \/ GSK"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"GSK | American College of Surgeons","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ GSK | American College of Surgeons","highestDevelopmentStatusID":"8","companyTruncated":"University of Wisconsin, Madison \/ GSK | American College of Surgeons"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"GSK | American Cancer Society","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ GSK | American Cancer Society","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ GSK | American Cancer Society"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Blisibimod","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Blisibimod","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Blisibimod","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anthera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Blisibimod","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Anthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anthera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Anthera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"GSK1550188","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"GSK1550188","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"LY2127399","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tabalumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tabalumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tabalumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Atacicept","moa":"Tumor necrosis factor ligand superfamily member 13B | Tumor necrosis factor ligand superfamily member 13","graph1":"Immunology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EMD Serono \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Atacicept","moa":"Tumor necrosis factor ligand superfamily member 13B | Tumor necrosis factor ligand superfamily member 13","graph1":"Immunology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EMD Serono \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Atacicept","moa":"Tumor necrosis factor ligand superfamily member 13B | Tumor necrosis factor ligand superfamily member 13","graph1":"Immunology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EMD Serono \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Undisclosed"},{"orgOrder":0,"company":"Cerecor","sponsor":"Horizon Technology Finance Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Financing","leadProduct":"AEVI-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cerecor \/ Horizon Technology Finance Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Horizon Technology Finance Corporation"},{"orgOrder":0,"company":"Cerecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AEVI-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cerecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Undisclosed"},{"orgOrder":0,"company":"Cerecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CERC-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cerecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"MDGN-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Autoimmunity Centers of Excellence | Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Baminercept","moa":"Tumor necrosis factor ligand superfamily member 14 | Heterotrimeric lymphotoxin LTa1b2","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Biogen","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Biogen"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":1.45,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":1.45,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Scleroderma Research Foundation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Scleroderma Research Foundation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scleroderma Research Foundation \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Scleroderma Research Foundation \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"KY1005","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"KY1005","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"VAY736","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"Tumor necrosis factor receptor superfamily member 17 | T cell surface glycoprotein CD3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Belantamab","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"KHK4083","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Immunology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"KHK4083","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Immunology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"ASKP1240","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bleselumab","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Bleselumab","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"CFZ533","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"CFZ533","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"CFZ533","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"CFZ533","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"CFZ533","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"CFZ533","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"CFZ533","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"CFZ533","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Iscalimab","moa":"||Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Iscalimab","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Pfizer Inc | Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Immunology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Pfizer Inc | Dana-Farber Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Pfizer Inc | Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2013","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Immunology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Andrographolide","moa":"Inflammation pathogenesis (IP)||Tumor necrosis factor; Interleukin-1 beta; Interleukin-6; Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Nutrition Science Partners","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Andrographolide","moa":"Inflammation pathogenesis (IP)||Tumor necrosis factor; Interleukin-1 beta; Interleukin-6; Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Nutrition Science Partners","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Nutrition Science Partners"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BGB-23339","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Alumis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alumis \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GLPG3667","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GLPG3667","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GLPG3667","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GLPG3667","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Immunology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Neuron23","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NEU-111","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuron23 \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neuron23 \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Surveyor Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Surveyor Capital"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Viela Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Viela Bio","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Viela Bio"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zasocitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zasocitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zasocitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Nimbus Lakshmi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Nimbus Lakshmi","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Nimbus Lakshmi"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":6,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":6,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":6,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":6,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CAS 1310726-60-3","moa":"tyrosine kinase inhibitors: janus kinase inhibitors","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"CAS 1310726-60-3","moa":"tyrosine kinase inhibitors: janus kinase inhibitors","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CAS 1310726-60-3","moa":"tyrosine kinase inhibitors: janus kinase inhibitors","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"CAS 1310726-60-3","moa":"tyrosine kinase inhibitors: janus kinase inhibitors","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CAS 1310726-60-3","moa":"tyrosine kinase inhibitors: janus kinase inhibitors","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hospital for Special Surgery, New York","sponsor":"Rudolph Rupert Scleroderma Program | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Immunology","graph2":"Phase II","graph3":"Hospital for Special Surgery, New York","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital for Special Surgery, New York \/ Rudolph Rupert Scleroderma Program | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Hospital for Special Surgery, New York \/ Rudolph Rupert Scleroderma Program | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"BGB-16673","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johns Hopkins University \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ AstraZeneca"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acerta Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ AstraZeneca"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BMS-986142","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BMS-986142","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BMS-986142","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BMS-986142","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986195","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986195","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BMS-986195","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986195","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Branebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CC-292","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Elsubrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Elsubrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Elsubrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Elsubrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elsubrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONO-4059","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Poseltinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Prn1008","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Massachusetts General Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tirabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Ono Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"ACEA Pharmaceutical Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AC0058TA","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase I","graph3":"ACEA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ACEA Therapeutics \/ ACEA Pharmaceutical Research","highestDevelopmentStatusID":"6","companyTruncated":"ACEA Therapeutics \/ ACEA Pharmaceutical Research"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BIIB068","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"SCRI Development Innovations, LLC","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"SCRI Development Innovations, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCRI Development Innovations, LLC \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"SCRI Development Innovations, LLC \/ Incyte Corporation"},{"orgOrder":0,"company":"University of Utah","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Utah \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Columbia University \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"||Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"University of Rochester \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Rochester \/ Incyte Corporation"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Hackensack Meridian Health | Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Hackensack Meridian Health | Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Hackensack Meridian Health | Incyte Corporation"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Momelotinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Francophone des Myelodysplasies \/ GSK"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"tyrosine kinase inhibitors||Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Melbourne Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Melbourne Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melbourne Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Melbourne Health \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roivant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Roivant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roivant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Priovant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Priovant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priovant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priovant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Priovant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Priovant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priovant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priovant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AC430","moa":"Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of North Carolina \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","sponsor":"Healthcare Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BANGLADESH","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh \/ Healthcare Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh \/ Healthcare Pharmaceuticals"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Peking Union Medical College Hospital \/ Eli Lilly"},{"orgOrder":0,"company":"University Hospital, Bordeaux","sponsor":"Eli Lilly | Biogen | Ministry for Health and Solidarity, France","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Bordeaux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Bordeaux \/ Eli Lilly | Biogen | Ministry for Health and Solidarity, France","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Bordeaux \/ Eli Lilly | Biogen | Ministry for Health and Solidarity, France"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Care Arthritis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase IV","graph3":"Care Arthritis","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Care Arthritis \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Care Arthritis \/ Undisclosed"},{"orgOrder":0,"company":"Care Arthritis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase IV","graph3":"Care Arthritis","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Care Arthritis \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Care Arthritis \/ Undisclosed"},{"orgOrder":0,"company":"McMaster University","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lupus Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Lupus Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"VX-509","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"VX-509","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"VX-509","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"VX-509","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Filgotinib Maleate","moa":"Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Filgotinib Maleate","moa":"Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Eisai \/ Gilead Sciences"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Commonwealth Of Pennsylvania\u2019S Covid-19 Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Tolimidone","moa":"Tyrosine-protein kinase Lyn","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melior Pharmaceuticals \/ Commonwealth Of Pennsylvania\u2019S Covid-19 Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Melior Pharmaceuticals \/ Commonwealth Of Pennsylvania\u2019S Covid-19 Vaccines"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase II","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ PSI CRO","highestDevelopmentStatusID":"8","companyTruncated":"Swedish Orphan Biovitrum AB \/ PSI CRO"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Swedish Orphan Biovitrum AB | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Swedish Orphan Biovitrum AB | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Swedish Orphan Biovitrum AB | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Tai Tien Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Tai Tien Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Tai Tien Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"JW Pharmaceutical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"JW Pharmaceutical Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Grifols International","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Grifols International"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Rigel Pharmaceuticals \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Knight Therapeutics"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Knight Therapeutics \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Knight Therapeutics \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Optime Care","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Optime Care","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Optime Care"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos | Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos | Ono Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Galapagos | Ono Pharmaceutical"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Oscotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cevidoplenib","moa":"Tyrosine-protein kinase SYK (SYK)","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Undisclosed"},{"orgOrder":0,"company":"Oscotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cevidoplenib","moa":"Tyrosine-protein kinase SYK (SYK)","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"GSK2646264","moa":"Tyrosine-protein kinase SYK (SYK)","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Oscotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SKI-O-703","moa":"Tyrosine-protein kinase SYK (SYK)","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Undisclosed"},{"orgOrder":0,"company":"Oscotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SKI-O-703","moa":"Tyrosine-protein kinase SYK (SYK)","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Undisclosed"},{"orgOrder":0,"company":"Oscotec","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SKI-O-703","moa":"Tyrosine-protein kinase SYK (SYK)","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ PPD"},{"orgOrder":0,"company":"Oscotec","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"SKI-O-703","moa":"Tyrosine-protein kinase SYK (SYK)","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ PPD"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"PF-06826647","moa":"Tyrosine-protein kinase TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase IV","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ Galapagos","highestDevelopmentStatusID":"11","companyTruncated":"Leiden University Medical Center \/ Galapagos"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Gilead Sciences"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Alfasigma"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Alfasigma"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.19,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alfasigma \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Gilead Sciences"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"||Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Eisai"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Eisai"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Eisai"},{"orgOrder":0,"company":"Aker BioMarine","sponsor":"Ampel BioSolutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"AKBM-3031","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aker BioMarine \/ Ampel BioSolutions","highestDevelopmentStatusID":"1","companyTruncated":"Aker BioMarine \/ Ampel BioSolutions"},{"orgOrder":0,"company":"Shanghai Bao Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KJ103","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Bao Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Bao Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Bao Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Escugen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ESG206","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Escugen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Escugen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Escugen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"DL-Tartaric acid","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kanda Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KD6005","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Shanghai Kanda Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Kanda Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Kanda Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SCT650C","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SCT650C","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SCTB35","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SCTT11","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sterna Biologicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SB012","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sterna Biologicals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Sterna Biologicals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sterna Biologicals \/ Undisclosed"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Collaboration","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F LY3950321","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"608","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"608","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"7HP935","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Pharma \/ CPRIT"},{"orgOrder":0,"company":"Jiangsu Renocell Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"89-Zr Oxine-RY_SW01","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Renocell Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Renocell Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Renocell Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Tianweiyuanhe Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"A-319","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Union Hospital \/ ITabMed","highestDevelopmentStatusID":"6","companyTruncated":"Wuhan Union Hospital \/ ITabMed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABBV-668","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2019","type":"Inapplicable","leadProduct":"ABI-M201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"ABI-M201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Termination","leadProduct":"ABI-M201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assembly Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"Suzhou Guangxin Biosciences Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABO2203","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ruijin Hospital \/ Suzhou Guangxin Biosciences Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Ruijin Hospital \/ Suzhou Guangxin Biosciences Co., Ltd."},{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Acded","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital T\u00fcbingen \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital T\u00fcbingen \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"South-Eastern Norway Regional Health Authority | Haukeland University Hospital | St. Olavs Hospital | University Hospital of North Norway","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Achim","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | Haukeland University Hospital | St. Olavs Hospital | University Hospital of North Norway","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | Haukeland University Hospital | St. Olavs Hospital | University Hospital of North Norway"},{"orgOrder":0,"company":"University of Western Ontario, Canada","sponsor":"Arthrex","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Acp","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Western Ontario, Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Western Ontario, Canada \/ Arthrex","highestDevelopmentStatusID":"1","companyTruncated":"University of Western Ontario, Canada \/ Arthrex"},{"orgOrder":0,"company":"Advagene Biopharma","sponsor":"Clinipace Worldwide | Taipei Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AD17002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Advagene Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advagene Biopharma \/ Clinipace Worldwide | Taipei Medical University","highestDevelopmentStatusID":"7","companyTruncated":"Advagene Biopharma \/ Clinipace Worldwide | Taipei Medical University"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"L2 Bio, LLC","sponsor":"FDAMap | Akan Biosciences, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"L2 Bio, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"L2 Bio, LLC \/ FDAMap | Akan Biosciences, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"L2 Bio, LLC \/ FDAMap | Akan Biosciences, Inc."},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ADS024","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adiso Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Adiso Therapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Adult Human Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"AGENT-797","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MiNK Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"MiNK Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"AI-1000 G2","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Abdi Ibrahim","sponsor":"Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TURKEY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AI201901","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Abdi Ibrahim","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdi Ibrahim \/ Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni","highestDevelopmentStatusID":"10","companyTruncated":"Abdi Ibrahim \/ Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AK106-001616","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asahi Kasei Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asahi Kasei Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AL-53817","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Invion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Ala-Cpn10","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Invion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Invion \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Alfamino Junior","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Bispebjerg Hospital","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Alk Alutard","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bispebjerg Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bispebjerg Hospital \/ ALK","highestDevelopmentStatusID":"1","companyTruncated":"Bispebjerg Hospital \/ ALK"},{"orgOrder":0,"company":"Alloksys Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Alkaline Phosphatase","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Alloksys Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alloksys Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alloksys Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Allergen Extract, White Birch","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"AllerPops Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Allerpops","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"AllerPops Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AllerPops Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AllerPops Corp \/ Undisclosed"},{"orgOrder":0,"company":"AllerPops","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"AllerPops","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"AllerPops","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Lollipop","sponsorNew":"AllerPops \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AllerPops \/ Undisclosed"},{"orgOrder":0,"company":"Anergis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Allert","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Anergis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anergis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anergis \/ Undisclosed"},{"orgOrder":0,"company":"Anergis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Allert","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Anergis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anergis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anergis \/ Undisclosed"},{"orgOrder":0,"company":"Anergis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Allert","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Anergis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Anergis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anergis \/ Undisclosed"},{"orgOrder":0,"company":"Arbor Biotechnologies","sponsor":"Allogene Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"ALLO-329","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Arbor Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies \/ Allogene Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Arbor Biotechnologies \/ Allogene Therapeutics"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ALLO-329","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ALLO-329","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ALLO-329","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Hope Biosciences Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Allogeneic Human Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"CryoCord","sponsor":"University of Malaya","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"MALAYSIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CryoCord","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CryoCord \/ University of Malaya","highestDevelopmentStatusID":"6","companyTruncated":"CryoCord \/ University of Malaya"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ALXN2030","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AMG357","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AMG357","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AMG623","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AMG623","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AMG732","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Edetec Ind\u00fastria Aliment\u00edcia S.A.","sponsor":"Faculdade de Ci\u00eancias M\u00e9dicas de Minas Gerais | Federal University of Minas Gerais","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Amix","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Edetec Ind\u00fastria Aliment\u00edcia S.A.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edetec Ind\u00fastria Aliment\u00edcia S.A. \/ Faculdade de Ci\u00eancias M\u00e9dicas de Minas Gerais | Federal University of Minas Gerais","highestDevelopmentStatusID":"8","companyTruncated":"Edetec Ind\u00fastria Aliment\u00edcia S.A. \/ Faculdade de Ci\u00eancias M\u00e9dicas de Minas Gerais | Federal University of Minas Gerais"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"AMP-110","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"AMP-110","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"ImmunoPharma AS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Andosan","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ ImmunoPharma AS","highestDevelopmentStatusID":"9","companyTruncated":"Oslo University Hospital \/ ImmunoPharma AS"},{"orgOrder":0,"company":"Angany","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ANG-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Angany","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angany \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Angany \/ Undisclosed"},{"orgOrder":0,"company":"Angany","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ANG-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Angany","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angany \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Angany \/ Undisclosed"},{"orgOrder":0,"company":"Greenyn Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Antrodia Cinnamomea Mycelia","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Greenyn Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Greenyn Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Greenyn Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"AprilBio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"APB-R3","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syneos Health \/ AprilBio","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ AprilBio"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"APL-1401","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Asieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APL-1401","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Asieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"APL-1401","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Asieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ApoGraft","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cellect Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellect Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cellect Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Cellect Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Apograft","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Cellect Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Cellect Biotechnology"},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"ApoGraft Treated Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Cellect Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellect Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cellect Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"APPL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AR201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Stallergenes Greer","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Divestment","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Nestle Health Sciences SA \/ Stallergenes Greer","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Stallergenes Greer"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Acquisition","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":1.9299999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":1.9299999999999999,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Allergy Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Collaboration","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Allergy Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Allergy Partners"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Arthrogen","sponsor":"Centre for Human Drug Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ART-I02","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Arthrogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arthrogen \/ Centre for Human Drug Research","highestDevelopmentStatusID":"6","companyTruncated":"Arthrogen \/ Centre for Human Drug Research"},{"orgOrder":0,"company":"Arthrogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ART-I02","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Arthrogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arthrogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arthrogen \/ Undisclosed"},{"orgOrder":0,"company":"Global Stem Cell Technology","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Arti-Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Global Stem Cell Technology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Stem Cell Technology \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"Global Stem Cell Technology \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ASP0892","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ASP0892","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ASP2390","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ASP2408","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ASP2409","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telsar Pharma Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ASP3291","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Telsar Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Telsar Pharma Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telsar Pharma Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Telsar Pharma Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ASP3291","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Telsar Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Telsar Pharma Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telsar Pharma Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ASP4070","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Immunomic Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"ASP4070","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Immunomic Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ASP5502","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"ASP8597","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH-063","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atopix Therapeutics","sponsor":"Simbec Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ATX2417","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Atopix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atopix Therapeutics \/ Simbec Research","highestDevelopmentStatusID":"6","companyTruncated":"Atopix Therapeutics \/ Simbec Research"},{"orgOrder":0,"company":"Celltex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Autologous Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Celltex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celltex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University College, London","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous Ebv-Ctl","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College, London \/ Bluebird Bio","highestDevelopmentStatusID":"6","companyTruncated":"University College, London \/ Bluebird Bio"},{"orgOrder":0,"company":"University of Miami","sponsor":"National Heart, Lung, and Blood Institute | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Autologous Human Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Miami \/ National Heart, Lung, and Blood Institute | The Emmes Company, LLC","highestDevelopmentStatusID":"7","companyTruncated":"University of Miami \/ National Heart, Lung, and Blood Institute | The Emmes Company, LLC"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Autologous Serum","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Eye Institute \/ The Emmes Company, LLC","highestDevelopmentStatusID":"8","companyTruncated":"National Eye Institute \/ The Emmes Company, LLC"},{"orgOrder":0,"company":"Translational Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Autologous Stromal Vascular Fraction","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Translational Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Translational Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Avobis Bio","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avobis Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avobis Bio \/ Alimentiv","highestDevelopmentStatusID":"1","companyTruncated":"Avobis Bio \/ Alimentiv"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Ceapro Inc. | Montreal Health Innovations Coordinating Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avenanthramide","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Montreal Heart Institute \/ Ceapro Inc. | Montreal Health Innovations Coordinating Center","highestDevelopmentStatusID":"7","companyTruncated":"Montreal Heart Institute \/ Ceapro Inc. | Montreal Health Innovations Coordinating Center"},{"orgOrder":0,"company":"Ceapro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avenanthramide","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ceapro \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Ceapro \/ Undisclosed"},{"orgOrder":0,"company":"Avaxia Biologics, Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"AVX 470","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Avaxia Biologics, Incorporated","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avaxia Biologics, Incorporated \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avaxia Biologics, Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD5492","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Fortrea","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Fortrea"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AZD6912","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Jiaolian Drug Research and Development Co., Ltd","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"B007","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Jiaolian Drug Research and Development Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Shanghai Jiaolian Drug Research and Development Co., Ltd","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"B007","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Jiaolian Drug Research and Development Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Danisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Bacterium Bifidobacterium Lactis","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Danisco \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BCD-055","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BCD-055","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BCD-261","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BCD-261","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BCMA","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bif-038","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Undisclosed"},{"orgOrder":0,"company":"Hvidovre University Hospital","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bif195","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hvidovre University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hvidovre University Hospital \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Hvidovre University Hospital \/ Chr. Hansen"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK-ABELLO INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"12 SQ-Bet Betula Verrucosa","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK-ABELLO INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK-ABELLO INC \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ALK-ABELLO INC \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences | Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Birch-Spire","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circassia \/ Adiga Life Sciences | Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Adiga Life Sciences | Quintiles Inc"},{"orgOrder":0,"company":"The Center for Applied Health Sciences, LLC","sponsor":"Brightseed, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Piperine","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Center for Applied Health Sciences, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Center for Applied Health Sciences, LLC \/ Brightseed, Inc","highestDevelopmentStatusID":"1","companyTruncated":"The Center for Applied Health Sciences, LLC \/ Brightseed, Inc"},{"orgOrder":0,"company":"UConn Health","sponsor":"Medical College of Wisconsin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Black Raspberry","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"UConn Health \/ Medical College of Wisconsin","highestDevelopmentStatusID":"6","companyTruncated":"UConn Health \/ Medical College of Wisconsin"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BLI-1300","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam | Biomay | European Commission | University of Salzburg","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BM41","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Odense University Hospital \/ Academisch Medisch Centrum - Universiteit van Amsterdam | Biomay | European Commission | University of Salzburg","highestDevelopmentStatusID":"6","companyTruncated":"Odense University Hospital \/ Academisch Medisch Centrum - Universiteit van Amsterdam | Biomay | European Commission | University of Salzburg"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986166","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BMS-986184","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986251","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BR9001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"DeepCure","sponsor":"IAG Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"Brd4","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"DeepCure","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"DeepCure \/ IAG Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"DeepCure \/ IAG Capital Partners"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"Shanghai Changzheng Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BRL-301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioray Laboratories \/ Shanghai Changzheng Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Bioray Laboratories \/ Shanghai Changzheng Hospital"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"First Affiliated Hospital of Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BRL-301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioray Laboratories \/ First Affiliated Hospital of Zhejiang University","highestDevelopmentStatusID":"1","companyTruncated":"Bioray Laboratories \/ First Affiliated Hospital of Zhejiang University"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"Wenzhou Medical University Ophthalmology Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BRL-302","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioray Laboratories \/ Wenzhou Medical University Ophthalmology Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Bioray Laboratories \/ Wenzhou Medical University Ophthalmology Hospital"},{"orgOrder":0,"company":"Chang Gung Memorial Hospital","sponsor":"Committee on Chinese Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Bu Zhong Yi Qi Tang","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Chang Gung Memorial Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chang Gung Memorial Hospital \/ Committee on Chinese Medicine and Pharmacy","highestDevelopmentStatusID":"10","companyTruncated":"Chang Gung Memorial Hospital \/ Committee on Chinese Medicine and Pharmacy"},{"orgOrder":0,"company":"Tenet Medicines","sponsor":"Eliem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Tenet Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tenet Medicines \/ Eliem Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Tenet Medicines \/ Eliem Therapeutics"},{"orgOrder":0,"company":"Tenet Medicines","sponsor":"Eliem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Tenet Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tenet Medicines \/ Eliem Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Tenet Medicines \/ Eliem Therapeutics"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eliem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eliem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Eliem Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Eliem Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Eliem Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Eliem Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Eliem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eliem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Climb Bio, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Climb Bio, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Climb Bio, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Climb Bio, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Climb Bio, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Climb Bio, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Climb Bio, Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Climb Bio, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"GPCR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Burixafor Hydrobromide","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ GPCR Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"TaiGen Biotechnology \/ GPCR Therapeutics"},{"orgOrder":0,"company":"Baylx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BX-U001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Baylx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baylx \/ Undisclosed"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"UMC Utrecht | Prothya Biosolutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"C1-esterase Inhibitor","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ UMC Utrecht | Prothya Biosolutions","highestDevelopmentStatusID":"10","companyTruncated":"Radboud University Medical Center \/ UMC Utrecht | Prothya Biosolutions"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Arla Food for Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Casein","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Arla Food for Health","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Arla Food for Health"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Casein Glycomacropeptide","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"University of Aarhus \/ Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Arla Foods"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Cat-Pad","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Circassia \/ Adiga Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Circassia \/ Adiga Life Sciences"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Cat-Pad","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Circassia \/ Adiga Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Circassia \/ Adiga Life Sciences"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Circassia","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Cat-Pad","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Circassia","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Circassia"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CB 4332","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"AnaptysBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"CBS004","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ AnaptysBio","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ AnaptysBio"},{"orgOrder":0,"company":"CytoCares","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CC312","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CytoCares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CytoCares \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoCares \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Chinese Herbal Medicine Drug Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CDD-2103","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Centre for Chinese Herbal Medicine Drug Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Chinese Herbal Medicine Drug Development \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Centre for Chinese Herbal Medicine Drug Development \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CDX-622","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BIOKEY","sponsor":"NeuCen BioMed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"CEN501","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"BIOKEY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Strip","sponsorNew":"BIOKEY \/ NeuCen BioMed","highestDevelopmentStatusID":"8","companyTruncated":"BIOKEY \/ NeuCen BioMed"},{"orgOrder":0,"company":"Hong Kong Sanatorium & Hospital","sponsor":"Chinese University of Hong Kong","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Chinese Herbal Formula - X","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hong Kong Sanatorium & Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hong Kong Sanatorium & Hospital \/ Chinese University of Hong Kong","highestDevelopmentStatusID":"1","companyTruncated":"Hong Kong Sanatorium & Hospital \/ Chinese University of Hong Kong"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"Cholera Vaccine, Inactivated","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Leiden University Medical Center \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"Leiden University Medical Center \/ Johnson & Johnson"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CHR-5154","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Citryll","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Citryll \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Undisclosed"},{"orgOrder":0,"company":"Citryll","sponsor":"ReumaNederland","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Funding","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Citryll \/ ReumaNederland","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ ReumaNederland"},{"orgOrder":0,"company":"Citryll","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Citryll \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Undisclosed"},{"orgOrder":0,"company":"Citryll","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Citryll \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Johnson & Johnson"},{"orgOrder":0,"company":"Citryll","sponsor":"Bom Brabant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Citryll","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Citryll \/ Bom Brabant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Citryll \/ Bom Brabant Ventures"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"CK0801","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellenkos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.28000000000000003,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Adage Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Adage Capital Partners"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CLS-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Comera Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Comera Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Chimagen Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"CMG1A46","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Chimagen Biosciences","amount2":0.84999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.84999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Chimagen Biosciences \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Chimagen Biosciences \/ GSK"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Financing","leadProduct":"CND106","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Undisclosed","sponsorNew":"Candid Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CNP-201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CNP-201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CNP-201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"CNTO 6785","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Florida State University","sponsor":"Compound Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Corebiome","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Florida State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Florida State University \/ Compound Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Florida State University \/ Compound Solutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Hyperimmune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ US Department of Defense"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Private Placement","leadProduct":"COYA 201","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ BTIG","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ BTIG"},{"orgOrder":0,"company":"UNeMed","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"COYA 301","moa":"||Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"UNeMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UNeMed \/ Coya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"UNeMed \/ Coya Therapeutics"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"COYA 301","moa":"||Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"COYA 301","moa":"||Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CPL\u2019 116","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celon Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"National Center for Research and Development, Poland","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CPL409116","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celon Pharma \/ National Center for Research and Development, Poland","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ National Center for Research and Development, Poland"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Nestle Health Sciences SA | Nestec","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Crown Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"PROMETHEUS LABS \/ Nestle Health Sciences SA | Nestec","highestDevelopmentStatusID":"8","companyTruncated":"PROMETHEUS LABS \/ Nestle Health Sciences SA | Nestec"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"CryJ2-DNA-LAMP Plasmid Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hanyang University Seoul Hospital","sponsor":"Corestemchemon | Ministry of Health & Welfare, Korea","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CS20AT04","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hanyang University Seoul Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hanyang University Seoul Hospital \/ Corestemchemon | Ministry of Health & Welfare, Korea","highestDevelopmentStatusID":"8","companyTruncated":"Hanyang University Seoul Hospital \/ Corestemchemon | Ministry of Health & Welfare, Korea"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CSL730","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CTX112","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Curacle","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CU104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Curacle","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Curacle \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Curacle \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Cupressus Arizonica","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"CuraVac","sponsor":"Aepodia | University Hospital Antwerp","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CV-MG01","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"CuraVac","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CuraVac \/ Aepodia | University Hospital Antwerp","highestDevelopmentStatusID":"9","companyTruncated":"CuraVac \/ Aepodia | University Hospital Antwerp"},{"orgOrder":0,"company":"CuraVac","sponsor":"Aepodia | University Hospital Antwerp | Leiden University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CV-MG01","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"CuraVac","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CuraVac \/ Aepodia | University Hospital Antwerp | Leiden University Medical Center","highestDevelopmentStatusID":"9","companyTruncated":"CuraVac \/ Aepodia | University Hospital Antwerp | Leiden University Medical Center"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CYP-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CYP-001","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CYP-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CYP-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Merger","leadProduct":"CYTO-200","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytocom \/ Cleveland Clinic","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland Clinic"},{"orgOrder":0,"company":"University Hospital, Bordeaux","sponsor":"Biotest","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cytofulvin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"University Hospital, Bordeaux","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Hospital, Bordeaux \/ Biotest","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Bordeaux \/ Biotest"},{"orgOrder":0,"company":"InventisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"D-2570","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InventisBio \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"D569","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"D9421-C","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"IPSC AG","sponsor":"Medical University of Graz | Sciotec Diagnostic Technologies GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"DAOSiN","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"IPSC AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IPSC AG \/ Medical University of Graz | Sciotec Diagnostic Technologies GmbH","highestDevelopmentStatusID":"1","companyTruncated":"IPSC AG \/ Medical University of Graz | Sciotec Diagnostic Technologies GmbH"},{"orgOrder":0,"company":"DAS-MG, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DAS-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"DAS-MG, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DAS-MG, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DAS-MG, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DB-2304","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DB-3Q","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"DBV Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ DBV Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ DBV Technologies"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DeepCure","sponsor":"LIRMM","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"DC-9476","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"DeepCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DeepCure \/ LIRMM","highestDevelopmentStatusID":"4","companyTruncated":"DeepCure \/ LIRMM"},{"orgOrder":0,"company":"University of S\u00e3o Paulo General Hospital","sponsor":"Butantan Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Dengue 1,2,3,4 (attenuated) Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"University of S\u00e3o Paulo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of S\u00e3o Paulo General Hospital \/ Butantan Institute","highestDevelopmentStatusID":"10","companyTruncated":"University of S\u00e3o Paulo General Hospital \/ Butantan Institute"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DEP114","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"AB Biotek","sponsor":"Hospital Clinic of Barcelona","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Diamino Oxidase","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"AB Biotek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotek \/ Hospital Clinic of Barcelona","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotek \/ Hospital Clinic of Barcelona"},{"orgOrder":0,"company":"Sahlgrenska University Hospital","sponsor":"Calmino group AB","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Dietary Fiber","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sahlgrenska University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sahlgrenska University Hospital \/ Calmino group AB","highestDevelopmentStatusID":"1","companyTruncated":"Sahlgrenska University Hospital \/ Calmino group AB"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Diindolylmethane","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Diphtheria And Tetanus Toxoid","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Delenex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"DLX105","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Delenex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Delenex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delenex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Regenerative Ocular Immunobiologics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"D-Mapps","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Regenerative Ocular Immunobiologics LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Regenerative Ocular Immunobiologics LLC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regenerative Ocular Immunobiologics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"DRL_RI","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DS-7011a","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DS-7011a","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Universitas Padjadjaran","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DTwP-HepB-Hib-IPV Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Universitas Padjadjaran","highestDevelopmentStatusID":"7","companyTruncated":"Bio Farma \/ Universitas Padjadjaran"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DWP212525","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"DWP422","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"Exponential Biotherapies Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"EA-230","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Radboud University Medical Center \/ Exponential Biotherapies Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Radboud University Medical Center \/ Exponential Biotherapies Inc."},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"Exponential Biotherapies Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"EA-230","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ Exponential Biotherapies Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Radboud University Medical Center \/ Exponential Biotherapies Inc."},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ectoine","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"EHF","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"TSH Biopharm Corporation Limited","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ENIA11","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Mycenax Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mycenax Biotech \/ TSH Biopharm Corporation Limited","highestDevelopmentStatusID":"10","companyTruncated":"Mycenax Biotech \/ TSH Biopharm Corporation Limited"},{"orgOrder":0,"company":"N-Fold, LLC","sponsor":"CBCC Global","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ENP-501","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"N-Fold, LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"N-Fold, LLC \/ CBCC Global","highestDevelopmentStatusID":"7","companyTruncated":"N-Fold, LLC \/ CBCC Global"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Ensure Enlive","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Johns Hopkins University \/ Abbott Laboratories"},{"orgOrder":0,"company":"Enovate Biolife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"E-RH-06","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Enovate Biolife","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enovate Biolife \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Enovate Biolife \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Etrozulimab","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Boramae Hospital","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eupatilin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Seoul National University Boramae Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Boramae Hospital \/ Dong-A ST Co., Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Boramae Hospital \/ Dong-A ST Co., Ltd."},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Maruho","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Maruho"},{"orgOrder":0,"company":"Exeliom Biosciences","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"EXL01","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Exeliom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exeliom Biosciences \/ Alimentiv","highestDevelopmentStatusID":"6","companyTruncated":"Exeliom Biosciences \/ Alimentiv"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Exogenus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Exo-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Exogenus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Exogenus Therapeutics"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ExoFlo","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ExoFlo","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Extensively Hydrolyzed Casein","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Mead Johnson Nutrition","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Mead Johnson Nutrition"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Extensively Hydrolyzed Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Extensively Hydrolyzed Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Extensively Hydrolyzed Rice Protein Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EydisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EYD-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EydisBio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"EydisBio \/ Undisclosed"},{"orgOrder":0,"company":"EydisBio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"EYD-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EydisBio \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"EydisBio \/ National Institutes of Health"},{"orgOrder":0,"company":"Bio Nature Health","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Eye Empower","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bio Nature Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bio Nature Health \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Bio Nature Health \/ Citruslabs"},{"orgOrder":0,"company":"Maoxiang Group Jilin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Fang Yi Qing Feng Shi","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Maoxiang Group Jilin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Maoxiang Group Jilin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maoxiang Group Jilin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Alger","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Forte Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Alger","highestDevelopmentStatusID":"4","companyTruncated":"Forte Biosciences \/ Alger"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FE 999322","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Xbiome Biotech Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Shenzhen Xbiome Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Xbiome Biotech Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Xbiome Biotech Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital of North Norway","sponsor":"Helse Nord","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"University Hospital of North Norway","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital of North Norway \/ Helse Nord","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital of North Norway \/ Helse Nord"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"St. Joseph's Health Care London","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ St. Joseph's Health Care London","highestDevelopmentStatusID":"1","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ St. Joseph's Health Care London"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"FEX60","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Fast Forward Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"FFP104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Fast Forward Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fast Forward Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fast Forward Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Fiber","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of Miami \/ Pfizer Inc"},{"orgOrder":0,"company":"Appalachian State University","sponsor":"Reoxcyn Discoveries Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Flavonoids","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Appalachian State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appalachian State University \/ Reoxcyn Discoveries Group","highestDevelopmentStatusID":"1","companyTruncated":"Appalachian State University \/ Reoxcyn Discoveries Group"},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"FOS","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"Mohammed Bin Rashid University of Medicine and Health Sciences","sponsor":"Mediclinic Middle East | Rashid Hospital | Dubai Health Authority","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.A.E","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Frondanol","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Mohammed Bin Rashid University of Medicine and Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mohammed Bin Rashid University of Medicine and Health Sciences \/ Mediclinic Middle East | Rashid Hospital | Dubai Health Authority","highestDevelopmentStatusID":"9","companyTruncated":"Mohammed Bin Rashid University of Medicine and Health Sciences \/ Mediclinic Middle East | Rashid Hospital | Dubai Health Authority"},{"orgOrder":0,"company":"Kang Stem Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Furestem-RA","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kang Stem Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kang Stem Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kang Stem Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kang Stem Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Furestem-RA","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kang Stem Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kang Stem Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kang Stem Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Sitala Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"FXS6837","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Fosun Pharmaceutical","amount2":0.67000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.67000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ Sitala Bio","highestDevelopmentStatusID":"8","companyTruncated":"Fosun Pharmaceutical \/ Sitala Bio"},{"orgOrder":0,"company":"Japan Blood Products Organization","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"GB-0998","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Japan Blood Products Organization","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Japan Blood Products Organization \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Japan Blood Products Organization \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"GC5107A","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Green Cross Lab Cell \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Green Cross Lab Cell \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GenSci098","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GenSci120","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GenSci120","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Georgiamune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GIM-407","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Georgiamune \/ Undisclosed"},{"orgOrder":0,"company":"GLSMED Learning Health S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"PORTUGAL","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Glycan","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"GLSMED Learning Health S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GLSMED Learning Health S.A. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GLSMED Learning Health S.A. \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GNC-038","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GNC-038","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNR-069","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNR-069","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GNR-086","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"ASIT biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ASIT biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASIT biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ASIT biotech \/ Undisclosed"},{"orgOrder":0,"company":"BioTech Tools","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"BioTech Tools","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioTech Tools \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTech Tools \/ Undisclosed"},{"orgOrder":0,"company":"BioTech Tools","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"BioTech Tools","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioTech Tools \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTech Tools \/ Undisclosed"},{"orgOrder":0,"company":"BioTech Tools","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"BioTech Tools","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioTech Tools \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTech Tools \/ Undisclosed"},{"orgOrder":0,"company":"BioTech Tools","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Gpasit+Tm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"BioTech Tools","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTech Tools \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTech Tools \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GR1603","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Lodz","sponsor":"Allergopharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Grass","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Medical University of Lodz","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Lodz \/ Allergopharma","highestDevelopmentStatusID":"11","companyTruncated":"Medical University of Lodz \/ Allergopharma"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Inflamax Research | Metronomia Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Grass MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Inflamax Research | Metronomia Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Inflamax Research | Metronomia Clinical Research"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Grass MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Syneos Health | Metronomia Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Grass MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Syneos Health | Metronomia Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"Allergy Therapeutics \/ Syneos Health | Metronomia Clinical Research"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Grass MATA MPL Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Harrison Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Grass Pollen Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Harrison Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Harrison Clinical Research"},{"orgOrder":0,"company":"Laboratorios Leti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Grass Pollen Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Laboratorios Leti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Leti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Leti \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Grass Pollen Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Circassia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Grass-Spire","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Circassia \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Circassia \/ Undisclosed"},{"orgOrder":0,"company":"Circassia","sponsor":"Adiga Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Grass-Spire","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Circassia \/ Adiga Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Circassia \/ Adiga Life Sciences"},{"orgOrder":0,"company":"GSK","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Group B Streptococcus Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GS-0151","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GS-0272","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"GSK2445053","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"GSK3358699","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GSK4347859","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GSK4381406","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GSK4527363","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GSK4528287","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GT719","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Affiliated Hospital of Nantong University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GT719","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRIT Biotechnology \/ Affiliated Hospital of Nantong University","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Affiliated Hospital of Nantong University"},{"orgOrder":0,"company":"ImmuneBiotech Medical Sweden AB","sponsor":"Karolinska Institutet","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Gutmagnific\u2122 H: Gutmagnific","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"ImmuneBiotech Medical Sweden AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneBiotech Medical Sweden AB \/ Karolinska Institutet","highestDevelopmentStatusID":"1","companyTruncated":"ImmuneBiotech Medical Sweden AB \/ Karolinska Institutet"},{"orgOrder":0,"company":"Genexine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"GX-P1","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genexine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genexine \/ Undisclosed"},{"orgOrder":0,"company":"Research Institute of Influenza, Russia","sponsor":"World Health Organization | Institute of Experimental Medicine, Russia | Joint Stock Company Microgen, Russia","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"H7N9 LAIV","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Research Institute of Influenza, Russia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Research Institute of Influenza, Russia \/ World Health Organization | Institute of Experimental Medicine, Russia | Joint Stock Company Microgen, Russia","highestDevelopmentStatusID":"6","companyTruncated":"Research Institute of Influenza, Russia \/ World Health Organization | Institute of Experimental Medicine, Russia | Joint Stock Company Microgen, Russia"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"HAL-MPE1","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"HAL-MPE1","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"HAL-MRE1","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Suspension","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"HB-adMSCs","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hope Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"HBM7020","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Harbour BioMed","amount2":0.67000000000000004,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.67000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Harbour BioMed \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Holoclara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HC002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Holoclara","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Holoclara \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Holoclara \/ Undisclosed"},{"orgOrder":0,"company":"HC Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HC022","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HC Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HC Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"HCP1102","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"HCP1102","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"ASIT biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"hdmASIT+TM","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ASIT biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASIT biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASIT biotech \/ Undisclosed"},{"orgOrder":0,"company":"Hemay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hemay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hemay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hemay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Hemay Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Tianjin Hemay Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Hemay Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Hemay007","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Tianjin Hemay Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Hemay Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Hemay007","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Tianjin Hemay Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Herpes Zoster Subunit Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"HGS1025","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HIB210","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HIB210","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HL237","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"HL237","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"HL237","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Himuka AM Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HM201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Himuka AM Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Himuka AM Pharma"},{"orgOrder":0,"company":"Nutrition Science Partners","sponsor":"Hutchmed | Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"HMPL004-6599","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Nutrition Science Partners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrition Science Partners \/ Hutchmed | Nestle Health Sciences SA","highestDevelopmentStatusID":"6","companyTruncated":"Nutrition Science Partners \/ Hutchmed | Nestle Health Sciences SA"},{"orgOrder":0,"company":"Shenzhen MagicRNA Biotechnology Co., Ltd","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HN2301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shenzhen MagicRNA Biotechnology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ The First Affiliated Hospital of University of Science and Technology of China","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ The First Affiliated Hospital of University of Science and Technology of China"},{"orgOrder":0,"company":"Shenzhen MagicRNA Biotechnology Co., Ltd","sponsor":"Songjiang Hospital, Shanghai Jiao Tong University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HN2301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shenzhen MagicRNA Biotechnology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ Songjiang Hospital, Shanghai Jiao Tong University","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ Songjiang Hospital, Shanghai Jiao Tong University"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HNSA-5487","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HNSA-5487","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Gachon University Gil Medical Center","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Hollisterstier","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Gachon University Gil Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gachon University Gil Medical Center \/ Thermo Fisher Scientific","highestDevelopmentStatusID":"6","companyTruncated":"Gachon University Gil Medical Center \/ Thermo Fisher Scientific"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Ecarf Institute GmbH | Bencard Allergie GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"holoBLG","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Ecarf Institute GmbH | Bencard Allergie GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Allergy Therapeutics \/ Ecarf Institute GmbH | Bencard Allergie GmbH"},{"orgOrder":0,"company":"HomeoTherapy Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Homeo-GH","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HomeoTherapy Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HomeoTherapy Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HomeoTherapy Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Raphas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Raphas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raphas \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Raphas \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Syneos Health"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stallergenes Greer \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Syneos Health"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Stallergenes Greer \/ Nuance Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Nuance Pharma"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"House Dust Mites Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stallergenes Greer \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Undisclosed"},{"orgOrder":0,"company":"Wayne State University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Wayne State University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wayne State University \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Wayne State University \/ Merck & Co"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HR19042","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Monash University | Beijing ShuangLu Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"hrIL-2","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Peking University People's Hospital \/ Monash University | Beijing ShuangLu Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Peking University People's Hospital \/ Monash University | Beijing ShuangLu Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Monash University | Beijing ShuangLu Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"hrIL-2","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Peking University People's Hospital \/ Monash University | Beijing ShuangLu Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Peking University People's Hospital \/ Monash University | Beijing ShuangLu Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Monash University | Beijing ShuangLu Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"hrIL-2","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Peking University People's Hospital \/ Monash University | Beijing ShuangLu Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Peking University People's Hospital \/ Monash University | Beijing ShuangLu Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-10374","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS628","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Big Bold Health, PBC","sponsor":"TruDiagnostic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"HTB Rejuvenate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Big Bold Health, PBC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Big Bold Health, PBC \/ TruDiagnostic","highestDevelopmentStatusID":"1","companyTruncated":"Big Bold Health, PBC \/ TruDiagnostic"},{"orgOrder":0,"company":"Qidong Gaitianli Medicines","sponsor":"Huazhong University of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Huaiqihuang","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Qidong Gaitianli Medicines","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Qidong Gaitianli Medicines \/ Huazhong University of Science and Technology","highestDevelopmentStatusID":"11","companyTruncated":"Qidong Gaitianli Medicines \/ Huazhong University of Science and Technology"},{"orgOrder":0,"company":"Newcastle University","sponsor":"Aelius Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Huel","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Newcastle University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newcastle University \/ Aelius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Newcastle University \/ Aelius Biotech"},{"orgOrder":0,"company":"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Amniotic Epithelial Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China \/ Undisclosed"},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Amniotic Epithelial Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","highestDevelopmentStatusID":"6","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Human Amniotic Epithelial Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University People's Hospital \/ Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","highestDevelopmentStatusID":"1","companyTruncated":"Peking University People's Hospital \/ Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China"},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Human Amniotic Membrane Allograft","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | Tunitas Therapeutics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Human Fc\u03b31-Fel d 1 Fusion Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Tunitas Therapeutics, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Tunitas Therapeutics, Inc."},{"orgOrder":0,"company":"Grand Biologic Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Human Histaglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Grand Biologic Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grand Biologic Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Grand Biologic Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"The W. Garfield Weston Foundation | St. Joseph's Health Care London | London Health Sciences Centre","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Human Milk Oligosaccharide","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ The W. Garfield Weston Foundation | St. Joseph's Health Care London | London Health Sciences Centre","highestDevelopmentStatusID":"6","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ The W. Garfield Weston Foundation | St. Joseph's Health Care London | London Health Sciences Centre"},{"orgOrder":0,"company":"Samsung Medical Center","sponsor":"Medipost","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Human Umbilical Cord Blood Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Samsung Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Samsung Medical Center \/ Medipost","highestDevelopmentStatusID":"7","companyTruncated":"Samsung Medical Center \/ Medipost"},{"orgOrder":0,"company":"Affiliated Hospital to Academy of Military Medical Sciences","sponsor":"Ivy Institute of Stem Cells Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Affiliated Hospital to Academy of Military Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affiliated Hospital to Academy of Military Medical Sciences \/ Ivy Institute of Stem Cells Co. Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Affiliated Hospital to Academy of Military Medical Sciences \/ Ivy Institute of Stem Cells Co. Ltd"},{"orgOrder":0,"company":"Shenzhen Hornetcorn Bio-technology Company, LTD","sponsor":"Futian People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Shenzhen Hornetcorn Bio-technology Company, LTD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Hornetcorn Bio-technology Company, LTD \/ Futian People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Hornetcorn Bio-technology Company, LTD \/ Futian People's Hospital"},{"orgOrder":0,"company":"Shenzhen Beike Bio-Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Beike Bio-Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Beike Bio-Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Beike Bio-Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Stony Brook University","sponsor":"Natural Wellness Now Health Products","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Hydrogen Water","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Stony Brook University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Stony Brook University \/ Natural Wellness Now Health Products","highestDevelopmentStatusID":"6","companyTruncated":"Stony Brook University \/ Natural Wellness Now Health Products"},{"orgOrder":0,"company":"Stony Brook University","sponsor":"Natural Wellness Now Health Products","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Hydrogen Water","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Stony Brook University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Stony Brook University \/ Natural Wellness Now Health Products","highestDevelopmentStatusID":"6","companyTruncated":"Stony Brook University \/ Natural Wellness Now Health Products"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Hydrolyzed Egg","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Hydrolyzed Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hydroxytriptolide","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"Hypoimmunogenic Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"AgeX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kate Farms Inc","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"IBD-AID Diet","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kate Farms Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kate Farms Inc \/ University of Minnesota","highestDevelopmentStatusID":"1","companyTruncated":"Kate Farms Inc \/ University of Minnesota"},{"orgOrder":0,"company":"IgGenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IGNX001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IgGenix \/ Undisclosed"},{"orgOrder":0,"company":"IgGenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IGNX001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IgGenix \/ Undisclosed"},{"orgOrder":0,"company":"IgGenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IGNX001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IgGenix \/ Undisclosed"},{"orgOrder":0,"company":"ILIAS Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ILB-202","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"ILIAS Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ILIAS Biologics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ILIAS Biologics \/ Undisclosed"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"IMIDomics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"IMB1001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ IMIDomics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ IMIDomics"},{"orgOrder":0,"company":"IMIDomics","sponsor":"TNAX Biopharma Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"IMB1001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMIDomics \/ TNAX Biopharma Corporation","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics \/ TNAX Biopharma Corporation"},{"orgOrder":0,"company":"IMIDomics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"IMB1001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMIDomics \/ UCB Pharma S.A","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"IMIDomics","sponsor":"University of Barcelona","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"IMB-1003","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMIDomics \/ University of Barcelona","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics \/ University of Barcelona"},{"orgOrder":0,"company":"GC Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Immuncell-Lc","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GC Cell \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Grifols International","highestDevelopmentStatusID":"1","companyTruncated":"University of Alabama at Birmingham \/ Grifols International"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Biopharma Plasma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Biopharma Plasma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biopharma Plasma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biopharma Plasma \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"University Health Network, Toronto \/ CSL Behring"},{"orgOrder":0,"company":"On Pharma","sponsor":"Hospital do Coracao","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"On Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"On Pharma \/ Hospital do Coracao","highestDevelopmentStatusID":"10","companyTruncated":"On Pharma \/ Hospital do Coracao"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Kedrion","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kedrion \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Icon Plc"},{"orgOrder":0,"company":"Genovis","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Immunoglobulin G Protease","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Genovis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genovis \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Genovis \/ Selecta Biosciences"},{"orgOrder":0,"company":"St. Louis University","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Immunoglobulins","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"St. Louis University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Louis University \/ CSL Behring","highestDevelopmentStatusID":"6","companyTruncated":"St. Louis University \/ CSL Behring"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Series B Financing","leadProduct":"Imotope","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Imcyse","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Imcyse \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Imcyse \/ Pfizer Inc"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"IMPT-514","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IMSB301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneSensor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneSensor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IMSB301","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneSensor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ImmuneSensor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IMSB301","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneSensor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ImmuneSensor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INCB000262","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"INCB047986","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bassett Healthcare","sponsor":"New York State Department of Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Bassett Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bassett Healthcare \/ New York State Department of Health","highestDevelopmentStatusID":"11","companyTruncated":"Bassett Healthcare \/ New York State Department of Health"},{"orgOrder":0,"company":"InnoUp Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"INP20","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"InnoUp Farma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoUp Farma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoUp Farma \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edifice Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Iron Bisglycinate Manganese Chloride","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Edifice Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edifice Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Edifice Health \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"IVIG","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ Grifols International","highestDevelopmentStatusID":"6","companyTruncated":"University of California, Irvine \/ Grifols International"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"IVIG","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ CSL Behring"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Jitongning","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"JJP Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JJP-1212","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"JJP Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JJP Biologics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"JJP Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"JMKX000189","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"JNJ38224342","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JNJ-39758979","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JNJ-39758979","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JNJ-66525433","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"JNJ-67864238","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JNJ-77242113","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai JunTop Biosciences Co., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JT002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai JunTop Biosciences Co., LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Shanghai JunTop Biosciences Co., LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai JunTop Biosciences Co., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Jantar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JT-1","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Jantar","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jantar \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Jantar \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Genocury Biotech","sponsor":"LiangZou","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JY231","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shenzhen Genocury Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen Genocury Biotech \/ LiangZou","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Genocury Biotech \/ LiangZou"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Kamuvudine-9","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inflammasome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inflammasome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Peter Timoney","sponsor":"Inflammasome Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Kamuvudine-9","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Peter Timoney","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Peter Timoney \/ Inflammasome Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Peter Timoney \/ Inflammasome Therapeutics"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KB-7898","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"KoBioLabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"KBL697","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"KoBioLabs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KoBioLabs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KoBioLabs \/ Undisclosed"},{"orgOrder":0,"company":"KeraNetics, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Keratin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"KeraNetics, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"KeraNetics, LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"KeraNetics, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Kinevant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"KIN-1901","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Kinevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kinevant Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kinevant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KK4277","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Changhai Hospital","sponsor":"Rui Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KN5501","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Changhai Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Changhai Hospital \/ Rui Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Changhai Hospital \/ Rui Therapeutics"},{"orgOrder":0,"company":"Kokua Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"KP001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Kokua Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kokua Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kokua Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KSP-0243","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"CHENLIJI Pharmaceutical | CHINESE RHEUMATISM DATA CENTER","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Kunxian","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chinese SLE Treatment And Research Group \/ CHENLIJI Pharmaceutical | CHINESE RHEUMATISM DATA CENTER","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ CHENLIJI Pharmaceutical | CHINESE RHEUMATISM DATA CENTER"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"L. Paracasei Fermented Milk","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Fondazione IRCCS Ca' Granda","sponsor":"Cultech Ltd | Universit\u00e4t Duisburg-Essen | School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK | IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"LAB4","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Fondazione IRCCS Ca' Granda","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione IRCCS Ca' Granda \/ Cultech Ltd | Universit\u00e4t Duisburg-Essen | School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK | IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy","highestDevelopmentStatusID":"7","companyTruncated":"Fondazione IRCCS Ca' Granda \/ Cultech Ltd | Universit\u00e4t Duisburg-Essen | School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK | IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy"},{"orgOrder":0,"company":"TearSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Lacripep","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"TearSolutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"TearSolutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TearSolutions \/ Undisclosed"},{"orgOrder":0,"company":"TNO","sponsor":"VSL Pharmaceuticals | NIZO Food Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Lactic Acid Bacteria","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"TNO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TNO \/ VSL Pharmaceuticals | NIZO Food Research","highestDevelopmentStatusID":"1","companyTruncated":"TNO \/ VSL Pharmaceuticals | NIZO Food Research"},{"orgOrder":0,"company":"University of East Anglia","sponsor":"Quadram Institute Bioscience | Norfolk and Norwich University Hospitals NHS Foundation Trust | YAKULT HONSHA CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Casei Shirota","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"University of East Anglia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of East Anglia \/ Quadram Institute Bioscience | Norfolk and Norwich University Hospitals NHS Foundation Trust | YAKULT HONSHA CO LTD","highestDevelopmentStatusID":"8","companyTruncated":"University of East Anglia \/ Quadram Institute Bioscience | Norfolk and Norwich University Hospitals NHS Foundation Trust | YAKULT HONSHA CO LTD"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Lactobacillus Fermentum CECT5716","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Undisclosed"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Lactobacillus Fermentum CECT5716","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Chr. Hansen","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Chr. Hansen"},{"orgOrder":0,"company":"Universidad Complutense de Madrid","sponsor":"National Research Council, Spain | University of Valencia | Danone Global Research & Innovation Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Salivarius PS2","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Universidad Complutense de Madrid","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Universidad Complutense de Madrid \/ National Research Council, Spain | University of Valencia | Danone Global Research & Innovation Center","highestDevelopmentStatusID":"1","companyTruncated":"Universidad Complutense de Madrid \/ National Research Council, Spain | University of Valencia | Danone Global Research & Innovation Center"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LAD191","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Oblenio Bio","sponsor":"Aditum Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"LBL-051","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Oblenio Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oblenio Bio \/ Aditum Bio","highestDevelopmentStatusID":"4","companyTruncated":"Oblenio Bio \/ Aditum Bio"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LB-P6","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LISCure Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Legend Biotech | Beijing GoBroad Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"LCAR-AIO T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wuhan Union Hospital \/ Legend Biotech | Beijing GoBroad Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Wuhan Union Hospital \/ Legend Biotech | Beijing GoBroad Hospital"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"LCAR-AIO T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kenox Pharmaceuticals","sponsor":"Lactiga","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"LCTG-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Kenox Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kenox Pharmaceuticals \/ Lactiga","highestDevelopmentStatusID":"4","companyTruncated":"Kenox Pharmaceuticals \/ Lactiga"},{"orgOrder":0,"company":"Lactiga","sponsor":"1517 Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Financing","leadProduct":"LCTG-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactiga \/ 1517 Fund","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ 1517 Fund"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"SYNBIO TECH INC. Kaohsiung Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"LDL557-HK","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ SYNBIO TECH INC. Kaohsiung Taiwan","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ SYNBIO TECH INC. Kaohsiung Taiwan"},{"orgOrder":0,"company":"Jiangsu Carephar Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Lincomycin Hydrochloride","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Carephar Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Carephar Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Carephar Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"LiteVax","sponsor":"University Hospital Ghent | HarmonyCR","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Litevax Adjuvanted Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"LiteVax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LiteVax \/ University Hospital Ghent | HarmonyCR","highestDevelopmentStatusID":"7","companyTruncated":"LiteVax \/ University Hospital Ghent | HarmonyCR"},{"orgOrder":0,"company":"Liveome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LIV001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Liveome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Liveome \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Liveome \/ Undisclosed"},{"orgOrder":0,"company":"Liveome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LIV001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Liveome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Liveome \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Liveome \/ Undisclosed"},{"orgOrder":0,"company":"Luminary Therapeutics","sponsor":"Nationwide Children","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"LMY-920","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Luminary Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luminary Therapeutics \/ Nationwide Children","highestDevelopmentStatusID":"6","companyTruncated":"Luminary Therapeutics \/ Nationwide Children"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Shanghai General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Shanghai General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Shanghai General Hospital"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Qiming Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Longbio Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Longbio Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longbio Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longbio Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Longbio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longbio Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LP-410","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Lu AG22515","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"LUCAR-DKS1 NK Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"LUCAR-G79 T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Zurita Laboratorio Farmaceutico Ltda.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ECUADOR","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Luffa Operculate","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Zurita Laboratorio Farmaceutico Ltda.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zurita Laboratorio Farmaceutico Ltda. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zurita Laboratorio Farmaceutico Ltda. \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Lumbar Puncture","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LW402","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Longwood Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Longwood Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"LY3454738","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3462817","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"LY3471851","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"LY3471851","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"LY3471851","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LY3541860","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Appalachian State University","sponsor":"LycoRed Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Lycored Product","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Appalachian State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appalachian State University \/ LycoRed Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Appalachian State University \/ LycoRed Ltd."},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Lymfactin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Herantis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Herantis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Lymfactin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Herantis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Herantis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"Lysosomal-Targeted Chimeras","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Lycia Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Lycia Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"3","companyTruncated":"Lycia Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"M254","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Momenta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Momenta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"M2591","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Magn\u00f3lia","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Maolactin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Maolactin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Bacthera","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MAP 315","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Microba Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Enteric Coated","sponsorNew":"Microba Life Sciences \/ Bacthera","highestDevelopmentStatusID":"6","companyTruncated":"Microba Life Sciences \/ Bacthera"},{"orgOrder":0,"company":"Supplement Formulators, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Marine Lipid Oil Concentrate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Supplement Formulators, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Supplement Formulators, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Supplement Formulators, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Supplement Formulators, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Marine Lipid Oil Concentrate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Supplement Formulators, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Supplement Formulators, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Supplement Formulators, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MAZ-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Mage Biologics","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MB-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Mage Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Mage Biologics \/ Alimentiv","highestDevelopmentStatusID":"6","companyTruncated":"Mage Biologics \/ Alimentiv"},{"orgOrder":0,"company":"Medibiofarma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MBF-118","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Medibiofarma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medibiofarma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medibiofarma \/ Undisclosed"},{"orgOrder":0,"company":"Modern Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"MBS2320","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Modern Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Modern Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Modern Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Modern Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MBS2320","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Modern Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Modern Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Modern Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Modern Biosciences","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"MBS2320","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Modern Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Modern Biosciences \/ Covance","highestDevelopmentStatusID":"8","companyTruncated":"Modern Biosciences \/ Covance"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MC0518","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MC0518","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Second Affiliated Hospital, Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MC-1-50","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Second Affiliated Hospital, Zhejiang University","highestDevelopmentStatusID":"6","companyTruncated":"Chongqing Precision Biotech \/ Second Affiliated Hospital, Zhejiang University"},{"orgOrder":0,"company":"Alivexis","sponsor":"Melodia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"MDI-0151","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Alivexis","amount2":0.28000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.28000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Alivexis \/ Melodia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Alivexis \/ Melodia Therapeutics"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MDR-102","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MDR-103","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medeor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medeor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Academy Military Medical Science | Peking University People's Hospital | Sun Yat-sen University | Guangdong Provincial People's Hospital | Guangzhou General Hospital of Guangzhou Military Command | Third Affiliated Hospital, Sun Yat-sen University | Shang","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Phase II","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Academy Military Medical Science | Peking University People's Hospital | Sun Yat-sen University | Guangdong Provincial People's Hospital | Guangzhou General Hospital of Guangzhou Military Command | Third Affiliated Hospital, Sun Yat-sen University | Shang","highestDevelopmentStatusID":"8","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Academy Military Medical Science | Peking University People's Hospital | Sun Yat-sen University | Guangdong Provincial People's Hospital | Guangzhou General Hospital of Guangzhou Military Command | Third Affiliated Hospital, Sun Yat-sen University | Shang"},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Guangdong Provincial People's Hospital | Third Affiliated Hospital, Sun Yat-sen University | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou First People's Hospital | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Southern ","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Guangdong Provincial People's Hospital | Third Affiliated Hospital, Sun Yat-sen University | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou First People's Hospital | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Southern ","highestDevelopmentStatusID":"9","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Guangdong Provincial People's Hospital | Third Affiliated Hospital, Sun Yat-sen University | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou First People's Hospital | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Southern "},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Avacta Group","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong Pharmaceutical \/ Avacta Group"},{"orgOrder":0,"company":"Thomas Advanced Medical LLC","sponsor":"HeartStem Institute | NuStem","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Thomas Advanced Medical LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas Advanced Medical LLC \/ HeartStem Institute | NuStem","highestDevelopmentStatusID":"7","companyTruncated":"Thomas Advanced Medical LLC \/ HeartStem Institute | NuStem"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Universidad de la Sabana","sponsor":"Fundaci\u00f3n Neumologica Colombiana | Innocell SAS | Stem Medicina Regenerativa","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"COLOMBIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Undisclosed","graph3":"Universidad de la Sabana","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad de la Sabana \/ Fundaci\u00f3n Neumologica Colombiana | Innocell SAS | Stem Medicina Regenerativa","highestDevelopmentStatusID":"1","companyTruncated":"Universidad de la Sabana \/ Fundaci\u00f3n Neumologica Colombiana | Innocell SAS | Stem Medicina Regenerativa"},{"orgOrder":0,"company":"UMC Utrecht","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"UMC Utrecht","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UMC Utrecht \/ ZonMw","highestDevelopmentStatusID":"7","companyTruncated":"UMC Utrecht \/ ZonMw"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Leman Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Metabolically Armed CD19 CAR-T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhejiang University \/ Leman Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Leman Biotech"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MG4101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Lallemand Bio-Ingredients","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"M-Gard","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Lallemand Bio-Ingredients","highestDevelopmentStatusID":"8","companyTruncated":"RDC Clinical \/ Lallemand Bio-Ingredients"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MHS552","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Antion Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"miCAR19","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Antion Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antion Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Antion Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TolerogenixX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MIC-Lx","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"TolerogenixX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TolerogenixX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TolerogenixX \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Micro-Fragmented Adipose Tissue","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Micronized Dhacm","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"University of Exeter","sponsor":"Advanced Growers Limited | Ecog Pro Limited","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Micro-Vegetable Blend","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Exeter","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Exeter \/ Advanced Growers Limited | Ecog Pro Limited","highestDevelopmentStatusID":"1","companyTruncated":"University of Exeter \/ Advanced Growers Limited | Ecog Pro Limited"},{"orgOrder":0,"company":"Hasanuddin University","sponsor":"Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hasanuddin University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hasanuddin University \/ Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"Hasanuddin University \/ Arla Foods"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"FrieslandCampina | Wageningen University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Milk Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ FrieslandCampina | Wageningen University","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ FrieslandCampina | Wageningen University"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Linical | Datamap","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mitizax","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Linical | Datamap","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Linical | Datamap"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MK-2225","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MK-2225","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MK-8457","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MK-8457","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"MK-8723","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"BioClever 2005","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MM09","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ BioClever 2005","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ BioClever 2005"},{"orgOrder":0,"company":"Inmunotek","sponsor":"LAT Research | Xolomon Tree S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MM09","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ LAT Research | Xolomon Tree S.L.","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ LAT Research | Xolomon Tree S.L."},{"orgOrder":0,"company":"Alivexis","sponsor":"Green Coinvest Investment Limited","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series C Financing","leadProduct":"MOD-A","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Alivexis","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Alivexis \/ Green Coinvest Investment Limited","highestDevelopmentStatusID":"3","companyTruncated":"Alivexis \/ Green Coinvest Investment Limited"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"The Alfred | Melbourne Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Moderate Oligosaccharide Group","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ The Alfred | Melbourne Health","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ The Alfred | Melbourne Health"},{"orgOrder":0,"company":"TolerogenixX","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Modified Immune Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"TolerogenixX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TolerogenixX \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"TolerogenixX \/ FGK Clinical Research"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Monosaccharides","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Egil Johnson","sponsor":"ImmunoPharma AS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Mushroom Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Egil Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egil Johnson \/ ImmunoPharma AS","highestDevelopmentStatusID":"1","companyTruncated":"Egil Johnson \/ ImmunoPharma AS"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MuSK-CAART","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MuSK-CAART","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Penn Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MuSK-CAART","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Penn Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Penn Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Penn Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mabylon","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Financing","leadProduct":"MY006","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Mabylon","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Mabylon \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Mabylon \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"National Human Genome Research Institute","sponsor":"National Center for Advancing Translational Sciences | Therapeutics for Rare and Neglected Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"N-Acetyl-D-Mannosamine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"National Human Genome Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Human Genome Research Institute \/ National Center for Advancing Translational Sciences | Therapeutics for Rare and Neglected Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Human Genome Research Institute \/ National Center for Advancing Translational Sciences | Therapeutics for Rare and Neglected Diseases"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nanohydroxyapatite","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"3E Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"Nasapaque","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"3E Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"3E Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"7","companyTruncated":"3E Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"Fraunhofer-Institute of Toxicology and Experimental Medicine","sponsor":"MetP Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Nascum Plus","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Fraunhofer-Institute of Toxicology and Experimental Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fraunhofer-Institute of Toxicology and Experimental Medicine \/ MetP Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Fraunhofer-Institute of Toxicology and Experimental Medicine \/ MetP Pharma"},{"orgOrder":0,"company":"Natrogen Therapeutics International, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Natura-Alpha","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Natrogen Therapeutics International, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natrogen Therapeutics International, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Natrogen Therapeutics International, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NCR102","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"New Extensively Hydrolysed Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Base Therapeutics","sponsor":"The First Affiliated Hospital of Anhui Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NK510","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Base Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Base Therapeutics \/ The First Affiliated Hospital of Anhui Medical University","highestDevelopmentStatusID":"1","companyTruncated":"Base Therapeutics \/ The First Affiliated Hospital of Anhui Medical University"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NNC 0141-0000-0100","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"NNC 0142-0000-0002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NNC 0151-0000-0000","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"NNC 0151-0000-0000","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"NNC0114-0000-0005","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"NNC0142-0002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NNC0215-0384","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"NNC0215-0384","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NNC109-0012","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Normal Human Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Georgetown University \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"Georgetown University \/ CSL Behring"},{"orgOrder":0,"company":"nibec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NP-201 Acetate","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"nibec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"nibec \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"nibec \/ Undisclosed"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NTB003","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"5","companyTruncated":"Biocytogen \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"Baptist Memorial Health Care Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Baptist Memorial Health Care Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baptist Memorial Health Care Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Baptist Memorial Health Care Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Funding","leadProduct":"OCi mAb","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunOs Therapeutics \/ Eurostars","highestDevelopmentStatusID":"4","companyTruncated":"ImmunOs Therapeutics \/ Eurostars"},{"orgOrder":0,"company":"Oryn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ORTD-1","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Oryn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oryn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oryn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oshadi Drug Administration","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SRI LANKA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Oshadi D","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Oshadi Drug Administration","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oshadi Drug Administration \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oshadi Drug Administration \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Osiris","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"International Vaccine Institute","sponsor":"EuBiologics | Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OSP:rTTHc Cholera Conjugate Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Vaccine Institute \/ EuBiologics | Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"International Vaccine Institute \/ EuBiologics | Massachusetts General Hospital"},{"orgOrder":0,"company":"Ossium Health","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Funding","leadProduct":"OSSM-007","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ossium Health \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Ossium Health \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Oncostellae S.L","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"OST-122","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Oncostellae S.L","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncostellae S.L \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncostellae S.L \/ Undisclosed"},{"orgOrder":0,"company":"TxCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Ovasave","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"TxCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TxCell \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TxCell \/ Undisclosed"},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Quan Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"P014","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Kira Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Kira Pharmaceuticals \/ Quan Capital","highestDevelopmentStatusID":"3","companyTruncated":"Kira Pharmaceuticals \/ Quan Capital"},{"orgOrder":0,"company":"Anhui Palo Alto Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PA9159","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Anhui Palo Alto Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Palo Alto Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anhui Palo Alto Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anhui Palo Alto Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PA9159","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Anhui Palo Alto Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Palo Alto Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anhui Palo Alto Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Strand Life Sciences"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Strand Life Sciences"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Giiant pharma \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Giiant pharma \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Pangramin Slit Hdm Mix","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"P-CD19CD20-ALLO1 Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"PD0360324","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Collaboration","leadProduct":"Peanut (Arachis Hypogaea) Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0.46999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.46999999999999997,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Scripps Health","sponsor":"Scripps Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Peanut Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scripps Health \/ Scripps Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Scripps Health \/ Scripps Research Institute"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"AllerGen NCE | McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Peanut Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ AllerGen NCE | McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ AllerGen NCE | McMaster University"},{"orgOrder":0,"company":"Instituto de Investigacion Sanitaria La Fe","sponsor":"Adventia Pharma | Biopolis S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Peptidic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Instituto de Investigacion Sanitaria La Fe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigacion Sanitaria La Fe \/ Adventia Pharma | Biopolis S.L.","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigacion Sanitaria La Fe \/ Adventia Pharma | Biopolis S.L."},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Guangdong Provincial People's Hospital | Third Affiliated Hospital, Sun Yat-sen University | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou First People's Hospital | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Southern ","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Peripheral Stem Cell Combined","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Guangdong Provincial People's Hospital | Third Affiliated Hospital, Sun Yat-sen University | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou First People's Hospital | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Southern ","highestDevelopmentStatusID":"9","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Guangdong Provincial People's Hospital | Third Affiliated Hospital, Sun Yat-sen University | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou First People's Hospital | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Southern "},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Academy Military Medical Science | Peking University People's Hospital | Sun Yat-sen University | Guangdong Provincial People's Hospital | Guangzhou General Hospital of Guangzhou Military Command | Third Affiliated Hospital, Sun Yat-sen University | Shang","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Peripheral Stem Cell Combined","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Academy Military Medical Science | Peking University People's Hospital | Sun Yat-sen University | Guangdong Provincial People's Hospital | Guangzhou General Hospital of Guangzhou Military Command | Third Affiliated Hospital, Sun Yat-sen University | Shang","highestDevelopmentStatusID":"9","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Academy Military Medical Science | Peking University People's Hospital | Sun Yat-sen University | Guangdong Provincial People's Hospital | Guangzhou General Hospital of Guangzhou Military Command | Third Affiliated Hospital, Sun Yat-sen University | Shang"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PF-06480605","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Pfizer Inc"},{"orgOrder":0,"company":"Telavant","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"PF-06480605","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Telavant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telavant \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/ Pfizer Inc"},{"orgOrder":0,"company":"Telavant","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PF-06480605","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Telavant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telavant \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PF-06687234","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PF-06755347","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Prime Gene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PG-011","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Prime Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Prime Gene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prime Gene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Curanex Pharmaceuticals","sponsor":"Dominari Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Public Offering","leadProduct":"Phyto-N","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Curanex Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Curanex Pharmaceuticals \/ Dominari Securities","highestDevelopmentStatusID":"4","companyTruncated":"Curanex Pharmaceuticals \/ Dominari Securities"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PIT565","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PIT565","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"PMG Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHILE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PK101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"PMG Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PMG Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PMG Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PMG Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHILE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PK101-002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"PMG Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PMG Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PMG Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Placenta Derived Cell PDA001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Celgene Corporation"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Plasma Exchange","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Grifols International","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Grifols International"},{"orgOrder":0,"company":"Chongqing Peg-Bio Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PN20","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Chongqing Peg-Bio Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Peg-Bio Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chongqing Peg-Bio Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Montpellier","sponsor":"H\u00f4pital Cochin | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Montpellier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Montpellier \/ H\u00f4pital Cochin | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Montpellier \/ H\u00f4pital Cochin | Pfizer Inc"},{"orgOrder":0,"company":"Karolinska University Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Karolinska University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska University Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska University Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"University Hospital, Montpellier","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Pneumococcal Polysaccharide Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Hospital, Montpellier","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Montpellier \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Montpellier \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Autoimmunity Centers of Excellence | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Polyclonal Regulatory T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PQGrass306","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PQGrass309","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Wageningen University","sponsor":"Winclove Probiotics B.V. | China Scholarship Council","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wageningen University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wageningen University \/ Winclove Probiotics B.V. | China Scholarship Council","highestDevelopmentStatusID":"1","companyTruncated":"Wageningen University \/ Winclove Probiotics B.V. | China Scholarship Council"},{"orgOrder":0,"company":"Stanford University","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Stanford University \/ Abbott Laboratories"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG-1801","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wuhan Union Hospital \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Wuhan Union Hospital \/ Pregene"},{"orgOrder":0,"company":"PurGenesis Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"PUR 0110","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"PurGenesis Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"PurGenesis Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PurGenesis Technologies \/ Undisclosed"},{"orgOrder":0,"company":"PurGenesis Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"PUR 0110","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"PurGenesis Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"PurGenesis Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PurGenesis Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Aravax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PVX-108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Aravax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aravax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aravax \/ Undisclosed"},{"orgOrder":0,"company":"Szeged University","sponsor":"Research Centre for Natural Sciences | University of Debrecen Dept. of Rheumatology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HUNGARY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Pyrophosphate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Szeged University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Szeged University \/ Research Centre for Natural Sciences | University of Debrecen Dept. of Rheumatology","highestDevelopmentStatusID":"1","companyTruncated":"Szeged University \/ Research Centre for Natural Sciences | University of Debrecen Dept. of Rheumatology"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Qbeco","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qu Biologics Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qu Biologics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"QBECO-SSI","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qu Biologics Inc \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Karolinska Institute"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"QBECO-SSI","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Qu Biologics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Quell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Quell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Quell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Quell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"eXmoor pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Partnership","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Quell Therapeutics \/ eXmoor pharma","highestDevelopmentStatusID":"7","companyTruncated":"Quell Therapeutics \/ eXmoor pharma"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Series B Financing","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0.16,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Quell Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Jeito Capital"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QL0911","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLS4131","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qualia Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Qualia Senolytic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Qualia Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualia Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qualia Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"R-3750","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"R932333","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neovii","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Rabbit Anti-human T-lymphocyte Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Neovii","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neovii \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Neovii \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RAY121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RAY121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RD06-04","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioheng Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RD06-04","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bioheng Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RD06-04","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioheng Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RD06-05","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bioheng Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Hasan Sadikin General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Hasan Sadikin General Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Hasan Sadikin General Hospital"},{"orgOrder":0,"company":"University of S\u00e3o Paulo General Hospital","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Herpes Zoster Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"University of S\u00e3o Paulo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of S\u00e3o Paulo General Hospital \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"University of S\u00e3o Paulo General Hospital \/ GSK"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human IL-7-hyFc","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ NeoImmuneTech","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ NeoImmuneTech"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Ventria Bioscience | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Recombinant Human Lactoferrin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johns Hopkins University \/ Ventria Bioscience | National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Ventria Bioscience | National Institute on Aging"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Recombinant Human Monoclonal Antibody Beta7","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Lubris Bio","sponsor":"Lubris Biopharma | Sydney Eye Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Proteoglycan-4","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Lubris Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lubris Bio \/ Lubris Biopharma | Sydney Eye Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Lubris Bio \/ Lubris Biopharma | Sydney Eye Hospital"},{"orgOrder":0,"company":"Lubris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Proteoglycan-4","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Lubris Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lubris Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lubris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"The Second Hospital of Hebei Medical University | Xijing Hospital | The Affiliated Hospital of Inner Mongolia Medical University | The Second Affiliated Hospital of Kunming Medical University | Second Affiliated Hospital, Guangzhou Medical University | Sh","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human Thrombopoietin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ The Second Hospital of Hebei Medical University | Xijing Hospital | The Affiliated Hospital of Inner Mongolia Medical University | The Second Affiliated Hospital of Kunming Medical University | Second Affiliated Hospital, Guangzhou Medical University | Sh","highestDevelopmentStatusID":"11","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ The Second Hospital of Hebei Medical University | Xijing Hospital | The Affiliated Hospital of Inner Mongolia Medical University | The Second Affiliated Hospital of Kunming Medical University | Second Affiliated Hospital, Guangzhou Medical University | Sh"},{"orgOrder":0,"company":"Beijing VDJBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Humanized Anti-IL-6 Receptor Monoclonal Antibody","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Beijing VDJBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing VDJBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing VDJBio \/ Undisclosed"},{"orgOrder":0,"company":"Xiaoming Gong","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Humanized Anti-IL-6 Receptor Monoclonal Antibody","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Xiaoming Gong","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiaoming Gong \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xiaoming Gong \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Rectal Dialysis","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"SEWON CELLONTECH CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Regenseal","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"SEWON CELLONTECH CO LTD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SEWON CELLONTECH CO LTD \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SEWON CELLONTECH CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HUNGARY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"RGB-03","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gedeon Richter \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gedeon Richter \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Statitec","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Rice","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Statitec","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Statitec"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"RO7049665","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"RO7049665","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RO7303509","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RO7507062","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RO7837195","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"RPT-2950","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rome Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Rome Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Rome Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Respivert","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"RV568","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Respivert","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Respivert \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Respivert \/ Undisclosed"},{"orgOrder":0,"company":"Pharmaceutical Project Solutions, Inc","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"RX0041-002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Pharmaceutical Project Solutions, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmaceutical Project Solutions, Inc \/ Cognitive Research Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Pharmaceutical Project Solutions, Inc \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"Jiangsu Renocell Biotech","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"RY_SW01 cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Renocell Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Renocell Biotech \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Renocell Biotech \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"S95011","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Samjin pharm Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SA001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Samjin pharm Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Samjin pharm Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Samjin pharm Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"UConn Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UConn Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"UConn Health \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital\/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital\/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Center for Child Health Universitas Gadjah Mada | Cipto Mangunkusumo Hospital\/Department of Child Health, Faculty of Medicine, University of Indonesia | General Hospital of Shenyang Military Region"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SB705498","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SB705498","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SB705498","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SB705498","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SBT777101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sonoma Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Series B Financing","leadProduct":"SBT-77-7101","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sonoma Biotherapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.27000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Ally Bridge Group","highestDevelopmentStatusID":"5","companyTruncated":"Sonoma Biotherapeutics \/ Ally Bridge Group"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SCH 39641","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"SCM Lifescience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SCM-CGH","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"SCM Lifescience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SCM Lifescience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SCM Lifescience \/ Undisclosed"},{"orgOrder":0,"company":"Laval University","sponsor":"Ministry of Agriculture, Fisheries and Food, Quebec | Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Seal Oil","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Laval University \/ Ministry of Agriculture, Fisheries and Food, Quebec | Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Laval University \/ Ministry of Agriculture, Fisheries and Food, Quebec | Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc."},{"orgOrder":0,"company":"Ting Chang, MD","sponsor":"Hebei Senlang Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SENL103","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Ting Chang, MD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ting Chang, MD \/ Hebei Senlang Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Ting Chang, MD \/ Hebei Senlang Biotechnology"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2015","type":"Inapplicable","leadProduct":"SER-287","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-287","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-287","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-287","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"SER-301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melior Discovery","sponsor":"SFA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"SFA005","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melior Discovery \/ SFA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Melior Discovery \/ SFA Therapeutics"},{"orgOrder":0,"company":"Sumgen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SG301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Sumgen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sumgen Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sumgen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Short Chain Fatty Acid","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Short Ragweed Pollen Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Short Ragweed Pollen Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"GREER LABORATORIES","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Short Ragweed Pollen Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"GREER LABORATORIES","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GREER LABORATORIES \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GREER LABORATORIES \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR1819","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-2106","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-2173","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-3032","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SHR-3045","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SK08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Zhiyi Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Zhiyi Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhiyi Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Roxall Medicina Espa\u00f1a","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Skin Prick Test","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Roxall Medicina Espa\u00f1a","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Roxall Medicina Espa\u00f1a \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roxall Medicina Espa\u00f1a \/ Undisclosed"},{"orgOrder":0,"company":"ASST Fatebenefratelli Sacco","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Slitone","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ASST Fatebenefratelli Sacco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASST Fatebenefratelli Sacco \/ ALK","highestDevelopmentStatusID":"10","companyTruncated":"ASST Fatebenefratelli Sacco \/ ALK"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SLITone ULTRA HDM immunotherapy","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"SinoMab BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SM03","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"SinoMab BioScience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SinoMab BioScience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SinoMab BioScience \/ Undisclosed"},{"orgOrder":0,"company":"SinoMab BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SM03","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"SinoMab BioScience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SinoMab BioScience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SinoMab BioScience \/ Undisclosed"},{"orgOrder":0,"company":"SinoMab BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SM03","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"SinoMab BioScience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SinoMab BioScience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SinoMab BioScience \/ Undisclosed"},{"orgOrder":0,"company":"LIPUM","sponsor":"QPS Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SOL-116","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"LIPUM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LIPUM \/ QPS Holdings","highestDevelopmentStatusID":"6","companyTruncated":"LIPUM \/ QPS Holdings"},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SPARC1203","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Sun Pharma Advanced Research Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharma Advanced Research Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma Advanced Research Company \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"SPARC1310","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Sun Pharma Advanced Research Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharma Advanced Research Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma Advanced Research Company \/ Undisclosed"},{"orgOrder":0,"company":"Clinique Sp\u00e9cialis\u00e9e en Allergies de la Capitale","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SQ-Bet","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Clinique Sp\u00e9cialis\u00e9e en Allergies de la Capitale","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clinique Sp\u00e9cialis\u00e9e en Allergies de la Capitale \/ ALK","highestDevelopmentStatusID":"11","companyTruncated":"Clinique Sp\u00e9cialis\u00e9e en Allergies de la Capitale \/ ALK"},{"orgOrder":0,"company":"SciRhom","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"SR-878","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"SciRhom","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"SciRhom \/ Andera Partners","highestDevelopmentStatusID":"5","companyTruncated":"SciRhom \/ Andera Partners"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SSGJ-613","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sublimity Therapeutics Holdco Limited","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ST-0529","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Sublimity Therapeutics Holdco Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sublimity Therapeutics Holdco Limited \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Sublimity Therapeutics Holdco Limited \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Affyxell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Stefin A","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Affyxell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Avacta Group \/ Affyxell Therapeutics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"ProCapZoom Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Stem Cell Lenses","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"ProCapZoom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProCapZoom Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProCapZoom Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2019","type":"Inapplicable","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Integrium","highestDevelopmentStatusID":"6","companyTruncated":"Siolta Therapeutics \/ Integrium"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Series B Financing","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Siolta Therapeutics \/ Khosla Ventures"},{"orgOrder":0,"company":"Beijing GoBroad Hospital","sponsor":"Starna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"STR-P004","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Beijing GoBroad Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing GoBroad Hospital \/ Starna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Beijing GoBroad Hospital \/ Starna Therapeutics"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"STSA-1002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu BioJeTay Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"STSA-1301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu BioJeTay Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu BioJeTay Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu BioJeTay Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"STSA-1301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sublivac Fix Mite Mixture","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Drops","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SUNPG1622","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SUNPG1623","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sunpharma1505","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Suono Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SUO-2002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Suono Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Suono Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Suono Bio \/ Undisclosed"},{"orgOrder":0,"company":"Synermore Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SYN060","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synermore Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synermore Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synermore Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Synthekine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SYNCAR-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthekine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Undisclosed"},{"orgOrder":0,"company":"Synthekine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthekine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Undisclosed"},{"orgOrder":0,"company":"Synthekine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthekine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Undisclosed"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Canadian Institutes of Health Research | Crohn's and Colitis Canada | Beneo","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Synergy1","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ Canadian Institutes of Health Research | Crohn's and Colitis Canada | Beneo","highestDevelopmentStatusID":"1","companyTruncated":"University of Alberta \/ Canadian Institutes of Health Research | Crohn's and Colitis Canada | Beneo"},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Synthetic AAV Capsid Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Dyno Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Dyno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SYS6020","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SYS6020","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Besancon","sponsor":"Etablissement Fran\u00e7ais du Sang | Bellicum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"T lymphocytes iCASP9 \u0394CD19","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Centre Hospitalier Universitaire de Besancon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centre Hospitalier Universitaire de Besancon \/ Etablissement Fran\u00e7ais du Sang | Bellicum Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Centre Hospitalier Universitaire de Besancon \/ Etablissement Fran\u00e7ais du Sang | Bellicum Pharmaceuticals"},{"orgOrder":0,"company":"Triastek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"T19","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Triastek \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Undisclosed"},{"orgOrder":0,"company":"Triastek","sponsor":"Matrix Partners China","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"T19","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Triastek \/ Matrix Partners China","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Matrix Partners China"},{"orgOrder":0,"company":"Triastek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"T21","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Triastek \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Undisclosed"},{"orgOrder":0,"company":"Triastek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"T21","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Triastek \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"T8","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"ITBMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TCD601","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ITBMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ITBMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ITBMed \/ Undisclosed"},{"orgOrder":0,"company":"ITBMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TCD601","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ITBMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ITBMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ITBMed \/ Undisclosed"},{"orgOrder":0,"company":"ITBMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TCD601","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ITBMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ITBMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ITBMed \/ Undisclosed"},{"orgOrder":0,"company":"ITBMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TCD601","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ITBMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ITBMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ITBMed \/ Undisclosed"},{"orgOrder":0,"company":"ITBMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TCD601","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ITBMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ITBMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ITBMed \/ Undisclosed"},{"orgOrder":0,"company":"ITBMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TCD601","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ITBMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ITBMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ITBMed \/ Undisclosed"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TCK-276","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teijin Pharma \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Teijin Pharma \/ Parexel"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TD-3504","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TEV-45779","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Jinling Hospital, China","sponsor":"Jiangsu Topcel-KH Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TH-SC01","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Jinling Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jinling Hospital, China \/ Jiangsu Topcel-KH Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Jinling Hospital, China \/ Jiangsu Topcel-KH Pharmaceutical"},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"Pillar VC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"THY-100","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Thymmune Therapeutics \/ Pillar VC","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune Therapeutics \/ Pillar VC"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"TILD","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"TILD","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"TILD","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"TL011","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TNX-2110","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Premier Research Group","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Premier Research Group"},{"orgOrder":0,"company":"3PBiovian","sponsor":"Toleranzia","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"TOL2","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3PBiovian \/ Toleranzia","highestDevelopmentStatusID":"4","companyTruncated":"3PBiovian \/ Toleranzia"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Tolerogenic Nanoparticle","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Cour Pharmaceuticals","amount2":0.93999999999999995,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.93999999999999995,"dosageForm":"Undisclosed","sponsorNew":"Cour Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Cour Pharmaceuticals \/ Genentech"},{"orgOrder":0,"company":"Thetis Pharmaceuticals","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"TP-317","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Thetis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thetis Pharmaceuticals \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"6","companyTruncated":"Thetis Pharmaceuticals \/ Helmsley Charitable Trust"},{"orgOrder":0,"company":"Thetis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TP-317","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Thetis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thetis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Thetis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Standard Process Inc.","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TPG1","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Standard Process Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Standard Process Inc. \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Standard Process Inc. \/ Nutrasource"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TQ05105","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQB3473","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQB3473","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQB3702","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQB3702","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQC2938","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TQC3564","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQH2722","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQH3821","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TQH3821","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"King's College London","sponsor":"Guy's and St Thomas' NHS Foundation Trust | Medical Research Council | St. George's Hospital, London | Miltenyi biotec","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TR004","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"King's College London","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"King's College London \/ Guy's and St Thomas' NHS Foundation Trust | Medical Research Council | St. George's Hospital, London | Miltenyi biotec","highestDevelopmentStatusID":"6","companyTruncated":"King's College London \/ Guy's and St Thomas' NHS Foundation Trust | Medical Research Council | St. George's Hospital, London | Miltenyi biotec"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tree MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tract Therapeutics","sponsor":"RXi Pharmaceuticals | Taiwan Bio Therapeutics Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TRK-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Tract Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tract Therapeutics \/ RXi Pharmaceuticals | Taiwan Bio Therapeutics Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Tract Therapeutics \/ RXi Pharmaceuticals | Taiwan Bio Therapeutics Inc."},{"orgOrder":0,"company":"Tract Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"TRK-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tract Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tract Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tract Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TS-152","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TU-100","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tsumura & Co \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Syneos Health"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TX200-TR101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TXR-711","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"twoXAR Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"UCB8600","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"LiveKidney.BIO","sponsor":"Medical University of South Carolina | Galilee CBR","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"UC-Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"LiveKidney.BIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LiveKidney.BIO \/ Medical University of South Carolina | Galilee CBR","highestDevelopmentStatusID":"6","companyTruncated":"LiveKidney.BIO \/ Medical University of South Carolina | Galilee CBR"},{"orgOrder":0,"company":"Cytopeutics","sponsor":"Universiti Tunku Abdul Rahman","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"MALAYSIA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Umbilical Cord Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cytopeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytopeutics \/ Universiti Tunku Abdul Rahman","highestDevelopmentStatusID":"7","companyTruncated":"Cytopeutics \/ Universiti Tunku Abdul Rahman"},{"orgOrder":0,"company":"Kang Stem Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Umbilical Cord Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kang Stem Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kang Stem Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kang Stem Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Alliancells Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alliancells Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alliancells Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alliancells Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Translational Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Translational Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Translational Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Restem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Umbilical Cord Outer Lining Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Restem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Restem \/ Undisclosed"},{"orgOrder":0,"company":"Neovii","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"US-ATG-F","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Neovii","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neovii \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neovii \/ Undisclosed"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"UTAA91","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PersonGen BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PersonGen BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"UTAA91","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PersonGen BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PersonGen BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"UTAA91","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PersonGen BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PersonGen BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"VE202","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedanta Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Vedanta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"VE202","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Vedanta Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Vedanta Biosciences"},{"orgOrder":0,"company":"Genrix Bio","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Velinotamig","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Genrix Bio","amount2":0.70999999999999996,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.70999999999999996,"dosageForm":"Injection","sponsorNew":"Genrix Bio \/ Cullinan Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Genrix Bio \/ Cullinan Therapeutics"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Viaskin Milk","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2025","type":"Financing","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0.31,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.31,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ MPM BioImpact","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ MPM BioImpact"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VIS171","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Visterra, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VIS171","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Visterra, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Visterra, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Visterra, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLP Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allergy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergy Therapeutics \/ AGC Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Allergy Therapeutics \/ AGC Biologics"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Allergy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP-based Peanut Allergy Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AGC Biologics \/ Allergy Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Allergy Therapeutics"},{"orgOrder":0,"company":"Vandria","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"VNA-052","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Vandria","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vandria \/ Eurostars","highestDevelopmentStatusID":"5","companyTruncated":"Vandria \/ Eurostars"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Charles University, Czech Republic","sponsor":"Iscare i.v.f., Czech Republic | CD Investments srl | University Of Perugia | University of Roma La Sapienza","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CZECH REPUBLIC","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"VSL#3","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Charles University, Czech Republic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles University, Czech Republic \/ Iscare i.v.f., Czech Republic | CD Investments srl | University Of Perugia | University of Roma La Sapienza","highestDevelopmentStatusID":"1","companyTruncated":"Charles University, Czech Republic \/ Iscare i.v.f., Czech Republic | CD Investments srl | University Of Perugia | University of Roma La Sapienza"},{"orgOrder":0,"company":"Wuhan Optics Valley Vcanbiopharma Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VUM02","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Wuhan Optics Valley Vcanbiopharma Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wuhan Optics Valley Vcanbiopharma Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan Optics Valley Vcanbiopharma Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Exosomm Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Whey Protein Milk-Derived Exosome","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Exosomm Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exosomm Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Exosomm Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Worg Biotherapeutics Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"WP1302","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Worg Biotherapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worg Biotherapeutics Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Worg Biotherapeutics Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Xbiome Biotech Co., Ltd.","sponsor":"Beijing Improve-Quality Tech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XBI-302","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Shenzhen Xbiome Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Xbiome Biotech Co., Ltd. \/ Beijing Improve-Quality Tech","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Xbiome Biotech Co., Ltd. \/ Beijing Improve-Quality Tech"},{"orgOrder":0,"company":"Heilongjiang Quanle Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Xiwujia","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Heilongjiang Quanle Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Heilongjiang Quanle Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Heilongjiang Quanle Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"YH35324","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"YH35324","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"YH35324","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Excyte Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YK012","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Excyte Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Excyte Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Excyte Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"YUNGJIN PHARM. CO. LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"YRA-1909","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"YUNGJIN PHARM. CO. LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YUNGJIN PHARM. CO. LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"YUNGJIN PHARM. CO. LTD \/ Undisclosed"},{"orgOrder":0,"company":"China Immunotech","sponsor":"The First Medical Center of Chinese PLA General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YTS109","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"China Immunotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China Immunotech \/ The First Medical Center of Chinese PLA General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"China Immunotech \/ The First Medical Center of Chinese PLA General Hospital"},{"orgOrder":0,"company":"China Immunotech","sponsor":"The First Affiliated Hospital of Anhui Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YTS109","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"China Immunotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China Immunotech \/ The First Affiliated Hospital of Anhui Medical University","highestDevelopmentStatusID":"6","companyTruncated":"China Immunotech \/ The First Affiliated Hospital of Anhui Medical University"},{"orgOrder":0,"company":"China Immunotech","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YTS109","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"China Immunotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China Immunotech \/ Institute of Hematology & Blood Diseases Hospital, China","highestDevelopmentStatusID":"6","companyTruncated":"China Immunotech \/ Institute of Hematology & Blood Diseases Hospital, China"},{"orgOrder":0,"company":"China Resources Sanjiu","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Yuxuebi","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"China Resources Sanjiu","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"China Resources Sanjiu \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"China Resources Sanjiu \/ Undisclosed"},{"orgOrder":0,"company":"Zalicus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Z102","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Zalicus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zalicus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zalicus \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ZB001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ZB002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Zephyrm Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"ZH901","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Zephyrm Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zephyrm Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zephyrm Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Chulalongkorn University","sponsor":"Government Pharmaceutical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"THAILAND","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Zingiber Cassumunar","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Chulalongkorn University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chulalongkorn University \/ Government Pharmaceutical Organization","highestDevelopmentStatusID":"10","companyTruncated":"Chulalongkorn University \/ Government Pharmaceutical Organization"},{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ZL-82","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZM001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"University of South Florida","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Zoster Vaccine, Live","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of South Florida","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of South Florida \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"University of South Florida \/ Merck & Co"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZP9830","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ludwig Enterprises \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ludwig Enterprises \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Peficitinib HBr","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Menarini"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-10561","moa":"Unknown","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IFN904","moa":"Unknown","graph1":"Immunology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"Uni-Pharma SA","sponsor":"Attikon Hospital | University Hospital of Patras | University Hospital of Crete | Thriasio General Hospital of Elefsina | General Hospital of Thessaloniki Ippokratio | General Hospital of Chalkida","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Immunology","graph2":"Phase IV","graph3":"Uni-Pharma SA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Uni-Pharma SA \/ Attikon Hospital | University Hospital of Patras | University Hospital of Crete | Thriasio General Hospital of Elefsina | General Hospital of Thessaloniki Ippokratio | General Hospital of Chalkida","highestDevelopmentStatusID":"11","companyTruncated":"Uni-Pharma SA \/ Attikon Hospital | University Hospital of Patras | University Hospital of Crete | Thriasio General Hospital of Elefsina | General Hospital of Thessaloniki Ippokratio | General Hospital of Chalkida"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Immunology","graph2":"Phase I","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"QATAR","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Venus Remedies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Undisclosed"},{"orgOrder":0,"company":"Famar","sponsor":"LaviPharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GREECE","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Famar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Famar \/ LaviPharm","highestDevelopmentStatusID":"15","companyTruncated":"Famar \/ LaviPharm"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"LaviPharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ LaviPharm","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ LaviPharm"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.5,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.5,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ SVB Leerink"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":10.800000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":10.800000000000001,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Celerion"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TEV-48574","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TEV-48574","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"TEV-48574","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":1.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":1.5,"dosageForm":"Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Massachusetts Eye and Ear Infirmary","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Immunology","graph2":"Phase II","graph3":"Massachusetts Eye and Ear Infirmary","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts Eye and Ear Infirmary \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts Eye and Ear Infirmary \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0.42999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.42999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Aveo Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncology \/ Kyowa Kirin"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":2.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":2.25,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":2.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":2.25,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mabpharm Limitied","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CMAB007","moa":"VEGF","graph1":"Immunology","graph2":"Phase III","graph3":"Mabpharm Limitied","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabpharm Limitied \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabpharm Limitied \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BCD-180","moa":"VEGF receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BCD-180","moa":"VEGF receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GB224","moa":"VEGFR2","graph1":"Immunology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GB224","moa":"VEGFR2","graph1":"Immunology","graph2":"Phase I","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Afimkibart","moa":"VEGI","graph1":"Immunology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Battery Bio Australia Pty Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BB-TL1A-VIAL-HLE","moa":"VEGI","graph1":"Immunology","graph2":"Phase I","graph3":"Battery Bio Australia Pty Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Battery Bio Australia Pty Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Battery Bio Australia Pty Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SPY072","moa":"VEGI","graph1":"Immunology","graph2":"Phase II","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spyre Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Bentonite","moa":"||Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nuance Pharma \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Nuance Pharma \/ DKSH"},{"orgOrder":0,"company":"Pharma Nordic","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pharma Nordic","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pharma Nordic \/ Altamira Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pharma Nordic \/ Altamira Therapeutics"},{"orgOrder":0,"company":"Pharma Nordic","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NORWAY","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pharma Nordic","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pharma Nordic \/ Altamira Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pharma Nordic \/ Altamira Therapeutics"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Nuance Pharma"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Nuance Pharma"},{"orgOrder":0,"company":"Harvard School of Public Health (HSPH)","sponsor":"University of Toronto | Unity Health Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Pyridoxine Hydrochloride","moa":"Aromatic-L-amino-acid decarboxylase (DDC)||Vitamin B6 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Harvard School of Public Health (HSPH)","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard School of Public Health (HSPH) \/ University of Toronto | Unity Health Toronto","highestDevelopmentStatusID":"6","companyTruncated":"Harvard School of Public Health (HSPH) \/ University of Toronto | Unity Health Toronto"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CANDLE-KIT Trial Study Group","sponsor":"Chugai Pharmaceutical | Japanese Society for the Promotion of Science | The Japan Kidney Foundation | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"CANDLE-KIT Trial Study Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CANDLE-KIT Trial Study Group \/ Chugai Pharmaceutical | Japanese Society for the Promotion of Science | The Japan Kidney Foundation | F. Hoffmann-La Roche","highestDevelopmentStatusID":"11","companyTruncated":"CANDLE-KIT Trial Study Group \/ Chugai Pharmaceutical | Japanese Society for the Promotion of Science | The Japan Kidney Foundation | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Beijing Life Oasis Public Service Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chinese SLE Treatment And Research Group \/ Beijing Life Oasis Public Service Center","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ Beijing Life Oasis Public Service Center"},{"orgOrder":0,"company":"University Medical Centre Ljubljana","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SLOVENIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Paricalcitol","moa":"Vitamin D receptor","graph1":"Immunology","graph2":"Phase III","graph3":"University Medical Centre Ljubljana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Centre Ljubljana \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Centre Ljubljana \/ Abbott Laboratories"},{"orgOrder":0,"company":"BioAdaptives","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Vitamin D","moa":"||Vitamin D receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"BioAdaptives","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAdaptives \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioAdaptives \/ Undisclosed"},{"orgOrder":0,"company":"McMaster University","sponsor":"Canadian Association of Gastroenterology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Canadian Association of Gastroenterology","highestDevelopmentStatusID":"1","companyTruncated":"McMaster University \/ Canadian Association of Gastroenterology"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Immunology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cadrenal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Warfarin Sodium","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"University College Cork","sponsor":"Health Research Board, Ireland","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Vitamin K1","moa":"Vitamin K-dependent gamma-carboxylase (GGCX)||Vitamin K-dependent gamma-carboxylase; Osteocalcin","graph1":"Immunology","graph2":"Phase IV","graph3":"University College Cork","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College Cork \/ Health Research Board, Ireland","highestDevelopmentStatusID":"11","companyTruncated":"University College Cork \/ Health Research Board, Ireland"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Immunology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aisa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Immunology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aisa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ventrus Biosciences, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Diltiazem Hydrochloride","moa":"Voltage-gated L-type calcium channel","graph1":"Immunology","graph2":"Phase I","graph3":"Ventrus Biosciences, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventrus Biosciences, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ventrus Biosciences, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"Voltage-gated potassium channel","graph1":"Immunology","graph2":"Phase III","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"Voltage-gated potassium channel","graph1":"Immunology","graph2":"Phase III","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Surrozen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Surrozen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Undisclosed"},{"orgOrder":0,"company":"Surrozen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Surrozen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tongren Hospital","sponsor":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Beijing Tongren Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Beijing Tongren Hospital \/ Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Tongren Hospital \/ Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"First Affiliated Hospital of Wenzhou Medical University","sponsor":"Shanghai First Song Therapeutics Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"First Affiliated Hospital of Wenzhou Medical University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"First Affiliated Hospital of Wenzhou Medical University \/ Shanghai First Song Therapeutics Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"First Affiliated Hospital of Wenzhou Medical University \/ Shanghai First Song Therapeutics Co., Ltd"},{"orgOrder":0,"company":"Changhai Hospital","sponsor":"Rui Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Changhai Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Changhai Hospital \/ Rui Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Changhai Hospital \/ Rui Therapeutics"},{"orgOrder":0,"company":"China Medical University Hospital","sponsor":"Chang Gung Memorial Hospital | China Medical University, China | NRPB, Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"China Medical University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"China Medical University Hospital \/ Chang Gung Memorial Hospital | China Medical University, China | NRPB, Taiwan","highestDevelopmentStatusID":"8","companyTruncated":"China Medical University Hospital \/ Chang Gung Memorial Hospital | China Medical University, China | NRPB, Taiwan"},{"orgOrder":0,"company":"The Children's Hospital of Zhejiang University School of Medicine","sponsor":"Chongqing Precision Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"The Children's Hospital of Zhejiang University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Children's Hospital of Zhejiang University School of Medicine \/ Chongqing Precision Biotech","highestDevelopmentStatusID":"6","companyTruncated":"The Children's Hospital of Zhejiang University School of Medicine \/ Chongqing Precision Biotech"},{"orgOrder":0,"company":"Ahn-Gook Pharmaceuticals","sponsor":"Seoul National University Bundang Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center | Samsung Medical Center | Kyunghee University Medical Center | Konkuk University Medical Center | Inha University | Seoul St. Mary's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Ahn-Gook Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ahn-Gook Pharmaceuticals \/ Seoul National University Bundang Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center | Samsung Medical Center | Kyunghee University Medical Center | Konkuk University Medical Center | Inha University | Seoul St. Mary's Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Ahn-Gook Pharmaceuticals \/ Seoul National University Bundang Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center | Samsung Medical Center | Kyunghee University Medical Center | Konkuk University Medical Center | Inha University | Seoul St. Mary's Hospital"},{"orgOrder":0,"company":"Innowage Limited","sponsor":"Mettle Networks","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innowage Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innowage Limited \/ Mettle Networks","highestDevelopmentStatusID":"1","companyTruncated":"Innowage Limited \/ Mettle Networks"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Sponsor GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Junshi Biosciences \/ Sponsor GmbH"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Hutchmed","amount2":0.92000000000000004,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.92000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hutchmed \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"HitGen","sponsor":"Morphic Therapeutic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ Morphic Therapeutic","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ Morphic Therapeutic"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pharmaceutical \/ Argenx"},{"orgOrder":0,"company":"Standigm","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Standigm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Standigm \/ SK Chemicals","highestDevelopmentStatusID":"4","companyTruncated":"Standigm \/ SK Chemicals"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyowa Kirin","amount2":0.44,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.44,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Kirin \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":1.8899999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8899999999999999,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Pfizer Inc"},{"orgOrder":0,"company":"Chiome Bioscience","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Chiome Bioscience","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Chiome Bioscience \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Chiome Bioscience \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujifilm holding \/ Sana Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Fujifilm holding \/ Sana Biotechnology"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Foundation for Biomedical Research and Innovation at Kobe","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe","highestDevelopmentStatusID":"4","companyTruncated":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"CSPC Pharmaceutical Group","amount2":5.3300000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":5.3300000000000001,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"CSPC Pharmaceutical Group \/ AstraZeneca"},{"orgOrder":0,"company":"MabGenesis","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"MabGenesis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MabGenesis \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"MabGenesis \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"EpimAb Biotherapeutics","amount2":1,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"EpimAb Biotherapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"EpimAb Biotherapeutics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"PrecisionLife","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ PrecisionLife","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ PrecisionLife"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0.40999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie Inc"},{"orgOrder":0,"company":"BioSyngen","sponsor":"A*STAR","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioSyngen \/ A*STAR","highestDevelopmentStatusID":"2","companyTruncated":"BioSyngen \/ A*STAR"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yangtze River Pharmaceutical Group \/ Alvotech","highestDevelopmentStatusID":"1","companyTruncated":"Yangtze River Pharmaceutical Group \/ Alvotech"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0.93000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.93000000000000005,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Candid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0.40999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie Inc"},{"orgOrder":0,"company":"Universit\u00e9 Libre de Bruxelles","sponsor":"DESCARTES Working Group On Transplantation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Universit\u00e9 Libre de Bruxelles","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e9 Libre de Bruxelles \/ DESCARTES Working Group On Transplantation","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e9 Libre de Bruxelles \/ DESCARTES Working Group On Transplantation"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"LFB Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ LFB Group","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Lille \/ LFB Group"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Undisclosed"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Diakonhjemmet Hospital","sponsor":"The Research Council of Norway | South-Eastern Norway Regional Health Authority","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Diakonhjemmet Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diakonhjemmet Hospital \/ The Research Council of Norway | South-Eastern Norway Regional Health Authority","highestDevelopmentStatusID":"11","companyTruncated":"Diakonhjemmet Hospital \/ The Research Council of Norway | South-Eastern Norway Regional Health Authority"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Undisclosed"},{"orgOrder":0,"company":"XVIVO Perfusion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"XVIVO Perfusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"XVIVO Perfusion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"XVIVO Perfusion \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Geneva","sponsor":"Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Hospital, Geneva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Geneva \/ Biomerieux","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Geneva \/ Biomerieux"},{"orgOrder":0,"company":"Circassia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circassia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Circassia \/ Undisclosed"},{"orgOrder":0,"company":"Galvani Bioelectronics","sponsor":"NAMSA | Q2 Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Galvani Bioelectronics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galvani Bioelectronics \/ NAMSA | Q2 Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Galvani Bioelectronics \/ NAMSA | Q2 Solutions"},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"University of Glasgow","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"University of Glasgow \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"University of Glasgow \/ Eli Lilly"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Imcyse","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Imcyse \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Imcyse \/ Pfizer Inc"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ALK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"FairJourney Biologics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"PORTUGAL","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"FairJourney Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FairJourney Biologics \/ Argenx","highestDevelopmentStatusID":"3","companyTruncated":"FairJourney Biologics \/ Argenx"},{"orgOrder":0,"company":"GlycoEra","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"GlycoEra","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"GlycoEra \/ 5Am Ventures","highestDevelopmentStatusID":"3","companyTruncated":"GlycoEra \/ 5Am Ventures"},{"orgOrder":0,"company":"Bit Bio","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bit Bio \/ BlueRock Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Secarna Pharma \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Pharma \/ Evotec"},{"orgOrder":0,"company":"Iontas","sponsor":"Quellis Biosciences Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iontas \/ Quellis Biosciences Inc","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ Quellis Biosciences Inc"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Scleroderma Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Scleroderma Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Scleroderma Research Foundation"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mestag Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Mestag Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Mestag Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Mestag Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Mestag Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Kynos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Kynos Therapeutics \/ Epidarex Capital","highestDevelopmentStatusID":"2","companyTruncated":"Kynos Therapeutics \/ Epidarex Capital"},{"orgOrder":0,"company":"Iontas","sponsor":"Inotrem","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iontas \/ Inotrem","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ Inotrem"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grunenthal \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal \/ Undisclosed"},{"orgOrder":0,"company":"PolTREG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolTREG \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"PolTREG \/ Undisclosed"},{"orgOrder":0,"company":"Mysthera Therapeutics","sponsor":"Forty51 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Mysthera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mysthera Therapeutics \/ Forty51 Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Mysthera Therapeutics \/ Forty51 Ventures"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Leo Pharma","amount2":1.7,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.7,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Leo Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"C4X Discovery","amount2":0.51000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.51000000000000001,"dosageForm":"Undisclosed","sponsorNew":"C4X Discovery \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"C4X Discovery \/ Sanofi"},{"orgOrder":0,"company":"Exscientia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Exscientia","amount2":1.2,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Exscientia \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"IMU Biosciences","sponsor":"Molten Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"IMU Biosciences","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"IMU Biosciences \/ Molten Ventures","highestDevelopmentStatusID":"3","companyTruncated":"IMU Biosciences \/ Molten Ventures"},{"orgOrder":0,"company":"Nucleome Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nucleome Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nucleome Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nucleome Therapeutics \/ M Ventures"},{"orgOrder":0,"company":"Aqilion","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Aqilion","amount2":1.03,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":1.03,"dosageForm":"Undisclosed","sponsorNew":"Aqilion \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Aqilion \/ Merck & Co"},{"orgOrder":0,"company":"Aqilion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Aqilion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aqilion \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Aqilion \/ Undisclosed"},{"orgOrder":0,"company":"Sygnature Discovery","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sygnature Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sygnature Discovery \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sygnature Discovery \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"POLAND","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ryvu Therapeutics \/ Galapagos","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Therapeutics \/ Galapagos"},{"orgOrder":0,"company":"Ermium Therapeutics","sponsor":"Kurma Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Ermium Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Ermium Therapeutics \/ Kurma Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ermium Therapeutics \/ Kurma Partners"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"BenevolentAI \/ AstraZeneca"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Tavotek Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Tavotek Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Genmab \/ Tavotek Biotherapeutics"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"OMass Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"OMass Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"1","companyTruncated":"OMass Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"Camallergy","sponsor":"OnDosis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Camallergy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Camallergy \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Camallergy \/ OnDosis"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Apollo Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Apollo Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"4","companyTruncated":"Apollo Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Mayewell Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"ThirtyFiveBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThirtyFiveBio \/ Mayewell Capital","highestDevelopmentStatusID":"4","companyTruncated":"ThirtyFiveBio \/ Mayewell Capital"},{"orgOrder":0,"company":"Nanna Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nanna Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nanna Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Nanna Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mestag Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Mestag Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bioqube Ventures","sponsor":"Metrion Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Bioqube Ventures","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioqube Ventures \/ Metrion Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Bioqube Ventures \/ Metrion Biosciences"},{"orgOrder":0,"company":"Lead Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Lead Pharma","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Lead Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Lead Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sanofi","sponsor":"Fidia Farmaceutici Spa","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Fidia Farmaceutici Spa","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Fidia Farmaceutici Spa"},{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mogrify \/ Sangamo Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mogrify \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inside Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inside Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"OSE Immunotherapeutics SA \/ Inside Therapeutics"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Slb Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Slb Pharma","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Slb Pharma"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minapharm Pharmaceuticals \/ Bioventure Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Minapharm Pharmaceuticals \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Raphael Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Raphael Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raphael Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Raphael Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Prollergy dba Ready Set Food","sponsor":"ObvioHealth","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Prollergy dba Ready Set Food","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prollergy dba Ready Set Food \/ ObvioHealth","highestDevelopmentStatusID":"1","companyTruncated":"Prollergy dba Ready Set Food \/ ObvioHealth"},{"orgOrder":0,"company":"Stanford Medical","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Stanford Medical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford Medical \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Stanford Medical \/ Sanofi"},{"orgOrder":0,"company":"Yale University","sponsor":"Aptorum","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Aptorum","highestDevelopmentStatusID":"4","companyTruncated":"Yale University \/ Aptorum"},{"orgOrder":0,"company":"Bend Beauty Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bend Beauty Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bend Beauty Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bend Beauty Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Steritas","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Steritas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steritas \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Steritas \/ Argenx"},{"orgOrder":0,"company":"Utah State University","sponsor":"USANA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Utah State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Utah State University \/ USANA Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Utah State University \/ USANA Health Sciences"},{"orgOrder":0,"company":"Rodeo Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Rodeo Therapeutics","amount2":0.71999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.71999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Rodeo Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Rodeo Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nuvig Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Inhalation","sponsorNew":"Nuvig Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Nuvig Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Baxalta Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Baxalta Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxalta Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baxalta Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Curia","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curia \/ Replicate Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Curia \/ Replicate Bioscience"},{"orgOrder":0,"company":"NexImmune","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NexImmune \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"2","companyTruncated":"NexImmune \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Gate Bioscience","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Gate Bioscience","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Pill","sponsorNew":"Gate Bioscience \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Gate Bioscience \/ Versant Ventures"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Kinnevik AB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Enveda Bioscience","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Spray, Metered","sponsorNew":"Enveda Bioscience \/ Kinnevik AB","highestDevelopmentStatusID":"2","companyTruncated":"Enveda Bioscience \/ Kinnevik AB"},{"orgOrder":0,"company":"Ceapro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ceapro \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ceapro \/ Undisclosed"},{"orgOrder":0,"company":"Ceapro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ceapro \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ceapro \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Alimentiv \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"SetPoint Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"SetPoint Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SetPoint Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SetPoint Medical \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Cincinnati Children\u2019s Hospital Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orange Grove Bio \/ Cincinnati Children\u2019s Hospital Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Cincinnati Children\u2019s Hospital Medical Center"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Orange Grove Bio \/ Viva BioInnovator","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Viva BioInnovator"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Biotechnology Value Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Biotechnology Value Fund","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Biotechnology Value Fund"},{"orgOrder":0,"company":"IgGenix","sponsor":"Alexandria Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Alexandria Venture","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ Alexandria Venture"},{"orgOrder":0,"company":"Federation Bio","sponsor":"Kanvas Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Federation Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Federation Bio \/ Kanvas Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Federation Bio \/ Kanvas Biosciences"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Seismic Therapeutic","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Seismic Therapeutic \/ Lightspeed Venture Partners"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"InveniAI","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"InveniAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InveniAI \/ Sosei Heptares","highestDevelopmentStatusID":"3","companyTruncated":"InveniAI \/ Sosei Heptares"},{"orgOrder":0,"company":"Atomwise","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atomwise \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Undisclosed"},{"orgOrder":0,"company":"TRexBio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"TRexBio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Ventus Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Ventus Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Immetas Therapeutics","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Immetas Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immetas Therapeutics \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Immetas Therapeutics \/ GC Biopharma"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Orange Grove Bio \/ Viva BioInnovator","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Viva BioInnovator"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Ventus Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ventus Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Atomwise","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":1.0800000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":1.0800000000000001,"dosageForm":"Undisclosed","sponsorNew":"Atomwise \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Jade Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Jade Biosciences \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"2","companyTruncated":"Jade Biosciences \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Nurix Therapeutics","amount2":2.5800000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":2.5800000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Nurix Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0.34000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.34000000000000002,"dosageForm":"Undisclosed","sponsorNew":"HotSpot Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"GRO Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"GRO Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"GRO Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ SAB Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ SAB Biotherapeutics"},{"orgOrder":0,"company":"Forward Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Forward Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Forward Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"Forward Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.66000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.66000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Evoq Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Odyssey Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Odyssey Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"4","companyTruncated":"Odyssey Therapeutics \/ Ascenta Capital"},{"orgOrder":0,"company":"Biotherapeutics","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotherapeutics \/ NImmune Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Biotherapeutics \/ NImmune Biopharma"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Applied BioMath","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celsius Therapeutics \/ Applied BioMath","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ Applied BioMath"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0.53000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.53000000000000003,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"TScan Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"LogiX Biosciences","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"LogiX Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LogiX Biosciences \/ Mayo Clinic","highestDevelopmentStatusID":"2","companyTruncated":"LogiX Biosciences \/ Mayo Clinic"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sonoma Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sonoma Biotherapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Orbital Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Orbital Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Beam Therapeutics \/ Orbital Therapeutics"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolojic Design \/ Nektar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Exo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Exo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Thymmune Therapeutics \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune Therapeutics \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.23999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Evoq Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.23999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Evoq Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"GentiBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forge Biologics \/ GentiBio","highestDevelopmentStatusID":"4","companyTruncated":"Forge Biologics \/ GentiBio"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":1.5600000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.5600000000000001,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Pan-Biome Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Pan-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pan-Biome Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Pan-Biome Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IGM Biosciences","amount2":6.1699999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":6.1699999999999999,"dosageForm":"Undisclosed","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Kumquat Biosciences","amount2":1.3300000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.3300000000000001,"dosageForm":"Undisclosed","sponsorNew":"Kumquat Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Kumquat Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Recludix Pharma","amount2":1.3300000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.3300000000000001,"dosageForm":"Undisclosed","sponsorNew":"Recludix Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Recludix Pharma \/ Sanofi"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Ingenia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Ingenia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Ingenia Therapeutics"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribon Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Ribon Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Synthekine","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synthekine \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Synthekine \/ Sanofi"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0.32000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.32000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Candid Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Candid Therapeutics"},{"orgOrder":0,"company":"Tolerance Bio","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Tolerance Bio","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Tolerance Bio \/ Columbus Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Tolerance Bio \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Tolerance Bio","sponsor":"Pacific 8 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Tolerance Bio","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Tolerance Bio \/ Pacific 8 Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Tolerance Bio \/ Pacific 8 Ventures"},{"orgOrder":0,"company":"GenEdit","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"GenEdit","amount2":0.64000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.64000000000000001,"dosageForm":"Undisclosed","sponsorNew":"GenEdit \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"GenEdit \/ Genentech"},{"orgOrder":0,"company":"ImmuneID","sponsor":"Alta Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"ImmuneID","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"ImmuneID \/ Alta Partners","highestDevelopmentStatusID":"3","companyTruncated":"ImmuneID \/ Alta Partners"},{"orgOrder":0,"company":"Dualogics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Dualogics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dualogics \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Dualogics \/ AbCellera"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Shattuck Labs","amount2":0.23000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Shattuck Labs \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AccutarBio \/ Evommune","highestDevelopmentStatusID":"3","companyTruncated":"AccutarBio \/ Evommune"},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Attovia Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Attovia Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Attovia Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Belharra Therapeutics","amount2":0.73999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.73999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Belharra Therapeutics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Belharra Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Lycia Therapeutics","amount2":1.6399999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":1.6399999999999999,"dosageForm":"Undisclosed","sponsorNew":"Lycia Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Lycia Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Terray Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Odyssey Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odyssey Therapeutics \/ Terray Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Odyssey Therapeutics \/ Terray Therapeutics"},{"orgOrder":0,"company":"Vyriad","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Vyriad","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vyriad \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Vyriad \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Vivtex","sponsor":"AI Proteins","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Vivtex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivtex \/ AI Proteins","highestDevelopmentStatusID":"3","companyTruncated":"Vivtex \/ AI Proteins"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligand Pharmaceuticals \/ Pandion Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ligand Pharmaceuticals \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Lycia Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Lycia Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"2","companyTruncated":"Lycia Therapeutics \/ Redmile Group"},{"orgOrder":0,"company":"Radar Therapeutics","sponsor":"NFX Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Radar Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Radar Therapeutics \/ NFX Bio","highestDevelopmentStatusID":"2","companyTruncated":"Radar Therapeutics \/ NFX Bio"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Twist Bioscience \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Evozyne","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Evozyne","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Evozyne \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"2","companyTruncated":"Evozyne \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Avilar Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Avilar Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Avilar Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Avilar Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Elektrofi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Elektrofi","amount2":0.46999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.46999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Elektrofi \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Elektrofi \/ Eli Lilly"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"S.R. One","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"HotSpot Therapeutics \/ S.R. One","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Therapeutics \/ S.R. One"},{"orgOrder":0,"company":"Metaphore Biotechnologies","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Metaphore Biotechnologies","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Metaphore Biotechnologies \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Metaphore Biotechnologies \/ Flagship Pioneering"},{"orgOrder":0,"company":"TetraGenetics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"TetraGenetics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TetraGenetics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"TetraGenetics \/ AbCellera"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evoq Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"BioMap","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"BioMap","amount2":1,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"BioMap \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"BioMap \/ Sanofi"},{"orgOrder":0,"company":"Pragma Bio","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Pragma Bio","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Pragma Bio \/ Viking Global Investors","highestDevelopmentStatusID":"2","companyTruncated":"Pragma Bio \/ Viking Global Investors"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"Empress Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Empress Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Empress Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Empress Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Jnana Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":1.04,"dosageForm":"Undisclosed","sponsorNew":"Jnana Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Jnana Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Odyssey Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odyssey Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Odyssey Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Visterra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Visterra","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Visterra"},{"orgOrder":0,"company":"Merida Biosciences","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Merida Biosciences","amount2":0.12,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Merida Biosciences \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Merida Biosciences \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"RayThera","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"RayThera","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"RayThera \/ Foresite Capital","highestDevelopmentStatusID":"4","companyTruncated":"RayThera \/ Foresite Capital"},{"orgOrder":0,"company":"IFM Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IFM Therapeutics","amount2":0.83999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.83999999999999997,"dosageForm":"Undisclosed","sponsorNew":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"IgGenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ Undisclosed"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generation Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Generation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nudge Therapeutics","sponsor":"Veralox Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Nudge Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nudge Therapeutics \/ Veralox Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nudge Therapeutics \/ Veralox Therapeutics"},{"orgOrder":0,"company":"Interline Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Interline Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Interline Therapeutics \/ Foresite Capital","highestDevelopmentStatusID":"4","companyTruncated":"Interline Therapeutics \/ Foresite Capital"},{"orgOrder":0,"company":"Amagma Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Amagma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amagma Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Amagma Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"ProThera Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"ProThera Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProThera Biologics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"ProThera Biologics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novelty Nobility","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Novelty Nobility","highestDevelopmentStatusID":"4","companyTruncated":"AGC Biologics \/ Novelty Nobility"},{"orgOrder":0,"company":"GeneFab","sponsor":"RegCell","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"GeneFab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneFab \/ RegCell","highestDevelopmentStatusID":"4","companyTruncated":"GeneFab \/ RegCell"},{"orgOrder":0,"company":"Holoclara","sponsor":"BOLD Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Holoclara","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Holoclara \/ BOLD Capital Partners","highestDevelopmentStatusID":"3","companyTruncated":"Holoclara \/ BOLD Capital Partners"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"BridGene Biosciences","amount2":0.81999999999999995,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.81999999999999995,"dosageForm":"Undisclosed","sponsorNew":"BridGene Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"BridGene Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Mirador Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Mirador Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Mirador Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Mirador Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flagship Pioneering \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Pfizer Inc"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Repertoire Immune Medicines","amount2":0.77000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.77000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Repertoire Immune Medicines \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Repertoire Immune Medicines \/ Genentech"},{"orgOrder":0,"company":"AbTherx","sponsor":"Wield Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AbTherx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbTherx \/ Wield Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"AbTherx \/ Wield Therapeutics"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Nurix Therapeutics","amount2":0.56999999999999995,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.56999999999999995,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Nurix Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Mozart Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Mozart Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Mozart Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"AB Studio","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"AB Studio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Studio \/ Candid Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"AB Studio \/ Candid Therapeutics"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sonoma Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"23andMe","sponsor":"Mirador Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"23andMe \/ Mirador Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"23andMe \/ Mirador Therapeutics"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Arcus Biosciences","amount2":1.72,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":1.72,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Quench Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Quench Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Quench Bio \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Quench Bio \/ RA Capital Management"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Quell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Quell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AGC Biologics \/ Quell Therapeutics"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0.58999999999999997,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.58999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Vida Ventures LLC","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Therapeutics \/ Vida Ventures LLC"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Schrodinger","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Ajax Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajax Therapeutics \/ Schrodinger","highestDevelopmentStatusID":"2","companyTruncated":"Ajax Therapeutics \/ Schrodinger"},{"orgOrder":0,"company":"Enlaza Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Enlaza Therapeutics","amount2":2.0499999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":2.0499999999999998,"dosageForm":"Undisclosed","sponsorNew":"Enlaza Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Enlaza Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Orogen Therapeutics","sponsor":"Chemspace","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Orogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orogen Therapeutics \/ Chemspace","highestDevelopmentStatusID":"3","companyTruncated":"Orogen Therapeutics \/ Chemspace"},{"orgOrder":0,"company":"Monash University","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Monash University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monash University \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Monash University \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Microba Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microba Life Sciences \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Microba Life Sciences \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"YANRU WANG","sponsor":"Rui Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"YANRU WANG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"YANRU WANG \/ Rui Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"YANRU WANG \/ Rui Therapeutics"},{"orgOrder":0,"company":"Peter Korsten","sponsor":"DiaMed GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Peter Korsten","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peter Korsten \/ DiaMed GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Peter Korsten \/ DiaMed GmbH"},{"orgOrder":0,"company":"Vitae Health Innovation","sponsor":"Hospital Vall d'Hebron","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Vitae Health Innovation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitae Health Innovation \/ Hospital Vall d'Hebron","highestDevelopmentStatusID":"1","companyTruncated":"Vitae Health Innovation \/ Hospital Vall d'Hebron"},{"orgOrder":0,"company":"Seattle Children\u2019s Research Institute","sponsor":"Gentbio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Seattle Children\u2019s Research Institute","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Seattle Children\u2019s Research Institute \/ Gentbio","highestDevelopmentStatusID":"3","companyTruncated":"Seattle Children\u2019s Research Institute \/ Gentbio"},{"orgOrder":0,"company":"Tolerance Bio","sponsor":"ZipCode Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Tolerance Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tolerance Bio \/ ZipCode Bio","highestDevelopmentStatusID":"4","companyTruncated":"Tolerance Bio \/ ZipCode Bio"},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Maxymune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Scipher Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scipher Medicine \/ Maxymune Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Scipher Medicine \/ Maxymune Therapeutics"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Monte Rosa Therapeutics","amount2":5.7000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":5.7000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"ALK","sponsor":"GeneScience Pharmaceuticals Co Ltd","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"American House Dust Mite Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"ALK \/ GeneScience Pharmaceuticals Co Ltd","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ GeneScience Pharmaceuticals Co Ltd"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Jasper Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Jasper Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Jasper Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trethera \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institutes of Health"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PL-14","moa":"IL-8 secretion","graph1":"Immunology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Polyrizon \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"LBL-047","moa":"BDCA2\/TACI","graph1":"Immunology","graph2":"IND Enabling","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GR1802","moa":"IL-4R?","graph1":"Immunology","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"The Affiliated Hospital of Xuzhou Medical University","sponsor":"Shanghai Xiniao Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"UCAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Affiliated Hospital of Xuzhou Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Affiliated Hospital of Xuzhou Medical University \/ Shanghai Xiniao Biotech Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"The Affiliated Hospital of Xuzhou Medical University \/ Shanghai Xiniao Biotech Co., Ltd."},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"GNR-127","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Afimkibart","moa":"VEGI","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Sint Maartenskliniek","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Sint Maartenskliniek","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sint Maartenskliniek \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Sint Maartenskliniek \/ ZonMw"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tarperprumig","moa":"Properdin","graph1":"Immunology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China | Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, Luoyang, China","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China | Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, Luoyang, China","highestDevelopmentStatusID":"7","companyTruncated":"Hebei Senlang Biotechnology \/ The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China | Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, Luoyang, China"},{"orgOrder":0,"company":"SecondWave Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"SecondWave Systems","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SecondWave Systems \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SecondWave Systems \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CM512","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Beijing GoBroad Hospital","sponsor":"Overland Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"OL-CD19-GDT","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Beijing GoBroad Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing GoBroad Hospital \/ Overland Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Beijing GoBroad Hospital \/ Overland Therapeutics"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Immunology","graph2":"Phase III","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BMS-986454","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Crovalimab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VC005","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CM336","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"CytoCares","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CC312","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CytoCares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoCares \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoCares \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAR-T Therapy","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SSGJ-626","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LY4268989","moa":"Integrin-alpha-4|beta-7","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"ProCapZoom Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Immunology","graph2":"Phase I","graph3":"ProCapZoom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Instillation","sponsorNew":"ProCapZoom Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProCapZoom Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"ShenZhen Cell Valley","sponsor":"First Affiliated Hospital of China Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"ShenZhen Cell Valley","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ShenZhen Cell Valley \/ First Affiliated Hospital of China Medical University","highestDevelopmentStatusID":"1","companyTruncated":"ShenZhen Cell Valley \/ First Affiliated Hospital of China Medical University"},{"orgOrder":0,"company":"CytoCares","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CC312","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CytoCares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CytoCares \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoCares \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GR1802","moa":"IL-4R?","graph1":"Immunology","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ RA Capital Management"},{"orgOrder":0,"company":"Hinge Bio","sponsor":"KYORIN PHARMACEUTICAL CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"HB2198","moa":"CD19\/20","graph1":"Immunology","graph2":"Preclinical","graph3":"Hinge Bio","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Hinge Bio \/ KYORIN PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"4","companyTruncated":"Hinge Bio \/ KYORIN PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hikma Pharmaceuticals \/ Celltrion","highestDevelopmentStatusID":"1","companyTruncated":"Hikma Pharmaceuticals \/ Celltrion"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"RPT904","moa":"IgE","graph1":"Immunology","graph2":"Phase I","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"B Group Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"PALI-2108","moa":"PDE4B","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Palisade Bio \/ B Group Capital","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ B Group Capital"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Aptar","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nasus Pharma \/ Aptar","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Aptar"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"OTX-201","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Orbital Therapeutics","amount2":1.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.5,"dosageForm":"Undisclosed","sponsorNew":"Orbital Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Orbital Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PL-14","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polyrizon \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"RheumaGen","sponsor":"RheumaGen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"RG0401","moa":"HLA","graph1":"Immunology","graph2":"IND Enabling","graph3":"RheumaGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RheumaGen \/ SiVEC Biotechnologies","highestDevelopmentStatusID":"5","companyTruncated":"RheumaGen \/ SiVEC Biotechnologies"},{"orgOrder":0,"company":"Nilo Therapeutics","sponsor":"Nilo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Neural circuits","graph1":"Immunology","graph2":"Preclinical","graph3":"Nilo Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nilo Therapeutics \/ The Column Group","highestDevelopmentStatusID":"4","companyTruncated":"Nilo Therapeutics \/ The Column Group"},{"orgOrder":0,"company":"ImmunoVec","sponsor":"ARPA-H","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"ImmunoVec","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"ImmunoVec \/ ARPA-H","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoVec \/ ARPA-H"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Sichuan Biokin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SHR-3045","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Surovatamig","moa":"CD19 | CD3","graph1":"Immunology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MAS825","moa":"IL-1?","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"RD06-05","moa":"CD19\/\u200bBCMA","graph1":"Immunology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bioheng Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Ayman Al Jurdi, MD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Ayman Al Jurdi, MD","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Ayman Al Jurdi, MD"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-2173","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Lifordi Immunotherapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LFD-200","moa":"GR\/VISTA","graph1":"Immunology","graph2":"Phase I","graph3":"Lifordi Immunotherapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lifordi Immunotherapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lifordi Immunotherapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"TJ Biopharma Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"TJ Biopharma Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TJ Biopharma Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TJ Biopharma Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"L-Dipivefrin","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insignis Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Chengdu Kangnuoxing Biopharma,Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R\u03b1","graph1":"Immunology","graph2":"Phase III","graph3":"Chengdu Kangnuoxing Biopharma,Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chengdu Kangnuoxing Biopharma,Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu Kangnuoxing Biopharma,Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cizutamig","moa":"BCMA|CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Candid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cizutamig","moa":"BCMA|CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Candid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Fernanda P Silveira","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Immunology","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Fernanda P Silveira","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Fernanda P Silveira"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mark Stegall","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Mark Stegall","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Mark Stegall"},{"orgOrder":0,"company":"GSK","sponsor":"E. Steve Woodle","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ E. Steve Woodle","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ E. Steve Woodle"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mehrdad Abedi, MD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Immunology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Mehrdad Abedi, MD","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Mehrdad Abedi, MD"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Paul Kim","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Paul Kim","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Paul Kim"},{"orgOrder":0,"company":"Novotech","sponsor":"De Motu Cordis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Novotech \/ De Motu Cordis","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ De Motu Cordis"},{"orgOrder":0,"company":"Novotech","sponsor":"De Motu Cordis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Novotech \/ De Motu Cordis","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ De Motu Cordis"},{"orgOrder":0,"company":"GSK","sponsor":"Region Skane","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Shingrix","moa":"antivirals","graph1":"Immunology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Region Skane","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Region Skane"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Chongbo Zhao","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gracell Biotechnologies \/ Chongbo Zhao","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Chongbo Zhao"},{"orgOrder":0,"company":"Genentech","sponsor":"Neufeld, Ellis J, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Neufeld, Ellis J, MD, PhD","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ Neufeld, Ellis J, MD, PhD"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Hannah Choe","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PLX51107","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plexxikon \/ Hannah Choe","highestDevelopmentStatusID":"7","companyTruncated":"Plexxikon \/ Hannah Choe"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"David Simon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ David Simon","highestDevelopmentStatusID":"7","companyTruncated":"Kyverna Therapeutics \/ David Simon"},{"orgOrder":0,"company":"Shanghai Ming Ju Biotechnology Co., Ltd.","sponsor":"Liangjing Lu","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Shanghai Ming Ju Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Ming Ju Biotechnology Co., Ltd. \/ Liangjing Lu","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Ming Ju Biotechnology Co., Ltd. \/ Liangjing Lu"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Helio Tedesco Silva Junior","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Thymoglobulin","moa":"CD2","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Helio Tedesco Silva Junior","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Helio Tedesco Silva Junior"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Schroppel, Bernd, M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Schroppel, Bernd, M.D.","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Schroppel, Bernd, M.D."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Sanjay Kulkarni","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Sanjay Kulkarni","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Sanjay Kulkarni"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Frank Behrens","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Janssen-Cilag \/ Frank Behrens","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Frank Behrens"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Julia Brown","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Julia Brown","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Julia Brown"},{"orgOrder":0,"company":"medac","sponsor":"Franco Locatelli","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Immunology","graph2":"Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Franco Locatelli","highestDevelopmentStatusID":"8","companyTruncated":"medac \/ Franco Locatelli"},{"orgOrder":0,"company":"Regimmune","sponsor":"Zachariah Michael DeFilipp","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Immunology","graph2":"Phase I","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regimmune \/ Zachariah Michael DeFilipp","highestDevelopmentStatusID":"6","companyTruncated":"Regimmune \/ Zachariah Michael DeFilipp"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Edward Geissler","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chiesi Group \/ Edward Geissler","highestDevelopmentStatusID":"11","companyTruncated":"Chiesi Group \/ Edward Geissler"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Simon Tremblay, PharmD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veloxis Pharmaceuticals \/ Simon Tremblay, PharmD, PhD","highestDevelopmentStatusID":"11","companyTruncated":"Veloxis Pharmaceuticals \/ Simon Tremblay, PharmD, PhD"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Heleen Grootjans","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Chiesi Group \/ Heleen Grootjans","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Heleen Grootjans"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Roy D. Bloom, MD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veloxis Pharmaceuticals \/ Roy D. Bloom, MD","highestDevelopmentStatusID":"11","companyTruncated":"Veloxis Pharmaceuticals \/ Roy D. Bloom, MD"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kim Seoung-Hoon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Kim Seoung-Hoon","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Kim Seoung-Hoon"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Byung-Sik Cho","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Byung-Sik Cho","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Byung-Sik Cho"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Raymond T. Chung, MD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Grazoprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Immunology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Raymond T. Chung, MD","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Raymond T. Chung, MD"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Mazen Dimachkie, MD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Mazen Dimachkie, MD","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Mazen Dimachkie, MD"},{"orgOrder":0,"company":"Miltenyi Biomedicine","sponsor":"Carsten Bindslev-Jensen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"Miltenyi Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Miltenyi Biomedicine \/ Carsten Bindslev-Jensen","highestDevelopmentStatusID":"11","companyTruncated":"Miltenyi Biomedicine \/ Carsten Bindslev-Jensen"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Carsten Bindslev-Jensen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Carsten Bindslev-Jensen","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Carsten Bindslev-Jensen"},{"orgOrder":0,"company":"Argenx","sponsor":"Chafic Karam","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alfa","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Chafic Karam","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Chafic Karam"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Ramesh Prasad","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Ramesh Prasad","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Ramesh Prasad"},{"orgOrder":0,"company":"Biogen","sponsor":"John Levine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ John Levine","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ John Levine"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Marc Schwartz","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Marc Schwartz","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Marc Schwartz"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Shilpa Grover, MD, MPH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Shilpa Grover, MD, MPH","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Shilpa Grover, MD, MPH"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Geert D'Haens","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Geert D'Haens","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Geert D'Haens"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Geert D'Haens","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Geert D'Haens","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Geert D'Haens"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Richard W Yee, MD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Immunology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Richard W Yee, MD","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Richard W Yee, MD"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Professor Mikkel \u00d8stergaard","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Professor Mikkel \u00d8stergaard","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Professor Mikkel \u00d8stergaard"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Andrew J Long","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Andrew J Long","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Andrew J Long"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Anne B. Newman","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Clazakizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Behring \/ Anne B. Newman","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Anne B. Newman"},{"orgOrder":0,"company":"Genentech","sponsor":"Chester Oddis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Chester Oddis","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Chester Oddis"},{"orgOrder":0,"company":"Biogen","sponsor":"Robert Lafyatis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Kelch-like ECH-associated protein 1","graph1":"Immunology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Robert Lafyatis","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Robert Lafyatis"},{"orgOrder":0,"company":"Kamada","sponsor":"Impatients N.V. trading as myTomorrows","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Alpha1-Proteinase Inhibitor (Human)","moa":"Leukocyte elastase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Impatients N.V. trading as myTomorrows","highestDevelopmentStatusID":"1","companyTruncated":"Kamada \/ Impatients N.V. trading as myTomorrows"},{"orgOrder":0,"company":"Biogen","sponsor":"Farsad Eskandary","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Farsad Eskandary","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Farsad Eskandary"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Ronald J. Rapoport, MD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Ronald J. Rapoport, MD","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Ronald J. Rapoport, MD"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Dana Ascherman","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase IV","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Dana Ascherman","highestDevelopmentStatusID":"11","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Dana Ascherman"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Rohit Aggarwal, MD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Rohit Aggarwal, MD","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Rohit Aggarwal, MD"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Justus J. Fiechtner","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Repository Corticotropin","moa":"Melanocortin receptor 2","graph1":"Immunology","graph2":"Phase IV","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Justus J. Fiechtner","highestDevelopmentStatusID":"11","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Justus J. Fiechtner"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Stanley Jordan, MD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"C1 Esterase Inhibitor","moa":"Plasma protease C1 inhibitor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Stanley Jordan, MD","highestDevelopmentStatusID":"7","companyTruncated":"CSL Behring \/ Stanley Jordan, MD"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Dinesh Khanna, MD, MS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Immunology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Dinesh Khanna, MD, MS","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Dinesh Khanna, MD, MS"},{"orgOrder":0,"company":"BASF","sponsor":"Joe Chan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"steroids (androgens","graph1":"Immunology","graph2":"Phase III","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Joe Chan","highestDevelopmentStatusID":"10","companyTruncated":"BASF \/ Joe Chan"},{"orgOrder":0,"company":"Genentech","sponsor":"Michael Roth","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Michael Roth","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Michael Roth"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Michael Schiff, MD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2010","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Michael Schiff, MD","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Michael Schiff, MD"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"R\u00fcdiger B. M\u00fcller","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ R\u00fcdiger B. M\u00fcller","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ R\u00fcdiger B. M\u00fcller"},{"orgOrder":0,"company":"Genentech","sponsor":"Dr. Larry W. Moreland","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Enbrel","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Dr. Larry W. Moreland","highestDevelopmentStatusID":"11","companyTruncated":"Genentech \/ Dr. Larry W. Moreland"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Shradha Agarwal","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PROMETHEUS LABS \/ Shradha Agarwal","highestDevelopmentStatusID":"1","companyTruncated":"PROMETHEUS LABS \/ Shradha Agarwal"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Hamed Rezaei","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Hamed Rezaei","highestDevelopmentStatusID":"11","companyTruncated":"Abbott Laboratories \/ Hamed Rezaei"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jonathan Graf","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Jonathan Graf","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Jonathan Graf"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Peter Higgins","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Peter Higgins","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Peter Higgins"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"waqqas.afif","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ waqqas.afif","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ waqqas.afif"},{"orgOrder":0,"company":"GSK","sponsor":"Rachel Jones","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Rachel Jones","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Rachel Jones"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"John Levine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ John Levine","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ John Levine"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Adeline Vanderver","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Adeline Vanderver","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Adeline Vanderver"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Matthew J Koster","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Matthew J Koster","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Matthew J Koster"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jeffrey Curtis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Jeffrey Curtis","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Jeffrey Curtis"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Atsushi Kawakami","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Atsushi Kawakami","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Atsushi Kawakami"},{"orgOrder":0,"company":"Galapagos","sponsor":"R.Bos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galapagos \/ R.Bos","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ R.Bos"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Atsushi Kawakami","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Atsushi Kawakami","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Atsushi Kawakami"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Ho Cheol Shin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Human Placenta Hydrolysate","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Green Cross Lab Cell \/ Ho Cheol Shin","highestDevelopmentStatusID":"10","companyTruncated":"Green Cross Lab Cell \/ Ho Cheol Shin"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Prof. Dr. Marc-H. Dahlke, Ph. D.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Multipotent Adult Progenitor Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Prof. Dr. Marc-H. Dahlke, Ph. D.","highestDevelopmentStatusID":"6","companyTruncated":"Healios K.K \/ Prof. Dr. Marc-H. Dahlke, Ph. D."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Gerhard Rogler","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"QAX567","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Gerhard Rogler","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Gerhard Rogler"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Iman Almansour","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"S.opt.FL COVID-19 pDNA Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Iman Almansour","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Iman Almansour"},{"orgOrder":0,"company":"MEDICE Health Family","sponsor":"Prim. Priv. Doz. Dr. Daniel Cejka","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Sodium Bicarbonate","moa":"Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)","graph1":"Immunology","graph2":"Phase II","graph3":"MEDICE Health Family","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEDICE Health Family \/ Prim. Priv. Doz. Dr. Daniel Cejka","highestDevelopmentStatusID":"8","companyTruncated":"MEDICE Health Family \/ Prim. Priv. Doz. Dr. Daniel Cejka"},{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"Nicole Lindenblatt","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"NanoPass Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoPass Technologies \/ Nicole Lindenblatt","highestDevelopmentStatusID":"6","companyTruncated":"NanoPass Technologies \/ Nicole Lindenblatt"}]

    Find Immunology Clinical Drug Pipeline Developments & Deals

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related...

                            Details : Rilzabrutinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Immunoglobulin G4-Related Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2025

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Seve...

                            Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Sev...

                            Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Seve...

                            Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Sev...

                            Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AbbVie Inc

                            U.S.A
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Risankizumab in Young Participants with Ulcerative Colitis

                            Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 17, 2025

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AbbVie Inc

                            U.S.A
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upadacitinib,Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

                            Details : Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor, small molecule drug candidate, which is indicated for the treatment of giant cell arteritis.

                            Product Name : Rinvoq

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 29, 2025

                            Lead Product(s) : Upadacitinib,Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AbbVie Inc

                            U.S.A
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upadacitinib,Corticosteroid

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Wins EU Nod for RINVOQ in Adults with Giant Cell Arteritis

                            Details : Rinvoq (upadacitinib) is a FDA approved selective JAK inhibitor that is being investigated in adult patients with giant cell arteritis in a Phase 3 clinical trial.

                            Product Name : Rinvoq

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 08, 2025

                            Lead Product(s) : Upadacitinib,Corticosteroid

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AbbVie Inc

                            U.S.A
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upadacitinib,Corticosteroid

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie gets Positive CHMP Opinion for RINVOQ® in Giant Cell Arteritis Treatment

                            Details : Rinvoq (upadacitinib) is a FDA approved selective JAK inhibitor that is being investigated in adult patients with giant cell arteritis in a Phase 3 clinical trial.

                            Product Name : Rinvoq

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 28, 2025

                            Lead Product(s) : Upadacitinib,Corticosteroid

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AbbVie Inc

                            U.S.A
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upadacitinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie’s Phase 3 SELECT-GCA Study of Upadacitinib Shows Positive Results in GCA

                            Details : Rinvoq (upadacitinib) is a FDA approved selective JAK inhibitor that is being investigated in adult patients with giant cell arteritis as a Phase 3 clinical trial.

                            Product Name : Rinvoq

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 23, 2024

                            Lead Product(s) : Upadacitinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth